Evidence-Based Series 24-1 Version 2

A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO)

Referral of Patients with Suspected Colorectal Cancer by Family Physicians and Other Primary Care Providers

The Colorectal Cancer Referral Expert Panel

An assessment conducted in January 2019 deferred the review of Evidence-Based Series (EBS) 24-1 Version 2. This means that the document remains current until it is assessed again next year. The PEBC has a formal and standardized process to ensure the currency of each document (PEBC Assessment & Review Protocol)

EBS 24-1 Version 2 is comprised of 4 sections. You can access the summary and full report here:


| Section 1: Guideline Recommendations (ENDORSED) |
| Section 2: Evidentiary Base |
| Section 3: EBS Development Methods and External Review Process |
| Section 4: Document Review Summary and Tool |

April 10, 2017

For information about the PEBC and the most current version of all reports, please visit the CCO website at http://www.cancercare.on.ca/ or contact the PEBC office at:
Phone: 905-527-4322 ext. 42822  Fax: 905-526-6775  E-mail: ccopgi@mcmaster.ca


Guideline Citation (Vancouver Style): The Colorectal Cancer Referral Expert Panel. Referral of patients with suspected colorectal cancer by family physicians and other primary care providers. Del Giudice L, Yao X, Kellett S, reviewers. Toronto (ON): Cancer Care Ontario; 2012 Apr 24 [Endorsed 2017 April 10]. Program in Evidence-based Care Evidence-Based Series No.: 24-1 Version 2 ENDORSED.

Guideline Report History

<table>
<thead>
<tr>
<th>GUIDELINE VERSION</th>
<th>SYSTEMATIC REVIEW</th>
<th>PUBLICATIONS</th>
<th>NOTES and KEY CHANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Search Dates</td>
<td>Data</td>
<td></td>
</tr>
<tr>
<td>Original</td>
<td>June 2004 -</td>
<td>Full Report</td>
<td></td>
</tr>
<tr>
<td>April 2012</td>
<td>August 2011</td>
<td></td>
<td>Peer review publication</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Web publication</td>
</tr>
<tr>
<td>Current Version</td>
<td>June 2009 -</td>
<td>New data</td>
<td>2012 recommendations</td>
</tr>
<tr>
<td>2 April, 2017</td>
<td>September 2015</td>
<td>found in</td>
<td>ENDORSED</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Section 4: Document Review Summary and Tool</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Updated CCO web publication</td>
<td></td>
</tr>
</tbody>
</table>

Table of Contents

Section 1: Guideline Recommendations ................................................................. 1
Section 2: Evidentiary Base ......................................................................................... 13
Section 3: Development Methods, Recommendations Development and External Review Process ............................................................................................................................ 86
Section 4: Guideline Review Summary and Tool ............................................................ 102
Evidence-Based Series 24-1: Section 1- Guideline Recommendations

Referral of Patients with Suspected Colorectal Cancer by Family Physicians and Other Primary Care Providers: Guideline Recommendations


A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO)

Report Date: April 24, 2012

These guideline recommendations have been ENDORSED in April 2017, which means that the recommendations are still current and relevant for decision making. Please see Section 4: Document Review Summary and Tool for a summary of updated evidence published between 2009 and 2015 and for details on how this Clinical Practice Guideline was ENDORSED on page 102.

QUESTIONS

Overall Question

How should patients presenting to family physicians (FPs) and other primary care providers (PCPs) with signs and/or symptoms of colorectal cancer (CRC) be managed? The following questions are the factors considered in answering the overall question:

1. What signs, symptoms, and other clinical features that present in primary care are predictive of CRC?
2. What is the diagnostic accuracy of investigations commonly considered for patients presenting with signs and/or symptoms of CRC?
3. What major, known risk factors increase the likelihood of CRC in patients presenting with signs and/or symptoms of CRC?
4. Which factors are associated with delayed referral? Which delay factors can be attributed to patients, and which factors can be attributed to providers? Does a delay in the time to consultation affect patient outcome?

TARGET POPULATION
Adult patients presenting in primary care settings comprise the target population. This guideline does not provide recommendations for patients who present with alarming emergency symptoms and signs of hemodynamic instability, acute gastrointestinal hemorrhaging, acute intestinal obstructions, or unremitting abdominal pain. These patients should be immediately referred to emergency for assessment and treatment. In addition, this guideline does not address CRC screening for asymptomatic patients.

INTENDED USERS

This guideline is intended for FPs, general practitioners, emergency room physicians, other PCPs (nurse practitioners, registered nurses, and physician assistants), surgeons and gastroenterologists. For the purposes of this document, we have referred to FPs, general practitioners, emergency room physicians, and other PCPs as ‘FPs and other PCPs’. Along the diagnostic assessment pathway, FPs and other PCPs should apply the College of Physicians and Surgeons of Ontario’s policy on Test Results Management to ensure that an appropriate response to test results is met (1). This guideline is also intended for policymakers to help ensure that resources are in place so that target wait times can be achieved. This guideline coincides with the introduction of colorectal cancer Diagnostic Assessment Programs (DAPS) in Ontario. DAPs provide a single point of referral, coordination of care using a clinical navigator, fast tracking of diagnostic tests and a multidisciplinary team approach. They are an Ontario-wide strategic priority designed to improve patient access and outcomes, and are outlined in Ontario Cancer Plan 2005-2011 and Ontario Cancer Plan 2011-2014 (2).

RECOMMENDATIONS

Clinical Presentation

A focused history and physical examination should be performed if patients present with one or more of the following signs or symptoms:

- Palpable rectal mass
- Palpable abdominal mass
- Anemia (especially iron-deficiency anemia)
- Rectal bleeding
- Change in bowel habits
- Weight loss
- Abdominal discomfort
- Perianal symptoms

The focused history should determine the following details:

- Age and gender
- Rectal bleeding, and if yes,
  - Colour (dark versus bright red)
  - Location of blood relative to stool (mixed in with stool versus separate from stool, on the toilet paper)
- Change in bowel habit over recent months/years, and if yes,
  - Increased loose or watery stools or diarrhea
  - Increased constipation or difficulty passing stools
  - Feeling of incomplete emptying
  - Increased urgency
  - Incontinence of stools or soiling
- Weight loss
- Abdominal discomfort (pain, tenderness, bloating)
- Perianal symptoms such as prolapsed lump, pruritus, pain, hemorrhoids
- Symptoms of anemia [e.g., fatigue, weakness - refer to anemia guidelines (3,4)]
- If unexplained iron-deficiency anemia present, explore possible causes of blood loss or blood dyscrasia (3,4).
- Personal history of colorectal polyps or inflammatory bowel disease (IBD) or a first-degree family history of CRC and the age of onset

To supplement the history, a focused physical examination or investigations should include the following:
- Digital rectal examination (DRE)
- Abdominal examination. If palpable mass detected, order abdominal/pelvic imaging.
- Look for signs of anemia - refer to anemia guidelines (3,4)
- Weight (and comparison to previous weights if possible)
- Complete blood count (CBC), and if low mean cell or corpuscular volume (MCV) (i.e., microcytic anemia), may order ferritin

Referral

**Qualifying Statement - Added to the Endorsement in April 2017:**
The original 2012 guideline included a discussion of an option to test with the fecal occult blood test (FOBT) in a narrow set of circumstances. In the 2017 version, because of the possible negative impact of the 2012 recommendation regarding FOBT on the organized colorectal cancer screening program in Ontario, it was decided to remove all recommendations associated with FOBT from the guidance for referral, from the summary of key evidence, and from the accompanying algorithm.

Referral and wait time recommendations for the following indications are based on evidence of the relative predictability for CRC of single or combined signs, symptoms, or diagnostic investigations (5). The referral wait times also align with the recommendations developed by the Canadian Association of Gastroenterology (6). In many jurisdictions, organized Diagnostic Assessment Programs (DAPs) with centralized referral access may facilitate timely tests and specialist appointments.

1. **URGENT REFERRAL**
   Referring physicians should send a referral to a CRC DAP or a specialist competent in endoscopy within 24 hours, expect a consultation within 2 weeks, and expect a definitive diagnostic workup to be completed within 4 weeks of referral, if a patient has at least one of the following:
   - Palpable rectal mass suspicious for CRC
   - Abnormal abdominal imaging result suspicious for CRC
2. **SEMI-URGENT REFERRAL**

Referring physicians should send a referral to a CRC DAP or a specialist competent in endoscopy within 24 hours, expect a consultation within 4 weeks, and expect a definitive diagnostic work up to be completed within 8 weeks of referral, if a patient has at least one of the following:

- **Unexplained** rectal bleeding in patients with at least one of the following characteristics or combinations of symptoms:
  - Dark rectal bleeding
  - Rectal bleeding mixed with stool
  - Rectal bleeding in the absence of perianal symptoms
  - Rectal bleeding and change in bowel habits
  - Rectal bleeding and weight loss
- **Unexplained** iron-deficiency anemia (hemoglobin of ≤110 g/L for males or ≤100 g/L for non-menstruating females and iron below normal range)

Referring physicians should include information that may increase the likelihood of CRC in the consultation request:

- Patients aged 60 years and older
- Male patients
- The presence of two or more signs or symptoms
- Patients with a personal history of colorectal polyps or IBD or a first-degree family history of CRC

3. If the unexplained signs or symptoms of patients do not meet the criteria for referral but, based on clinical judgement, there remains a:

- high level of suspicion of CRC, then refer to a CRC DAP or a specialist competent in endoscopy
- low level of suspicion of CRC, then treat the sign and/or symptom if applicable. Review and ensure resolution of symptoms within four to six weeks. If signs and/or symptoms have not resolved in four to six weeks, then confer with or refer to a CRC DAP or specialist competent in endoscopy.

In situations where wait times for specialists to perform colonoscopy are considered excessive, referring physicians may order (depending on locally available resources):

- Computed tomographic (CT) colonography
- Double-contrast barium enema (DCBE)

This is best done in coordination with the CRC DAP or specialist, if possible. Normal or negative results should not lead to a cancellation of the consult with the CRC DAP or specialist. Positive results may facilitate more timely investigation of a patient.
Recommendations to Reduce Diagnostic Delay

- Information regarding the signs and symptoms of CRC, how to obtain a proper detailed history, physical examination, appropriate investigations, and referral of patients presenting with suspicious signs and symptoms should be widely disseminated to FPs and other PCPs using various knowledge translation strategies.
- During the periodic health examination, FPs and other PCPs should ask adult patients about rectal bleeding, changes in bowel habits, and unintentional weight loss.
- While discussing colorectal cancer screening with patients, FPs and other PCPs should ask about family history for CRC and the signs and symptoms predictive of CRC.
- FPs and other PCPs should investigate unexplained anemia, especially iron-deficiency anemia. Refer to anemia guidelines (3,4)
- For signs and symptoms that may not have prompted initial referral, FPs and other PCPs should reassess and further workup if signs/symptoms do not resolve.
- FPs and other PCPs should consider training staff regarding triaging of patients calling with signs and/or symptoms suggestive of CRC to expedite initial appointments.
- CRC DAPs and specialists competent in endoscopy should develop triage protocols to avoid delays in the diagnosis of CRC in patients with suspicious signs and/or symptoms.
- Sustainable public education about the signs and symptoms of CRC, the importance of early detection and management, as well as common fears and concerns that may delay referral, should be developed and implemented.
- Special efforts should be made to reduce delays in presentation often observed among women, single patients, younger patients, visible minorities, and patients with co-morbidities, decreased social support, lower levels of education, or a rural residence.
ALGORITHM

Colorectal Cancer Guideline Recommendations for Symptomatic Patients

Does the patient have one or more of the following signs/symptoms?
- Palpable rectal mass
- Palpable abdominal mass
- Anemia
- Rectal Bleeding
- Change in bowel habits
- Weight loss
- Abdominal discomfort
- Perianal symptoms

If Yes, perform a focused history and physical exam

FOCUSED HISTORY:
- Age and gender
- Rectal bleeding, if yes: colour, location
- Change in bowel habit, if yes: increased stool, looseness, constipation and/or urgency; feel incomplete emptying; stool incontinence
- Weight loss
- Abdominal discomfort
- Personal symptoms (lump, pruritus, pain)
- Symptoms of anemia
- If IDA - explore possible causes of blood loss
- Personal history of colorectal polyps or IBD or family history of 1st degree relative with CRC

FOCUSED PHYSICAL EXAM/TEST:
- Digital rectal exam
- Abdominal exam (if palpable mass do abdominal/pelvic Imaging)
- Look for signs of anemia
- Weight
- CBC (if microcytic do ferritin)

- Suspicious palpable rectal mass
- Suspicious abnormal abdominal imaging

UGLY REFERRAL
to a specialist competent in endoscopy or to a CRC DAP within 24 hours
Expect a consultation within 2 weeks and definitive diagnostic work-up completed within 4 weeks of referral

- Unexplained RECTAL BLEEDING with one or more of the following features:
  - dark blood
  - blood mixed with stool
  - absence of perianal symptoms
  - with change in bowel habits
  - with weight loss
- Unexplained IDA:
  - males: Hb ≤110 g/L
  - menopausal females: Hb ≤100 g/L

For all other unexplained signs/symptoms that do not meet criteria for urgent or semi-urgent referral:

low level of CRC
- suspension
High level of CRC
- suspension

- treat sign/symptom if applicable
- review and ensure resolution of symptoms within 4-6 weeks

If signs/symptoms have not resolved in 4 to 6 weeks, then confer with or refer to a CRC DAP or endoscopy specialist

REFER TO A CRC DAP OR ENDOSCOPY SPECIALIST

SAMI-URGENT REFERRAL
to a specialist competent in endoscopy or to a CRC DAP within 24 hours
Expect a consultation within 4 weeks and definitive diagnostic work-up completed within 8 weeks of referral

IF WAIT TIME IS CONSIDERED EXCESSIVE, ORDER:
- CT Colonography or
- DCBE
This is best done in coordination with a CRC DAP or specialist, if possible. Normal or negative results should not lead to a cancellation of the consult with the CRC DAP or specialist. Positive results may facilitate more timely investigation of a patient.

CRC: complete blood count
CCC: Colon Cancer Check
CRC: colorectal cancer
CT: computed tomography
DAP: Diagnostic Assessment Program
DCBE: double contrast barium enema
Hb: hemoglobin
IBD: inflammatory bowel disease
IDA: iron deficiency anemia
KEY EVIDENCE
Clinical Presentation
The Colorectal Cancer Referral Working Group believe that the signs and symptoms listed under clinical presentation should alert FPs and other PCPs about the suspicion of CRC. The presenting signs or symptoms for which urgent or semi-urgent referral was recommended met one of two criteria: the sign or symptom presented in at least 5% of patients with confirmed CRC, or the sign or symptom was a statistically significant predictor of CRC. The exception to this is perianal symptoms. The absence of perianal symptoms with rectal bleeding strengthens the positive predictive value (PPV) for CRC rather than the presence of perianal symptoms. The studies included in calculating median PPVs or that contained multiple regression analyses can be found in Section 2 of this report.

For the signs and symptoms of anemia as well as the questions to ask patients presenting with unexplained anemia, the Working Group decided that primary care physicians could refer to reference documents such as the Anemia Guidelines for Primary Care developed by Medication Use Management Services Guidelines Clearinghouse and/or the Guidelines for the Management of Iron deficiency Anaemia by the British Society of Gastroenterology (3,4).

Risk factors
In a patient presenting with rectal bleeding, anemia or change in bowel habits, there is evidence to suggest that increasing age and male gender may increase the predictability of suspicion for CRC (described below under Referral).

Meta-analyses by Olde Bekkink et al and Jellema et al found high specificity but low sensitivity for a family history of CRC in symptomatic patients (9,10). In addition, Jellema et al reported a pooled PPV of 6% for a family history of CRC in symptomatic patients (9). There is well-established evidence that patients with a personal history of colorectal polyps or IBD are at increased risk of CRC (11). Based on the consensus, the Working Group decided that for these patients who are part of a surveillance program and present with interim signs or symptoms of CRC, early re-referral to specialists is recommended.

Investigations
There was a paucity of studies examining the diagnostic accuracy investigations for patients presenting with signs and/or symptoms of CRC. The physical examination manoeuvres that were included were based on consensus. They are simple, can be easily performed in primary care, and can provide valuable information leading to expedited referral. Proctoscopy was not recommended as a standard of care due to a lack of evidence for its use, a lack of widespread availability, and a low rate of use in primary care. However, based on consensus, it may still be used at the discretion of the clinician.

The following diagnostic investigations are recommended by the Working Group for completion of the assessment: CBC and imaging for palpable abdominal masses. The results of these tests should be made available to the specialists. Although there were very few studies examining the diagnostic accuracy of a CBC for predicting CRC in symptomatic patients, there was consensus that this should be ordered to assist in the evaluation of whether anemia, and especially iron-deficiency anemia, is present. A ferritin should be ordered if IDA is suspected. It is common practice to image abdominal masses found during a physical examination. Imaging may help to determine whether the mass is intra-colonic or extra-colonic and direct the workup of the mass, as well as indicate appropriate specialty referral.

Because there were very few studies examining the diagnostic accuracy of carcinoembryonic antigen (CEA), erythrocyte sedimentation rate (ESR), and other blood tests for predicting CRC in symptomatic patients, they were not recommended.
Referral

The Working Group chose to include signs or symptoms with median PPVs greater than 10%, identified in studies in Section 2 of this report, as indicators for referral. For triaging purposes in patients who are being referred semi-urgently, the following combinations of clinical features have been found to increase the index of suspicion for CRC and are described in Section 2 of this report:

- Increasing age (most studies used a cutoff of greater than or equal to 60 years) and rectal bleeding or change in bowel habits or anemia (especially iron-deficiency anemia)
- Male patients with rectal bleeding or change in bowel habits or anemia (especially iron-deficiency anemia)
- A combination of signs or symptoms

For signs or symptoms that did not lead to referral, the Working Group chose to rely on clinical judgement to decide whether there was a high level or low level of suspicion for CRC. The Working Group decided that if a clinician has a low level of suspicion, signs and symptoms should be treated and resolution in four to six weeks should be ensured. This timeframe was chosen based on the clinical experience of the Working Group and to be consistent with the NICE and NZGG guidelines that recommend referral when some of these symptoms (e.g., rectal bleeding, change in bowel habits) persist for at least six weeks (7,8).

If the time to referral exceeds the recommended wait times or is considered excessive, the Working Group recommended that the referring physician may consider ordering a CT colonography or DCBE, depending on locally available resources. This would ensure that as much information as possible would be made available to the specialist during the consultation. There is some evidence to suggest that CT colonography or DCBE may have good diagnostic properties in symptomatic patients. The sensitivities and/or specificities were over 83% when CT colonography or DCBE were compared to colonoscopy alone (12-24). Flexible sigmoidoscopy (FS) also showed good sensitivity for detecting CRC, especially when combined with DCBE (13,16,22,25). However, the Working Group preferred that the entire colon be visualized. There were few studies examining the diagnostic accuracy of abdominal CT or abdominal or pelvic ultrasound among symptomatic patients; however, as described above, they may be helpful in differentiating abdominal/pelvic masses.

Factors Contributing to Diagnostic Delay

Although the evidence suggests that delay in referral does not have an impact on patient survival, the Working Group believed it was important to improve wait times with the intention of decreasing patient anxiety. Evidence from prospective and retrospective studies described in Section 2 of this report suggest that the following may delay the diagnosis of CRC:

- FP and other PCP-related delays (7,8,26-28)
  - failure to recognize signs and symptoms were suggestive of CRC
  - failure to investigate iron-deficiency anemia
  - failure to perform DRE
  - initial referral to a specialist without a gastrointestinal interest
  - receiving inaccurate or inadequate tests
  - frequent visits following an inconclusive first visit
  - patients with colon cancer referred less quickly than patients with rectal cancer
  - younger patients
  - gender (females had longer delays than males)
visible minorities

- Patient-related delays (7, 8, 26, 27, 29)
  - patient’s lack of appreciation regarding the association of symptoms with CRC
  - fear that tests might be unpleasant or embarrassing
  - uncomfortable with or embarrassed about symptoms, including pain, nausea, and vomiting
  - decreased social support
  - presence of comorbidity
  - rural residency
  - lower education level
  - single/separated/divorced
  - female colon cancer patients had longer delays than male
  - male rectal cancer patients had longer delays than females

FUTURE RESEARCH

Further studies should be designed to determine which educational initiatives would be best at decreasing practitioner or patient-related delay. Also, more studies to determine the diagnostic performance of signs and symptoms for CRC are needed in the primary care setting.

Updating

This document will be reviewed in three years to determine if it is still relevant to current practice and to ensure that the recommendations are based on the best available evidence. The outcome of the review will be posted on the CCO website. If new evidence that will result in changes to these recommendations becomes available before three years have elapsed, an update will be initiated as soon as possible.

Funding

The PEBC is a provincial initiative of Cancer Care Ontario supported by the Ontario Ministry of Health and Long-Term Care through Cancer Care Ontario. All work produced by the PEBC is editorially independent from its funding source.

Copyright

This report is copyrighted by Cancer Care Ontario; the report and the illustrations herein may not be reproduced without the express written permission of Cancer Care Ontario. Cancer Care Ontario reserves the right at any time, and at its sole discretion, to change or revoke this authorization.

Disclaimer

Care has been taken in the preparation of the information contained in this report. Nonetheless, any person seeking to apply or consult the report is expected to use independent medical judgment in the context of individual clinical circumstances or seek out the supervision of a qualified clinician. Cancer Care Ontario makes no representation or guarantees of any kind whatsoever regarding the report content or use or application and disclaims any responsibility for its application or use in any way.

Contact Information

For information about the PEBC and the most current version of all reports, please visit the CCO website at http://www.cancercare.on.ca/ or contact the PEBC office at:
Phone: 905-527-4322 ext. 42822 Fax: 905-526-6775 E-mail: ccopgi@mcmaster.ca
REFERENCES


2. Cancercare.on.ca. [Internet]. Toronto (ON): Cancer Care Ontario (CCO); 2011 [cited 2010 Aug 3].


Evidence-Based Series 24-1: Section 2 - Evidentiary Base

Referral of Patients with Suspected Colorectal Cancer by Family Physicians and Other Primary Care Providers: Evidentiary Base


A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO)

Report Date: April 24, 2012

The 2012 guideline recommendations have been ENDORSED, which means that the recommendations are still current and relevant for decision making. Below is the original summary of evidence from 2012. Please see Section 4: Document Review Summary and Tool for a summary of updated evidence published between 2009 and 2015 and for details on how this Clinical Practice Guideline was ENDORSED.

QUESTIONS

Overall Question

How should patients presenting to family physicians (FPs) and other primary care providers (PCPs) with signs and/or symptoms of colorectal cancer (CRC) be managed? The following questions are the factors considered in answering the overall question:

1. What signs, symptoms, and other clinical features that present in primary care are predictive of CRC?
2. What is the diagnostic accuracy of investigations commonly considered for patients presenting with signs and/or symptoms of CRC?
3. What major, known risk factors increase the likelihood of CRC in patients presenting with signs and/or symptoms of CRC?
4. Which factors are associated with delayed referral? Which delay factors can be attributed to patients, and which factors can be attributed to providers? Does a delay in the time to consultation affect patient outcome?

INTRODUCTION

CRC is one of the most common types of cancer for both men and women in Ontario, with an incidence of 7494 cases in 2006 (1). The number of cases has increased over the past three decades, mostly as a result of population aging (1). CRC is also the second leading cause of cancer-related deaths in Ontario, with 3026 deaths in 2006 (1). However, when CRC is detected early, there is a 90% chance that it can be cured. In recent years, half the reported CRC cases were diagnosed at an early stage (I or II), and half were diagnosed at later stages (III or IV) (1).

In an attempt to improve the rate of early detection of CRC in Ontario, a population-based screening program, ColonCancerCheck, has recently been implemented (2). However, although CRC screening rates are increasing, they are currently still low (30% in 2007-2008) (1). As a result, many patients with CRC will present to their FPs and other PCPs unscreened and with signs or symptoms of CRC. To date, there are no evidence-based guidelines that can assist FPs and other PCPs in Ontario to identify CRC and initiate the management of these patients. The CCO Provincial Primary Care and Cancer Network (PPCCN) has collaborated with the PEBC to develop guidelines for patients who present with signs and symptoms that could be suspicious of CRC. The New Zealand Guidelines Group (NZGG) 2009 guideline Suspected Cancer in Primary Care: Guidelines for Investigation, Referral and Reducing Ethnic Disparities and the National Institute for Health and Clinical Excellence (NICE) 2005 guideline Referral Guidelines for Suspected Cancer in Adults and Children were chosen as baseline documents for the development of this systematic review (3,4). As well, the Ontario recommendations were designed to complement the Ontario CRC Screening Program (2). The aim of this guideline is to assist FPs and other PCPs to recognize features that should raise their suspicions about the presence of CRC in their patients and ultimately lead to more timely and appropriate referrals for them.

METHODS

The evidence-based series guidelines developed by the CCO PEBC use the methods of the Practice Guidelines Development Cycle (5). A priori, the Colorectal Cancer Referral Working Group chose the evidence-based NZGG 2009 and NICE 2005 documents as a foundation, because they were considered to be of high quality, comprehensive, recent in publication, and relevant to this topic (3,4). In addition, the Working Group chose to use the modified research questions from the NZGG guideline (4). The Working Group updated the literature searches of the NZGG and the NICE systematic reviews (3,4). Evidence was selected by one methodologist and reviewed by the Working Group and Colorectal Cancer Referral Expert Panel (Appendix 1).

This systematic-review update is a convenient and up-to-date source of the best available evidence on primary care referral for suspected CRC. The body of evidence in this review is primarily comprised of guidelines, meta-analyses, and prospective and retrospective studies. This evidence forms the basis of the recommendations developed by the Working Group and approved by the Expert Panel. The systematic review and companion recommendations are intended to promote evidence-based practice in Ontario, Canada. The PEBC is supported by the Ontario Ministry of Health and Long-Term Care through Cancer Care Ontario. All work produced by the PEBC is editorially independent from its funding source.

Literature Search Strategy
To determine whether there were other higher quality guidelines compared to the NICE or NZGG reports or guidelines with more recent systematic reviews, or what other agencies were recommending, a targeted environmental scan of international guideline developers and key organizations was conducted (July 3, 2009) for documents about primary care referral for suspected CRC. Appendix 2 provides a list of the organizations that were examined.

As a result of this search for other guidelines, the Working Group considered the NICE 2005 and NZGG 2009 guidelines to be of the highest quality and updated their literature search strategies (3,4). The search strategies from NZGG 2009 and NICE 2005 were kindly provided to us for this systematic review (3,4).

For signs and symptoms, an updated search, since the NICE publication, of MEDLINE (Ovid, June 2004- June 2009) and EMBASE (Ovid, 2004-2009 week 23) was performed using the combined NZGG and NICE literature search strategies (3,4). For diagnostic tests, the NZGG search strategies were modified to reflect tests that primary care providers in Ontario can perform or order such as a complete blood count (CBC), fecal occult blood testing (FOBT), barium enema, anoscopy, and ultrasound, and included terms suggested by the Working Group such as serum iron, iron blood level, virtual colonography, and virtual colonoscopy (4). An updated search, since the NICE publication, of MEDLINE (Ovid, June 2004- June 2009) and EMBASE (Ovid, 2004-2009 week 24) was then performed.

For the research question about delay, an updated search, since the NZGG publication, of MEDLINE (Ovid, Sept 2007-June 2009) and EMBASE (Ovid, 2007-2009 week 25) using the NZGG search strategies for delay for colorectal cancer was performed (4). For risk factors, an updated search, since the NICE publication, of MEDLINE (Ovid, June 2004- June 2009) and EMBASE (Ovid, 2004-2009 week 23), using the NICE search strategies for systematic reviews for CRC was performed (3). The search strategies can be found in Appendix 3. A literature search update of all strategies for studies available to August 2011 was conducted.

**Study Selection Criteria**

Guidelines were included if they addressed at least one of our research questions, were not cited in the NZGG or NICE guidelines, and included recommendations not found or different from those in either the NICE or NZGG guidelines (3,4).

Studies, found from reference lists, that were published before the NICE or NZGG guidelines but were not included in their reports were included in this systematic review if they addressed any of the research questions and met the inclusion criteria (3,4).

This report focuses on adult patients presenting to primary care with signs or symptoms of CRC. For the clinical question regarding the predictive characteristics of signs or symptoms, all comparative studies of symptom recognition and/or identification for CRC were included. Studies that reported only the main signs or symptoms for each patient, ignoring the presence of additional signs or symptoms, were excluded. Studies where CRC was found in only one patient were also excluded. Studies conducted in secondary care settings were included if they provided predictive information about signs and/or symptoms for suspected CRC; however, they may not have been taken as strongly into consideration as were primary care data when developing the recommendations. Screening studies were excluded because they include asymptomatic patients.

All diagnostic studies were sought in which adult symptomatic primary care patients underwent one or more investigations that included computed tomographic (CT) colonography, barium enema, sigmoidoscopy, ultrasound, CT scan, digital rectal examination (DRE), proctoscopy, rectoscopy, anoscopy, fecal occult blood tests (FOBTs), or complete blood counts (CBC). Studies involving investigations for carcinoembryonic antigen (CEA), C-reactive protein, erythrocyte sedimentation rate (ESR), ferritin, or serum iron were also
searched. Studies conducted in secondary care settings were included if they provided diagnostic information for suspected CRC for the specified investigations; however, they may not have been considered as strongly as the primary care data when developing the recommendations. Screening studies were excluded.

For the clinical questions concerning risk factors and delay, a search for practice guidelines, systematic reviews with meta-analyses, and systematic reviews without meta-analyses was performed. If these articles did not definitively answer the particular clinical question, searches for randomized phase III trials and randomized phase II trials, followed by comparative studies, were performed. If the information from systematic reviews definitely answered the question(s), articles from the time of publication of the systematic review and onwards were searched. To develop recommendations with feasible wait times for Ontario, articles assessing wait times in Canada were also included, regardless of study design.

Non-English publications were not eligible due to the lack of translation funding. Non-systematic reviews, abstracts, case studies, letters, editorials, and commentaries were excluded.

**Synthesizing and Presenting the Evidence**

Data were not pooled because considerable heterogeneity existed between studies for the selection of the patient population, diagnostic tests used to confirm CRC, and prevalence of CRC across studies. Formulas used to calculate the confidence intervals (CIs) of sensitivity, specificity, positive-predictive values (PPV), and negative-predictive values (NPV) were found in Lipsey and Wilson 2001, for likelihood ratios in Katz et al 1978, and for odds ratios (ORs) in Deeks 2001 (6-8). Due to the heterogeneity between studies, median PPVs were calculated only if PPVs were reported in at least four studies for any given sign or symptom. PPVs from each included study were used to calculate median PPVs for a given sign or symptom. (9)

**Quality Appraisal of Evidence-Based Guidelines and Systematic Reviews**

The Appraisal of Guidelines Research and Evaluation (AGREE II) tool was used by three independent methodologists to evaluate the quality of included evidence-based guidelines (10,11). Only clinical practice guidelines where the guideline objective was specifically described and the document included a review of the evidence were evaluated using the AGREE II tool. Systematic reviews and meta-analyses were assessed for quality using the ‘assessment of multiple systematic reviews’ tool, the AMSTAR tool (12).

**RESULTS**

**Literature Search Results**

Of 21,006 articles identified in the literature search done since the NICE and NZGG guidelines searches, 121 were deemed relevant for a full-article review (3,4). For the clinical question pertaining to the diagnostic accuracy of signs and symptoms in predicting CRC, a post hoc decision was made to focus on PPVs. Since PPVs are affected by the prevalence in the population, PPVs from primary studies conducted in the secondary care setting were excluded. Other excluded studies included those that did provide PPVs or PPVs could not be calculated, or where the main outcome was organic disease or polyps and not CRC. Therefore, 29 articles since the NICE and NZGG systematic reviews met the revised inclusion criteria and were retained (13-41). Nineteen articles were found in the updated literature search (42-61), 31 articles were found in reference lists of included articles (62-92), and one guideline was found during the environmental scan (9). In total, in addition to the NICE and NZGG guidelines, four guidelines, nine meta-analyses, two systematic reviews, and 66 primary studies were included (3,4,9,13-92). Table 1 summarizes the included articles for each research question.
### Table 1. Summary of literature used for each research question.

<table>
<thead>
<tr>
<th>Research Question</th>
<th>Guideline</th>
<th>Meta-analysis</th>
<th>Systematic review</th>
<th>RCT</th>
<th>Prospective studies</th>
<th>Retrospective studies</th>
<th>Case-control studies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Signs / symptoms</td>
<td>2*</td>
<td>6**</td>
<td>1</td>
<td>0</td>
<td>18</td>
<td>5</td>
<td>3</td>
</tr>
<tr>
<td>Tests</td>
<td>2*</td>
<td>2**</td>
<td>0</td>
<td>1</td>
<td>18</td>
<td>10</td>
<td>1</td>
</tr>
<tr>
<td>Risk factors</td>
<td>2*</td>
<td>2**</td>
<td>0</td>
<td>0</td>
<td>3</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Delay</td>
<td>3*</td>
<td>2</td>
<td>1</td>
<td>0</td>
<td>5</td>
<td>12</td>
<td>0</td>
</tr>
</tbody>
</table>

Abbreviation: RCT = randomized controlled trial.

* 2 guidelines for each research question were from NICE and NZGG (3,4)

** 2 meta-analyses for signs/symptoms and risk factors were from Jellema et al (47) and Olde Bekkink et al (50); Jellema et al (47) was also included in the tests section.

### Study Design and Quality Guidelines

The NICE and NZGG guidelines were evaluated using the AGREE II Tool as described in the Methods section (Table 2) (3,4). Although the overall quality of these recent guidelines was rated as high, the Working Group decided the recommendations needed to be modified to reflect the availability of resources among Ontario FPs and other PCPs and to align them with the Ontario Colorectal Screening Program (2). However, the NICE and NZGG clinical questions and recommendations were used as a framework in the development of this guideline. As well, the evidentiary base of the NICE and NZGG guidelines were used to formulate new recommendations.

Two other guidelines had lower overall AGREE II scores (Table 2). One guideline by the Association of Coloproctology of Great Britain and Ireland (2007) was based on a literature review and consensus that were not described in detail (9). That guideline was not used as a basis for the development of this guideline, but the reference lists were searched for additional articles. A consensus guideline by the Canadian Association of Gastroenterology provided recommendations for wait times in Canada (31). Its lower overall score was due to the lack of literature in this area, resulting in the recommendations being developed through consensus. The target wait times were used as a framework to develop the recommendations in this guideline.

### Table 2. Results of AGREE Tool quality rating of evidence-based guidelines.

<table>
<thead>
<tr>
<th>Guideline</th>
<th>Scope and Purpose (%)</th>
<th>Stakeholder Involvement (%)</th>
<th>Rigour of Development (%)</th>
<th>Clarity and Presentation (%)</th>
<th>Applicability (%)</th>
<th>Editorial Independence (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>NICE 2005 (3)</td>
<td>96.3</td>
<td>88.9</td>
<td>77.8</td>
<td>87.0</td>
<td>81.9</td>
<td>27.8</td>
</tr>
<tr>
<td>NZGG 2009 (4)</td>
<td>92.3</td>
<td>94.4</td>
<td>59.2</td>
<td>88.9</td>
<td>44.4</td>
<td>72.2</td>
</tr>
<tr>
<td>Irish 2007 (9)</td>
<td>81.5</td>
<td>50</td>
<td>48.6</td>
<td>92.6</td>
<td>8.3</td>
<td>0</td>
</tr>
<tr>
<td>Canadian (Paterson 2006) (31)</td>
<td>79.6</td>
<td>74.1</td>
<td>58.3</td>
<td>96.3</td>
<td>8.3</td>
<td>83.3</td>
</tr>
</tbody>
</table>

Abbreviations: NICE = National Institute for Health and Clinical Excellence; NZGG = New Zealand’s Guideline Group.

Two guidelines were not evaluated by the AGREE II Tool. A guideline developed through consensus by the British Society of Gastroenterology (2005) provided
recommendations for the management of iron-deficiency anemia (IDA) and did not include a literature search (62). In addition, the consensus process was not described in detail. The other report, by Lee and Laberge (2005), provided a diagnostic algorithm for the investigation of gastrointestinal bleeding (26). Although it did contain a narrative review of the literature, it was not clear whether the report was intended to be a clinical practice guideline.
**Reviews**

There were eleven systematic reviews found in the literature since the publication of the NICE and NZGG guidelines (3,4,18,22,28,32,33,42,44,47,48,50,54). One systematic review that investigated the diagnostic accuracy of signs or symptoms for CRC had a similar research question but included studies with asymptomatic patients and included studies where only one symptom was reported per patient (42). Since their inclusion criteria were different from this review, only the reference list was searched for additional articles. Table 3 shows how the ten remaining systematic reviews and meta-analyses scored on each of the 11 AMSTAR items. Six of the systematic reviews, five with meta-analyses, investigated the diagnostic accuracy of symptoms or signs for CRC (18,44,47,48,50,54). The five reviews with meta-analyses had high overall scores. Unlike this review, three of these reviews required the construction of two-by-two tables from the data (18,47,50) and one included signs or symptoms with PPVs greater than or equal to five percent (54). The systematic review without meta-analysis by John et al 2010 scored lower because the characteristics of included studies were not provided, and although the quality of each study was scored, the results for each study were not reported (48). Therefore, only the reference list for this article was searched for additional studies. Three other systematic reviews, two with meta-analyses, examined the factors associated with delay or the impact of delay on survival, and also had high overall AMSTAR scores (28,32,33). One meta-analysis by Koo (2006) investigating the diagnostic accuracy of minimal-preparation CT did not include a systematic review and, therefore, was scored lower (22).

**Table 3. Evaluation of included publications using AMSTAR.**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Was an ‘a priori’ design provided?</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>2. Was there duplicate study selection and data extraction?</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>N</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>3. Was a comprehensive literature search performed?</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>4. Was the status of publication (i.e., grey literature) used as an inclusion criterion?</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>N</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>5. Was a list of studies (included and excluded) provided?</td>
<td>N</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>N</td>
<td>Y</td>
<td>Y</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td>6. Were the characteristics of the included studies provided?</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>N</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>7. Was the scientific quality of the included studies assessed and documented?</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>N</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>8. Was the scientific quality of the included studies used appropriately in formulating conclusions?</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>N</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>9. Were the methods used to combine the findings of the studies appropriate?</td>
<td>Y</td>
<td>Y</td>
<td>NA</td>
<td>Y</td>
<td>NA</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>10. Was the likelihood of publication bias assessed?</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>N</td>
</tr>
<tr>
<td>11. Was the conflict of interest stated?</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td><strong>TOTAL AMSTAR POINTS</strong></td>
<td>8</td>
<td>9</td>
<td>10</td>
<td>5</td>
<td>3</td>
<td>7</td>
<td>8</td>
<td>9</td>
<td>9</td>
<td>8</td>
</tr>
</tbody>
</table>

**Abbreviations:** N = no; Y = yes; NA = Not applicable.
Primary Studies

The primary studies identified in the literature search, reference lists, and environmental scan included one randomized controlled trial (91); 35 prospective studies (14,16,17,21,23-25,27,34,35,37,45,49,58,61,64,65,68-71,73-75,77,79,80,82,85-90,92); 27 retrospective studies (13,15,19,29,36-41,43,46,51-53,55-57,59,60,63,66,67,76,78,81,83,84); and three case-control studies (20,30,72). The randomized controlled trial addressed the second research question, was not blinded, and was not performed in a primary care setting (91). Based on the Cochrane Collaboration method for assessing the methodological quality of diagnostic studies, using a modified QUADAS tool, several factors affected the quality of the included prospective, retrospective, and case-control studies (93). The details of these factors can be found in the evidence tables below. Some of these studies selected patients with specific signs or symptoms such as rectal bleeding and, therefore, may not be representative of the primary care population. Some studies did not recruit consecutive patients or were not blinded to the patients’ diagnoses. There were also studies that did not adequately explain the missing or uninterpretable data or the reasons for patient withdrawals. In addition, the gold standard of colonoscopy for detecting CRC was not always used.

Outcomes

1. What signs, symptoms and other clinical features that present in primary care are predictive of CRC?

To facilitate relative comparisons between clinical features with screen-positive FOBTs, the evidence summaries below report PPVs. PPV is the probability that the disease is truly present when the test is positive. The majority of studies reported PPVs or the PPV could be easily calculated. The estimated PPV for the detection of CRC, using Hema Screen, the FOBT used in the Ontario ColonCancerCheck screening program, of single (one-time) testing in asymptomatic patients was 10.9% (94). The combined median PPV for all guaiac FOBTs evaluated in a recent review was 5.7% (94). Therefore, PPVs in symptomatic patients greater than 5% and 10% are specifically highlighted in the summaries that follow. Since the focus was on PPVs, and PPVs are affected by the prevalence of the disease in the population, we only included PPVs from studies performed in primary care populations, although we did report the findings from two meta-analyses (18,47) that included secondary care studies, because their results focused on primary care referral. Jellema et al included secondary care studies only if the prevalence of CRC was less than 15%, which was the highest prevalence reported in the primary care studies (47). Two studies that were considered primary care in the Ford et al (2008) meta-analysis were categorized as secondary care studies in the Jellema et al meta-analysis (18,47). Based on the opinion of our Working Group, we have included these studies as primary care studies (82,92). Furthermore, we have included the studies conducted in the United Kingdom (UK) two-week referral clinics as primary care studies, because they were at the interface between primary and secondary care (13,61,67,71). These studies have been noted in the tables and appendices. The meta-analysis by Olde Bekkink et al (2010) included studies only from primary care, but all the studies selected for patients with rectal bleeding (50).

The PPVs of signs or symptoms and results from regression analyses can be found in the evidence tables (Appendices 4-14). Other pooled diagnostic parameters such as sensitivity, specificity, and positive-likelihood ratios are reported from the meta-analyses (Appendix 15). Study characteristics are provided in Table 4 and calculated median PPVs in Table 5. Studies were from the updated literature search done since the NZGG and NICE reports and reference lists and studies found in the NICE and NZGG reports. Since NICE and NZGG did not focus on PPVs and organized the data within the context of each study rather
than each symptom or sign, the data in this review may not be easily compared to the data in these original reviews.

Table 4. Study characteristics for clinical questions about signs, symptoms or risk factors of colorectal cancer.

<table>
<thead>
<tr>
<th>Author</th>
<th>Study, country, setting</th>
<th>No. of patients</th>
<th>No. of patients with CRC (%)</th>
<th>Investigation used</th>
<th>Consecutive patients</th>
<th>Blinded to index</th>
<th>Missing / uninterpretable data explained</th>
<th>Withdrawals explained</th>
</tr>
</thead>
<tbody>
<tr>
<td>Astin 2011</td>
<td>Meta-analysis, UK, primary care</td>
<td>23 studies, 81,464 patients</td>
<td>0.4%-23.2%</td>
<td>various</td>
<td>various</td>
<td>various</td>
<td>various</td>
<td>various</td>
</tr>
<tr>
<td>Barwick 2004</td>
<td>Retrospective between January and August 2001, UK, Primary care (2WW)</td>
<td>144</td>
<td>14 (10)</td>
<td>various including barium enema, FS, ultrasound, colonoscopy</td>
<td>unclear</td>
<td>no</td>
<td>unclear</td>
<td>yes</td>
</tr>
<tr>
<td>Bat 1992</td>
<td>Prospective, Israel, primary care</td>
<td>101 ≥80 yrs with rectal bleeding</td>
<td>29 (29)</td>
<td>all colonoscopy</td>
<td>unclear</td>
<td>no</td>
<td>no</td>
<td>no</td>
</tr>
<tr>
<td>Chohan 2005</td>
<td>Retrospective over 18-month period, UK, Primary care 2WW referral</td>
<td>462</td>
<td>64 (13.8)</td>
<td>unclear, but included histopathology</td>
<td>yes</td>
<td>no</td>
<td>yes</td>
<td>yes</td>
</tr>
<tr>
<td>du Toit 2006</td>
<td>Prospective, UK, Primary care</td>
<td>265 Age ≥45 yrs, with rectal bleeding</td>
<td>15 (5.7)</td>
<td>mostly sigmoidoscopy with barium enema, FS, or colonoscopy; f/u 10 yrs 3 mths</td>
<td>yes</td>
<td>no</td>
<td>no</td>
<td>yes</td>
</tr>
<tr>
<td>Ellis 2005</td>
<td>Prospective, UK, primary care</td>
<td>319 with rectal bleeding</td>
<td>11 (3.4)</td>
<td>FS and barium enema or colonoscopy; f/u 18 mths</td>
<td>yes</td>
<td>unclear</td>
<td>yes</td>
<td>yes</td>
</tr>
<tr>
<td>Fijten 1995</td>
<td>Prospective from September 1988 to April 1990, Netherlands, primary care</td>
<td>269 with rectal bleeding</td>
<td>9 (3)</td>
<td>endoscopy, radiography, sigmoidoscopy, proctoscopy, sonography; f/u at least 1 yr</td>
<td>yes</td>
<td>yes</td>
<td>unclear</td>
<td>yes</td>
</tr>
<tr>
<td>Flashman 2004</td>
<td>Prospective over 1-yr period, UK, primary or secondary 2WW referral</td>
<td>695</td>
<td>65 (9) with bowel cancer</td>
<td>NR</td>
<td>yes</td>
<td>no</td>
<td>yes</td>
<td>yes</td>
</tr>
<tr>
<td>Ford 2008</td>
<td>Meta-analysis, Canada, primary and secondary care</td>
<td>15 prospective studies included</td>
<td>6% (5% to 8%)</td>
<td>colonoscopy, barium enema, CT colography, FS or any combination of the four</td>
<td>various</td>
<td>various</td>
<td>various</td>
<td>various</td>
</tr>
<tr>
<td>Hamilton 2008</td>
<td>Case control, UK, primary care records</td>
<td>3183 cases, 10,514 controls</td>
<td>3183</td>
<td>Electronic records, Hb taken in year</td>
<td>no</td>
<td>unclear</td>
<td>yes</td>
<td>unclear</td>
</tr>
<tr>
<td>Author</td>
<td>Study, country, setting</td>
<td>No. of patients</td>
<td>No. of patients with CRC (%)</td>
<td>Investigation used</td>
<td>Consecutive patients</td>
<td>Blinded to index</td>
<td>Missing / uninterpretable data explained</td>
<td>Withdrawals explained</td>
</tr>
<tr>
<td>-----------------</td>
<td>----------------------------------------------</td>
<td>-----------------</td>
<td>------------------------------</td>
<td>--------------------</td>
<td>---------------------</td>
<td>------------------</td>
<td>----------------------------------------</td>
<td>----------------------</td>
</tr>
<tr>
<td>Hamilton 2005 (72)</td>
<td>Case control, UK, Primary care records</td>
<td>349 cases, 1744 controls</td>
<td>349</td>
<td>Cancer registry</td>
<td>no</td>
<td>Yes to case/ control status</td>
<td>yes</td>
<td>yes</td>
</tr>
<tr>
<td>Heintz 2005 (21)</td>
<td>Prospective over 1-yr period, Germany, Primary care</td>
<td>422 with first sign of rectal bleeding</td>
<td>17 (4.0)</td>
<td>colonoscopies (n=195), rectoscopies (n=29), sigmoidoscopies (n=26)</td>
<td>no</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
</tr>
<tr>
<td>Helfand 1997 (73)</td>
<td>Prospective, USA, Primary care</td>
<td>201 with rectal bleeding</td>
<td>13 (6.5)</td>
<td>all sigmoidoscopy and barium enema, f/u 6-12 mths</td>
<td>no</td>
<td>no</td>
<td>yes</td>
<td>yes</td>
</tr>
<tr>
<td>Jellem 2010 (47)</td>
<td>Meta-analysis, Netherlands, Primary and secondary care</td>
<td>47 studies included</td>
<td>3%-15%</td>
<td>various</td>
<td>various</td>
<td>various</td>
<td>various</td>
<td>various</td>
</tr>
<tr>
<td>Jones 2007 (76)</td>
<td>Retrospective from January 1994 to December 2000, UK, Primary care records</td>
<td>7523 men, 7766 women with rectal bleeding</td>
<td>184 (2.4) men, 154 (2.0) women</td>
<td>NR from research database</td>
<td>no</td>
<td>no</td>
<td>yes</td>
<td>yes</td>
</tr>
<tr>
<td>Lawremson 2005 (24)</td>
<td>Prospective, UK, Primary care records</td>
<td>2,793,468 (age 40-89 yr)</td>
<td>9143 (0.3% CRC after at least 1-yr f/u)</td>
<td>Medical database (symptoms included after 1-yr f/u)</td>
<td>yes</td>
<td>no</td>
<td>no</td>
<td>yes</td>
</tr>
<tr>
<td>Mant 1989 (77)</td>
<td>Prospective over 11 months, Australia, Primary care</td>
<td>145 Age &gt;40 yr with rectal bleeding</td>
<td>16 (11)</td>
<td>mainly colonoscopy, some FS and air contrast barium enema; histopathology</td>
<td>yes</td>
<td>no</td>
<td>unclear</td>
<td>yes</td>
</tr>
<tr>
<td>Metcalf 1996 (90)</td>
<td>Prospective, UK, Primary care</td>
<td>99 Age &gt;40 yrs with rectal bleeding</td>
<td>8 (8)</td>
<td>all colonoscopy, histopathology</td>
<td>yes</td>
<td>no</td>
<td>yes</td>
<td>yes</td>
</tr>
<tr>
<td>Muris 1993 (79)</td>
<td>Prospective over 15-month period, Netherlands, Primary care</td>
<td>578 with abdominal pain</td>
<td>3 (0.5)</td>
<td>X-ray, sonogram, endoscopy; f/u 15 mths</td>
<td>yes</td>
<td>unclear</td>
<td>no</td>
<td>yes</td>
</tr>
<tr>
<td>Norrelund 1996 (80)</td>
<td>Prospective, study 1: 1989-1991, study 2: 1991-1992, Denmark, primary care</td>
<td>study 1 = 208, study 2 = 209; all with rectal bleeding</td>
<td>study 1 = 32(15%), study 2 = 22(11%); excluded from analysis: if current bleeding</td>
<td>Possibly barium enema/colonoscopy; microscopically verified; f/u study 1: 32-57 mths, study 2: 22-36 mths</td>
<td>yes</td>
<td>unclear</td>
<td>no</td>
<td>yes</td>
</tr>
<tr>
<td>Author</td>
<td>Study, country, setting</td>
<td>No. of patients</td>
<td>No. of patients with CRC (%)</td>
<td>Investigation used</td>
<td>Consecutive patients</td>
<td>Blinded to index</td>
<td>Missing / uninterpretable data explained</td>
<td>Withdrawals explained</td>
</tr>
<tr>
<td>-------------------------</td>
<td>-------------------------</td>
<td>-----------------</td>
<td>------------------------------</td>
<td>--------------------</td>
<td>----------------------</td>
<td>------------------</td>
<td>------------------------------------------</td>
<td>----------------------</td>
</tr>
<tr>
<td>Olde Bekkink 2010 (50)</td>
<td>Meta-analysis, Ireland, Scotland, Netherlands, Primary care</td>
<td>8 prospective studies, patients with rectal bleeding</td>
<td>7.0%</td>
<td>various</td>
<td>various</td>
<td>various</td>
<td>various</td>
<td>various</td>
</tr>
<tr>
<td>Panzuto 2003 (82)</td>
<td>Prospective over 8-week period, Italy, Primary care</td>
<td>280 exclude previous CRC diagnosis, recent large bowel examination</td>
<td>41 (14.6)</td>
<td>all colonoscopy or barium enema</td>
<td>yes</td>
<td>no</td>
<td>yes</td>
<td>yes</td>
</tr>
<tr>
<td>Park 2009 (30)</td>
<td>Nested case control, UK, primary care</td>
<td>159 cases and 771 controls</td>
<td>159</td>
<td>National cancer registry, avg 12-yr f/u</td>
<td>no</td>
<td>unclear</td>
<td>unclear</td>
<td>yes</td>
</tr>
<tr>
<td>Parker 2007 (83)</td>
<td>Retrospective over three mths, Spain, primary care</td>
<td>29,007 Age ≥25 yrs with rectal bleeding;</td>
<td>645 (2.2)</td>
<td>Primary care UK electronic records, f/u 2 yrs</td>
<td>yes</td>
<td>no</td>
<td>yes</td>
<td>yes</td>
</tr>
<tr>
<td>Robertson 2006 (34)</td>
<td>Prospective, 1996-1999, UK, primary care</td>
<td>604 with rectal bleeding</td>
<td>22 (3.6)</td>
<td>all FS, hospital records; f/u at least 4 yrs</td>
<td>no</td>
<td>no</td>
<td>yes</td>
<td>yes</td>
</tr>
<tr>
<td>Sanchez 2005 (85)</td>
<td>Prospective during 9-month period, Norway, Primary care</td>
<td>126 with rectal bleeding with 63 over 50 yrs old</td>
<td>6 (4.8)</td>
<td>all colonoscopy</td>
<td>yes</td>
<td>no</td>
<td>yes</td>
<td>yes</td>
</tr>
<tr>
<td>Shapley 2010 (54)</td>
<td>Meta-analysis, UK, primary care</td>
<td>25 studies, 12 studies included in meta-analysis</td>
<td>various</td>
<td>various</td>
<td>various</td>
<td>various</td>
<td>various</td>
<td>various</td>
</tr>
<tr>
<td>Steine 1994 (92)</td>
<td>Prospective over five-yr period, UK, primary care</td>
<td>1852</td>
<td>55 (3.0)</td>
<td>all barium enema</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
</tr>
<tr>
<td>Stellon 1997 (86)</td>
<td>Prospective over 8-week period, Italy, Primary care</td>
<td>26 over 50 yrs with iron deficiency anemia</td>
<td>2 (7.7)</td>
<td>26 had FS and 22 had DCBE</td>
<td>yes</td>
<td>no</td>
<td>yes</td>
<td>yes</td>
</tr>
<tr>
<td>Wauters 2000 (89)</td>
<td>Prospective, 1993-1994, Belgium, Primary care</td>
<td>386 with rectal bleeding</td>
<td>27 (7.0)</td>
<td>endoscopy in some cases, others not reported; CRC histologically confirmed; f/u 18-30 mths</td>
<td>yes</td>
<td>unclear</td>
<td>yes</td>
<td>unclear</td>
</tr>
<tr>
<td>Yates 2004 (41)</td>
<td>Retrospective from June 1997 to May 2001, UK</td>
<td>431 with IDA; excluded history of anemia</td>
<td>37 (8.6)</td>
<td>various, f/u at least 12 mths</td>
<td>yes</td>
<td>no</td>
<td>yes</td>
<td>yes</td>
</tr>
<tr>
<td>Author</td>
<td>Study, country, setting</td>
<td>No. of patients</td>
<td>No. of patients with CRC (%)</td>
<td>Investigation used</td>
<td>Consecutive patients</td>
<td>Blinded to index</td>
<td>Missing / uninterpretable data explained</td>
<td>Withdrawals explained</td>
</tr>
<tr>
<td>--------</td>
<td>------------------------</td>
<td>-----------------</td>
<td>-------------------------------</td>
<td>--------------------</td>
<td>---------------------</td>
<td>----------------</td>
<td>---------------------------------------</td>
<td>---------------------</td>
</tr>
<tr>
<td></td>
<td>within previous 12 mths or known hematologic abnormalities</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations:** Avg = average; CRC = colorectal cancer; CT = computed tomography; f/u = follow-up; FS = flexible sigmoidoscopy; Hb = hemoglobin; IBD = irritable bowel disease; IDA = iron-deficiency anemia; mths = months; No. = number; NR = not reported; 2WW = two-week wait; UK = United Kingdom; yr = year.
Table 5. Calculated median PPVs for signs or symptoms.

<table>
<thead>
<tr>
<th>Study (sample size)</th>
<th>RB</th>
<th>RB first episode</th>
<th>RB &amp; male</th>
<th>RB female</th>
<th>RB ≥50 yrs or RB ≥55 yrs</th>
<th>RB ≥60 yrs or RB ≥65 yrs</th>
<th>RB ≥70 yrs or RB ≥75 yrs</th>
<th>RB dark</th>
<th>RB mixed with stool</th>
<th>RB &amp; no perianal symptoms</th>
<th>RB &amp; ABD pain</th>
<th>RB &amp; WT loss</th>
<th>CBH or diarrhea</th>
<th>RB &amp; CBH</th>
<th>RB &amp; diarrhea</th>
<th>IDA</th>
<th>Wt loss</th>
<th>ABD pain</th>
</tr>
</thead>
<tbody>
<tr>
<td>Parker 2007 (83)</td>
<td>2.2</td>
<td>2.2</td>
<td></td>
<td></td>
<td>4.0</td>
<td>4.6</td>
<td>4.9</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jones 2007 (76)</td>
<td>2.2</td>
<td>2.2</td>
<td>2.4</td>
<td>2.0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hamilton 2005 (72)</td>
<td>2.4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Steine 2004 (92)</td>
<td>5.9</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flashman 2004 (71)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Robertson 2006 (34)</td>
<td>3.6</td>
<td>4.8</td>
<td>2.7</td>
<td>5.7</td>
<td>7.5</td>
<td>7.4</td>
<td>5.4</td>
<td>1.7</td>
<td>4.8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Muris 1993 (79)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chohan 2005 (67)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yates 2004 (41)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heintze 2005 (21)</td>
<td>4.0</td>
<td>4.0</td>
<td></td>
<td></td>
<td>5.6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Norrelund 1996 (80)</td>
<td>14</td>
<td>14</td>
<td>17</td>
<td>13</td>
<td>31</td>
<td>23</td>
<td>23</td>
<td>27</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wauters 2000 (89)</td>
<td>7.0</td>
<td></td>
<td></td>
<td></td>
<td>11</td>
<td>13</td>
<td>15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ellis 2005 (17)</td>
<td>3.4</td>
<td>4.7</td>
<td></td>
<td></td>
<td>5.2</td>
<td>9.7</td>
<td>3.0</td>
<td>11</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Panzuto 2003 (82)</td>
<td>16</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fitjen 1995 (70)</td>
<td>3.3</td>
<td>5.2</td>
<td>5.9</td>
<td>1</td>
<td>20</td>
<td>14</td>
<td>2.2</td>
<td>9.5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Study (sample size)

<table>
<thead>
<tr>
<th>Study (sample size)</th>
<th>RB &amp; male</th>
<th>RB &amp; female</th>
<th>RB &amp; no perianal symptoms</th>
<th>CBH or diarrhea</th>
<th>IDA</th>
<th>Wt loss</th>
<th>ABD pain</th>
</tr>
</thead>
<tbody>
<tr>
<td>du Toit 2006 (69)</td>
<td>5.7</td>
<td>5.7</td>
<td>6.1 8.6 7.9</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(n=265)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Helfand 1997 (73)</td>
<td>6.5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(n=201)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mant 1989 (77)</td>
<td>10</td>
<td>9.1</td>
<td>13 17 21 9.3 14 11</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(n=145)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Barwick 2004 (13)</td>
<td>16</td>
<td>5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(n=144)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sanchez 2005 (126)</td>
<td>4.8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(n=144)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metcalf 1996 (90)</td>
<td>8.1</td>
<td>8.1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(n=99)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stellon 1997 (86)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(n=26)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Median across studies</strong></td>
<td>5.3 5.0 7.5 3.9 5.9 8.6 7.9 9.7 11 10.8 5.1 13 7.5 10.5 9 11 4.9 2.1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations:** ABD = abdominal; CBH = change in bowel habits; IDA = iron-deficiency anemia; RB = rectal bleeding; Wt = weight; yrs = years.
Rectal Bleeding

Twenty-one studies provided PPVs on rectal bleeding as a single presenting symptom (13,17,19,24,34,65,67,69-73,76,77,80,82,83,85,89,90,92). Rectal bleeding as a broad classification had PPVs ranging from 2.2% to 16% in 16 studies, with a median value of 5.3% (Table 5) (17,21,34,69,70,72,73,76,77,80,82,83,85,89,90,92). Half of those studies had PPVs greater than or equal to 5% (69,73,77,80,82,85,89,90,92). Similarly, three meta-analyses calculated pooled PPVs for rectal bleeding between 5% and 8% (44,47,54).

The PPVs of rectal bleeding characterized as new was reported in eight studies and had a median of 4.95% (17,21,69,70,76,80,83,90). Ellis et al (2005) and Fitjen et al (1995) found that patients with a previous history of rectal bleeding had lower PPVs (3.8% and 0%, respectively) compared to rectal bleeding presented as a first episode (4.7% and 5.2%, respectively) (Appendix 4) (17,70).

Five of six studies found higher PPVs for males than for females, collapsed across all ages (13,34,70,76,77,80). The median PPV for males with rectal bleeding was 7.5%, ranging from 2.4% to 17%, whereas for females, the median PPV was calculated to be 3.9%, ranging from 1% to 13% (Table 5). In addition, PPVs for rectal bleeding tended to increase with age. Patients in their fifties or older with rectal bleeding had a median PPV of 5.9%, whereas patients in their sixties or older had a median PPV of 8.6% (Table 5) (17,21,34,69,70,83,85,89).

Patients in their seventies or older with rectal bleeding had a median PPV of 7.9% for CRC (34,69,80,83,89). These findings likely reflect higher incidence rates of CRC from ages 60 to 79 (95). Both Lawrenson et al (2005) and Jones et al (2007) also observed increasing CRC with the increasing age of both males and females presenting with rectal bleeding; however, males had higher PPVs within each age group compared to females in the same age group (Appendix 4) (24,76). In addition, using multivariate analysis with a large sample of 29,007 patients with rectal bleeding, Parker et al (2007) found that the risk of CRC was strongly associated with age and was higher in males than in females (Appendix 14) (83).

Four studies examined rectal bleeding without anal symptoms such as hemorrhoids and found PPVs ranging from 6.9% to 18% with a median of 10.8% (Table 5) (13,17,67,71). Ellis et al found that bleeding and no perianal symptoms had a PPV of 11%, whereas bleeding with perianal symptoms had a PPV of only 2.0% (17).

The PPVs of rectal bleeding also varied depending on the colour or shade of blood and the location of blood in relation to stool. Four studies investigating dark rectal bleeding found PPVs from 7.4% to 17%, with a median PPV of 9.7% (Table 5) (17,34,77,90). The PPV of bright red blood in three of these studies ranged from 4.0% to 9.9% (17,77,90). Five studies with PPVs for rectal bleeding mixed with stool had a median of 11%, ranging from 3% to 21% (Table 5) (17,34,70,77,90). Robertson et al (2006) found higher PPV values when rectal blood was mixed with stool (5.4%) or was dark (7.4%) or was both mixed with stool and dark (10%), compared to when it was neither dark nor mixed with stool (1.9%) (34). Mant et al (1989) also found higher PPV values when rectal bleeding was dark (17%) or mixed with stool (21%), compared to when rectal bleeding was bright (9.9%) or separate from stool (6.6%) (77). Similarly, Metcalf et al (1996) found dark rectal bleeding had a higher PPV (9.7%) than bright rectal bleeding (8.6%), and Fitjen et al (1995) found rectal bleeding mixed with stool had a higher PPV (14%) than did rectal bleeding seen on or mixed with stool (7%) (70,90).

Furthermore, Ellis et al (2005) found dark rectal bleeding had a PPV of 9.7% compared to 4.0% for bright blood, although rectal blood mixed with stool had a PPV of 3% compared to 4.3% for rectal bleeding not mixed with stool (17).

In regression analysis, rectal bleeding (72,92), including blood mixed with stool (34,70), was a significant predictor of CRC in four studies. Three meta-analyses found higher specificity but lower sensitivity for dark rectal bleeding (minimum-maximum=sensitivity 15%-35%, specificity 84%-96%) (18,47,50). The high level of pooled specificity led Ford et al (2008)
to conclude that dark rectal bleeding would be useful in prioritizing patients for referral in primary care (18). Likewise, Jellema et al, using bivariate analysis, found that patients with dark rectal bleeding had a significantly higher risk of CRC than did those without dark rectal bleeding (47). They calculated a pooled PPV, from primary and secondary care studies, of 7% for rectal bleeding, 14% for dark rectal bleeding, and 6% for blood mixed with stool.

Olde Bekkink et al and Jellema et al found modest diagnostic performance for blood mixed with stool with higher specificity but lower sensitivity for CRC (sensitivity 40% and 51%, specificity 81% and 71%, respectively) (47,50). However, Olde Bekkink et al suggested this symptom should lead to referral for further investigation, because it nearly doubled the post-test probability of CRC (pooled likelihood ratio=1.91; 95% confidence interval [CI], 0.75 to 5.51) (50).

**Change in Bowel Habits**

Six studies provided information regarding change in bowel habits as predictors of CRC (24,67,71,72,82,92). Two studies investigated undefined or undifferentiated change in bowel habits (82,92), three studies investigated diarrhea (67,72,82), and two studies examined constipation (72,82). The PPV for change in bowel habits or diarrhea ranged from 0.94% to 14%, with a median of 7.5% (Table 5) (67,72,82,92). If PPVs were reported for change in bowel habits as well as diarrhea in any given study, the lesser PPV was included in the calculation. Based on Lawrenson et al (2005), the PPVs of change in bowel habit appear to increase with age and differ between men and women (24). The PPV for men at ten-year age bins was greater than 5% beginning at 60 years, whereas for women the PPV never exceeded 4.09% even in the oldest age group.

In regression analysis, change in bowel habits including constipation or diarrhea was found to be a significant predictor of CRC in three studies (70,72,80). One study examining the association between the characteristics of changes in bowel habit and risk of CRC found that loose stools significantly increased the risk of CRC compared to soft stools after adjusting for age, sex, and lifestyle variables (30). Frequency of bowel movement, stool quantity, feelings of discomfort, and laxative use were not significantly associated with risk of CRC.

All three meta-analyses found that change in bowel habits showed poor diagnostic performance (minimum-maximum-sensitivity 41%-62%, specificity 61%-69%) (18,47,50). Diarrhea or constipation as single symptoms showed poor diagnostic performance with slightly higher specificity ranging from 72% to 80% but a low sensitivity of 13% to 20% (18,47). Jellema et al calculated a pooled PPV of 9% for change in bowel habits and pooled PPVs of 6% for diarrhea or constipation (47). However, studies included from primary care selected for patients with rectal bleeding; therefore, the PPVs were for patients with rectal bleeding and change in bowel habits.

**Anemia or Iron-Deficiency Anemia (IDA)**

Nine studies provided PPVs for anemia or IDA as predictors of CRC (13,20,24,41,67,71,72,82,86). Hamilton et al (2005) and Hamilton et al (2008) provided PPVs for anemia for both men and women combined at two hemoglobin levels (100-130 g/L: PPV, 0.97%; <100 g/L: PPV, 2.3%; 100-129 g/L: PPV, 0.3%; <99 g/L: PPV=2.0%, respectively) (20,72). Two studies by Hamilton et al (2008) and Lawrenson et al (2005) had PPVs for anemia for men or women at different age groups (20,24). In both studies, PPVs generally increased with age and were higher in males than in females. The highest PPVs in the Lawrenson et al study were found among males with anemia aged 70-79 with a PPV of 3.38% and among women with anemia aged 80-89 with a PPV of 2.01% (24). In the Hamilton et al (2008) study, PPVs were higher than 5% in males or females greater than 60 years old, divided into ten-year age bins, and with hemoglobin levels less than 90 g/L (20). Males aged 60-69 or greater than
79 years and with hemoglobin levels of 90-99 g/L also had PPVs greater than 5%. In most cases, these PPVs increased to greater than 10% if the patients had IDA as well. Four of six primary care studies that examined IDA in both males and females also found PPVs higher than 10% and ranged from 7.7% to 41%, with a median of 11% (Table 5) (13,41,67,71,82,86).

In regression analyses, three studies included anemia or IDA and associated features of iron deficiency in their regression models (20,72,82). Both Hamilton et al (2005, 2008) case-control studies found lower hemoglobin categories were significantly associated with increased CRC risk (20,72). Furthermore, microcytosis (mean cell or corpuscular volume [MCV] <80.0 fl) and low ferritin (<20 ng/mL) were both strongly associated with CRC (20). Panzuto et al (2003) also found IDA (Hb <140 g/L for males and <120 g/L for females, with ferritin <30 µg/L and MCV of <80 fl) to be a significant predictor of CRC (82).

All three meta-analyses found higher specificity for anemia and/or IDA but poorer sensitivity for either test (minimum-maximum=sensitivity 13%-23%, specificity 87%-95%) (18,47,50). Olde Bekkink et al found that IDA had the highest pooled likelihood ratio of 3.67 (95% CI, 1.30 to 10.35) of all signs or symptoms reported (50). They suggested that IDA was predictive of CRC and required further diagnostic testing.

Rectal or Abdominal Mass

Three studies provided PPVs for rectal or abdominal masses as predictors of CRC (13,67,71) and were all conducted in the UK in two-week referral clinics. Chohan et al (2005) and Flashman et al (2004) found PPVs greater than 10% for rectal or abdominal masses (67,71). Barwick et al (2004) found a PPV for CRC of 17% when patients had either an abdominal or rectal mass (13). A meta-analysis by Ford et al (2008) found that finding an abdominal mass had a high level of a pooled specificity of 96%, and they suggested that this alarm feature would be helpful in prioritizing patients for referral to a specialist (18).

Weight Loss

Four studies had PPVs for weight loss as a predictor of CRC (Table 5) (13,72,82,92). The PPVs ranged from 1.2% to 36% and had a median of 4.9%. In regression analysis, loss of weight was found to be a significant predictor in two studies (72,92). All three meta-analyses found high specificity (minimum-maximum=89%-91%) but low sensitivity for weight loss (minimum-maximum=17%-22%) (18,47,50). Jellema et al suggested that only weight loss had some diagnostic value because of its high specificity (47). They calculated a pooled PPV of 9%, but all studies from primary care selected for patients with rectal bleeding. Olde Bekkink et al proposed that weight loss should lead to referral for further investigation, because it almost doubled the post-test probability of CRC (pooled likelihood ratio, 1.89; 95% CI, 1.03 to 3.07) (50).

Abdominal Pain

Five studies had PPVs for abdominal pain or bloating as a predictor of CRC (13,72,79,82,92). For abdominal pain, PPVs ranged from 0.5% to 13%, with a median of 2.1% (Table 5). Astin et al 2011 calculated a pooled PPV with three studies of 3.29% (44). In regression analysis, abdominal pain and abdominal tenderness were each reported as significant predictors in Hamilton et al (2005) (72). Jellema et al found poor diagnostic performance and heterogeneity in sensitivity and specificity (pooled: sensitivity 35%, specificity 59%) across studies investigating abdominal pain (47). They calculated a pooled PPV of 5% from primary and secondary care studies. Olde Bekkink et al found poor diagnostic performance (pooled: sensitivity 25%, specificity 73%) and a lower positive-likelihood ratio for abdominal pain (0.94, 0.19-1.59) than for other symptoms (50).
Symptom Combinations

Ten studies provided PPVs for symptoms combinations (17,34,67,70-72,77,80,89,90). The Hamilton et al (2005) case-control study included a figure with PPVs for various symptom combinations (72) and found that all PPVs were higher when there was a combination of symptoms compared to the PPVs of single symptoms. The only exception was rectal bleeding and constipation, where the PPV remained unchanged compared to rectal bleeding as a single symptom (PPV=2.4%). PPVs for symptom combinations with a least three studies available are described below.

Rectal Bleeding and Change in Bowel Habit

Nine studies provided PPVs for rectal bleeding and change in bowel habits including diarrhea as presenting symptoms (Table 5)(17,34,67,70-72,77,80,90). Six of these studies selected for patients with rectal bleeding (17,34,70,77,80,90). Four studies included PPVs for rectal bleeding and change in bowel habits undefined (17,77,80,90). In all of these studies, PPVs were higher with the combination of rectal bleeding and change in bowel habits compared to rectal bleeding alone. The PPVs ranged from 9.2% to 27% and had a median of 10.5%. Similarly, Astin et al reported a pooled PPV of 11.8% (44). Seven studies reported PPVs for patients with rectal bleeding and diarrhea (17,34,67,70-72,90). The median PPV was 9% and ranged from 3.4% to 19%. Three studies found higher PPVs for the combination of rectal bleeding with diarrhea compared to rectal bleeding with constipation (17,72,90).

Rectal Bleeding and Weight Loss

Seven studies had PPVs for rectal bleeding and weight loss as a combination of symptoms (34,70,72,77,80,89,90). Six of these studies selected patients with rectal bleeding (34,70,77,80,89,90). In all of these studies, PPVs were higher with the combination of rectal bleeding and weight loss compared to rectal bleeding alone. The PPVs ranged from 4.7% to 23% and had a median of 13%. Astin et al 2011 also found a pooled PPV of 13.4% for this combination of symptoms (44).

Rectal Bleeding and Abdominal Pain

Six studies included PPVs for rectal bleeding and abdominal pain as presenting symptoms (34,70,72,77,80,90). Five of these studies selected for patients with rectal bleeding (34,70,77,80,90). For only two of the six studies, the combination of rectal bleeding and abdominal pain had a higher PPV compared to rectal bleeding alone. The PPVs ranged from 1.7% to 23%, with a median of 5.1%. Astin et al 2011 found a pooled PPV of 7.58% for rectal bleeding and abdominal pain (44).

Rectal Bleeding and Hemorrhoids

The PPVs for rectal bleeding with hemorrhoids were reported in three studies (34,70,77). All of these studies selected for patients with rectal bleeding. The PPVs were from 3.1% to 10%.

Summary/Interpretation

In summary, based on the a priori criteria of a PPV of 10%, FPs and other PCPs should make referrals for the following signs and symptoms considered predictive of CRC: dark rectal bleeding, rectal bleeding mixed with stool, rectal bleeding in the absence of perianal symptoms, rectal bleeding combined with change in bowel habits, rectal bleeding combined with weight loss, and IDA. The evidence also suggests that the PPVs of combinations of symptoms are higher than PPVs of single symptoms.
2. What is the diagnostic accuracy of investigations commonly considered for patients presenting with signs and/or symptoms of CRC?

The study characteristics are listed in Table 6. The studies were from the updated literature search (done since the NZGG and NICE searches), the reference lists, and the NICE and NZGG reports (3,4). Since we did not specifically focus on PPVs for the diagnostic accuracy of tests, studies from secondary care were included. In addition, NICE and NZGG organized the data within the context of each study rather than each test; therefore, the data in this review are not easily compared to the data in those reviews (3,4). Colonoscopy is considered the gold standard for working up symptomatic patients with signs or symptoms suspicious of CRC. The following tests are compared to colonoscopy where possible to provide FPs and other PCPs with some perspective of test utility where colonoscopy is delayed or not possible. The outcomes from the studies can be found in Appendix 16.

Table 6. Study characteristics for clinical question about diagnostic tests for colorectal cancer.

<table>
<thead>
<tr>
<th>Author</th>
<th>Study, country, setting</th>
<th>No. of patients</th>
<th>No. of patients with CRC (%)</th>
<th>Investigation used</th>
<th>Consecutive patients</th>
<th>Blinded to index/standard</th>
<th>Missing/uninterpretable data explained</th>
<th>Withdrawals explained</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andersen</td>
<td>Retrospective over 3-yr period, NZ, Secondary care</td>
<td>89 with CRC</td>
<td>89</td>
<td>SCBE or DCBE vs. colonoscopy</td>
<td>yes</td>
<td>no/no</td>
<td>yes</td>
<td>yes</td>
</tr>
<tr>
<td>Andersen</td>
<td>Retrospective over 3-yr period, UK, primary and secondary care</td>
<td>978, excluded patients with cancers other than CRC</td>
<td>78 (8.0)</td>
<td>Pathology records 3 yrs following 2WW referral</td>
<td>yes</td>
<td>no/no</td>
<td>yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Bjerregaard</td>
<td>Prospective, Denmark, primary/secondary care</td>
<td>256 without CRC</td>
<td>8 (3.1)</td>
<td>Hemoccult Sensa® FOBT; either colonoscopy or FS, one patient had FS and DBCE/virtual colonoscopy; mean f/u 18.1 mths</td>
<td>no</td>
<td>no/yes</td>
<td>yes</td>
<td>yes</td>
</tr>
<tr>
<td>Brewster</td>
<td>Retrospective over 3-yr period, UK, Primary &amp; Secondary care</td>
<td>462</td>
<td>21 (4.5)</td>
<td>Barium enema and/or FS vs. colonoscopy</td>
<td>unclear</td>
<td>no/yes</td>
<td>yes</td>
<td>unclear</td>
</tr>
<tr>
<td>Chen</td>
<td>Prospective from Jan 2001 to July 2004, Taiwan, Tertiary care</td>
<td>511 with abdominal distension</td>
<td>97 (19)</td>
<td>Ultrasonography vs. colonoscopy (for positive f/u); CT scan (for negative f/u); histologically confirmed</td>
<td>yes</td>
<td>yes/yes</td>
<td>yes</td>
<td>yes</td>
</tr>
<tr>
<td>Church</td>
<td>Prospective, USA, Secondary care</td>
<td>269 with rectal bleeding</td>
<td>34 (13)</td>
<td>Barium enema (n=78) vs. colonoscopy</td>
<td>unclear</td>
<td>unclear/ no</td>
<td>no</td>
<td>yes</td>
</tr>
<tr>
<td>Duff</td>
<td>Prospective, UK, Secondary care</td>
<td>112 symptomatic patients who could not undergo colonoscopy/barium enema</td>
<td>8 (7.1)</td>
<td>CT colonography vs. 1-yr f/u (for negatives); endoscopic f/u (for positives)</td>
<td>yes</td>
<td>unclear/ yes</td>
<td>yes</td>
<td>yes</td>
</tr>
<tr>
<td>Fijten</td>
<td>Prospective from Sept 1988 to Apr 1990, Netherlands, Primary care</td>
<td>269 with rectal bleeding</td>
<td>9 (3)</td>
<td>Endoscopy, radiography, sigmoidoscopy, proctoscopy, sonography; f/u at least 1 yr</td>
<td>yes</td>
<td>yes/unclear</td>
<td>unclear</td>
<td>yes</td>
</tr>
<tr>
<td>Hamilton</td>
<td>Case control, UK, Primary care records</td>
<td>349 cases, 1744 controls</td>
<td>349</td>
<td>Cancer registry</td>
<td>no</td>
<td>yes to case / control status</td>
<td>yes</td>
<td>yes</td>
</tr>
<tr>
<td>Helfand</td>
<td>Prospective, USA, Primary care</td>
<td>201 with rectal bleeding (red)</td>
<td>13 (6.5)</td>
<td>All sigmoidoscopy and barium enema, f/u 6-month follow-up</td>
<td>no</td>
<td>no/yes</td>
<td>yes</td>
<td>yes</td>
</tr>
</tbody>
</table>
## Section 2: Evidentiary Base

<table>
<thead>
<tr>
<th>Author</th>
<th>Study, country, setting</th>
<th>No. of patients</th>
<th>No. of patients with CRC (%)</th>
<th>Investigation used</th>
<th>Consecutive patients</th>
<th>Blinded to index/standard</th>
<th>Missing/uninterpretable data explained</th>
<th>Withdrawals explained</th>
</tr>
</thead>
<tbody>
<tr>
<td>Irvine 1988</td>
<td>Prospective between Aug 1985 and Dec 1986, Canada, unclear</td>
<td>71 with rectal bleeding</td>
<td>5 (7.0)</td>
<td>FS or DCBE or colonoscopy vs. results on FS and DCBE and colonoscopy or histology</td>
<td>no</td>
<td>yes/yes</td>
<td>yes</td>
<td>yes</td>
</tr>
<tr>
<td>Jensen 1993</td>
<td>Prospective, Sweden, secondary care</td>
<td>149</td>
<td>5 (3.4)</td>
<td>Rectosigmoidoscopy and DCBE vs. surgical removal; 3-5 yr f/u</td>
<td>yes</td>
<td>No/yes</td>
<td>yes</td>
<td>Unclear</td>
</tr>
<tr>
<td>Koo 2006</td>
<td>Meta-analysis, UK, NR</td>
<td>6 studies, 1508 patients (frail and elderly)</td>
<td>various</td>
<td>Minimal preparation computed tomography vs. various reference standards; systematic review was not performed</td>
<td>various</td>
<td>various</td>
<td>various</td>
<td>various</td>
</tr>
<tr>
<td>Mant 1989</td>
<td>Prospective over 11-mth period, Australia, Primary care</td>
<td>145</td>
<td>16 (11)</td>
<td>Mainly colonoscopy, some FS and air contrast barium enema; histopathology</td>
<td>yes</td>
<td>no/yes</td>
<td>yes</td>
<td>yes</td>
</tr>
<tr>
<td>Martinez-Ares 2005</td>
<td>Prospective from Sept to Dec 2003 and Jul to Oct 2004, Spain, Secondary care</td>
<td>145</td>
<td>43 (30)</td>
<td>Abdominal ultrasound vs. endoscopy, performed on same day or same hospital stay</td>
<td>yes</td>
<td>yes/yes</td>
<td>yes</td>
<td>yes</td>
</tr>
<tr>
<td>Martinez-Ares 2009</td>
<td>Prospective from Aug 2004 to Dec 2005, Spain, Secondary care</td>
<td>153 suspicious of CRC</td>
<td>70 (46)</td>
<td>Abdominal ultrasound vs. endoscopy, performed on same day or same hospital stay</td>
<td>no</td>
<td>yes/yes</td>
<td>yes</td>
<td>yes</td>
</tr>
<tr>
<td>McSherry 1969</td>
<td>Retrospective over 30-yr period, USA, Secondary care</td>
<td>1625 with CRC</td>
<td>1625</td>
<td>Hospital records, histologically confirmed</td>
<td>no</td>
<td>no/unclear</td>
<td>no</td>
<td>yes</td>
</tr>
<tr>
<td>Oono 2010</td>
<td>Retrospective from June 2007 to June 2008, Japan, secondary care</td>
<td>1073</td>
<td>91 (8.5)</td>
<td>Immunochromal FOBT; colonoscopy</td>
<td>no</td>
<td>Unclear/y es</td>
<td>no</td>
<td>no</td>
</tr>
<tr>
<td>Ott 1989</td>
<td>Retrospective over 4-yr period, USA, unclear</td>
<td>128</td>
<td>12 (9.4)</td>
<td>Single or double barium enema vs. colonoscopy</td>
<td>yes</td>
<td>no/no</td>
<td>yes</td>
<td>yes</td>
</tr>
<tr>
<td>Rex 1990</td>
<td>RCT from Mar 1985 to Nov 1987, USA, Secondary and tertiary care</td>
<td>380 recruited with rectal bleeding, 168 completed FS + ACBE, 164 completed colonoscopy</td>
<td>22 (6.6)</td>
<td>Air contrast barium enema and FS vs. colonoscopy</td>
<td>no</td>
<td>no/no</td>
<td>yes</td>
<td>yes</td>
</tr>
<tr>
<td>Roberts-Thomson 2008</td>
<td>Prospective, Australia, Secondary care</td>
<td>202</td>
<td>9 (4.5)</td>
<td>CT colonography vs. colonoscopy, performed on same day</td>
<td>unclear</td>
<td>yes/yes</td>
<td>yes</td>
<td>yes</td>
</tr>
<tr>
<td>Robinson 2011</td>
<td>Retrospective, UK, Japan, China, secondary care</td>
<td>137 with CRC</td>
<td>137</td>
<td>CT colonography vs. histology on colonoscopic biopsy or surgically resected tumour or post-mortem examination</td>
<td>yes</td>
<td>unclear/no</td>
<td>unclear</td>
<td>unclear</td>
</tr>
<tr>
<td>Shaw 2009</td>
<td>Retrospective</td>
<td>2159</td>
<td>unknown</td>
<td>Hemoccult® FOBT vs.</td>
<td>yes</td>
<td>no/yes</td>
<td>unclear</td>
<td>unclear</td>
</tr>
</tbody>
</table>

- **blood in stool/on toilet paper during last 3 mths**
- **FS**
- **DCBE**
- **CRC**
- **IBD**
- **ACBE**
- **DCBE**
- **FOBT**
- **CT**
- **predominantly elderly**
- **CT colonography vs. colonoscopy, performed on same day**
- **unclear**
- **Unclear/y es**
<table>
<thead>
<tr>
<th>Author</th>
<th>Study, country, setting</th>
<th>No. of patients</th>
<th>No. of patients with CRC (%)</th>
<th>Investigation used</th>
<th>Consecutive patients</th>
<th>Blinded to index/standard</th>
<th>Missing/uninterpretable data explained</th>
<th>Withdrawals explained</th>
</tr>
</thead>
<tbody>
<tr>
<td>(36)</td>
<td>over 2-yr period, UK, Primary care</td>
<td>n</td>
<td>cancer status from hospital database</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sofic 2010 (58)</td>
<td>Prospective, Bosnia and Herzegovina,</td>
<td>227 (25)</td>
<td>All had CT colonography, barium enema and colonoscopy vs. histology</td>
<td>unclear</td>
<td>yes/yes</td>
<td>yes</td>
<td>yes</td>
<td>yes/yes</td>
</tr>
<tr>
<td>(1988)</td>
<td>Prospective, UK, Primary or Secondary</td>
<td>130 open-access</td>
<td>DCE vs. colonoscopy; histology performed</td>
<td>yes for hospital &amp; GP referrals</td>
<td>no/yes</td>
<td>yes</td>
<td>yes</td>
<td>yes/yes</td>
</tr>
<tr>
<td>Taylor 2003 (88)</td>
<td>Prospective over 13-mth period, UK,</td>
<td>49 (12)</td>
<td>CT colonography vs. colonoscopy, performed on same day</td>
<td>yes/yes/yes</td>
<td>yes/yes</td>
<td>yes</td>
<td>yes</td>
<td>yes/yes</td>
</tr>
<tr>
<td>Thompson 2008 (37)</td>
<td>Prospective, UK, Secondary care</td>
<td>16,433 referrals in 15,363 patients over age 16 yrs</td>
<td>Mostly FS with barium enema/colonoscopy/ CT colonography/ ultrasonography vs. 3-yr f/u</td>
<td>yes/yes/yes</td>
<td>yes/yes</td>
<td>yes</td>
<td>yes</td>
<td>yes/yes</td>
</tr>
<tr>
<td>Tolan 2007 (38)</td>
<td>Retrospective over 14-mth period, UK,</td>
<td>400 &gt;70 yrs of age</td>
<td>CT colonography vs. radiology and laboratory reports after 12.5 mths</td>
<td>yes/yes/yes</td>
<td>yes/yes</td>
<td>yes</td>
<td>yes</td>
<td>yes/yes</td>
</tr>
<tr>
<td>Vilala 2007 (39)</td>
<td>Retrospective over 2-yr period, Australia, Tertiary hospital</td>
<td>1632 (4)</td>
<td>FOBT; colonoscopy</td>
<td>no/unclear/yes</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
</tr>
<tr>
<td>Wauters 2000 (89)</td>
<td>Prospective, Belgium, Primary care</td>
<td>386 with rectal bleeding</td>
<td>Endoscopy in some cases, other investigations NR; CRC histologically confirmed; f/u 18-30 mths</td>
<td>yes/yes/yes</td>
<td>yes/yes</td>
<td>yes</td>
<td>yes</td>
<td>yes/yes</td>
</tr>
<tr>
<td>White 2009 (61)</td>
<td>Prospective between Jul 2002 and Apr 2004, USA, ZWW</td>
<td>150 (12)</td>
<td>CT colonoscopy vs. colonoscopy (performed on same day) and operative/pathological findings</td>
<td>no/yes/yes</td>
<td>yes/yes</td>
<td>yes</td>
<td>yes</td>
<td>yes/yes</td>
</tr>
</tbody>
</table>

Abbreviations: ACBE, = air contrast barium enema; CRC = colorectal cancer; CT = computed tomography; DCBE = double-contrast barium enema; FOBT fecal occult blood test; f/u = follow-up; FS = flexible sigmoidoscopy; GP = general practitioner; IBD = irritable bowel disease; mth = month; No. = number; NR = not reported; NZ = New Zealand; SCBE = single-contrast barium enema; 2WW = two-week wait; UK = United Kingdom; USA = United States of America; vs. = versus; yr = year.

Fecal Occult Blood Test (FOBT)

The Jellema et al meta-analysis investigated the diagnostic performance of FOBTs in patients symptomatic for CRC (47). Most of the studies were conducted in secondary care, and most of the studies did not specify the patients’ symptoms. Although there was heterogeneity across the studies, the authors found good diagnostic performance with both guaiac-based tests (pooled sensitivity=75%, specificity=86%, PPV=28%, NPV=99%) and immunochemical-based tests (pooled sensitivity=95%, specificity=84%, PPV=21%, NPV=100%) in comparison to other indicators for CRC. Only one study, investigating guaiac-based tests, was conducted in the primary care setting. In subgroup analysis, immunochemical-based tests showed higher sensitivity than did guaiac-based tests in detecting CRC. These results are in contrast to the NICE guidelines that recommend against the use of FOBTs in symptomatic patients because of poor diagnostic performance (3).
Five other studies found in the literature search were not included in Jellema et al (36,39,45,51,78). In a two-week-wait clinic, Shaw et al (2008) found a PPV of 7.7% for Hemoccult® FOBT, and in a tertiary care setting, Viala et al (2007) found a PPV of 14.3% and an OR of 5.9 for FOBT (36,39). McSherry et al (1969) performed in a secondary care setting found a sensitivity of 73.3% for a guaiac-based FOBT (78). Using the Hemoccult Sensa® FOBT in primary or secondary care settings, Bjerregaard et al 2009 found a PPV of 10.5%, a NPV of 99.0%, a sensitivity of 75.0% and a specificity of 79.4% for the detection of CRC (45). Oono et al 2010 used an immunochemical FOBT in a secondary care setting and found for CRC a PPV of 33.7%, a NPV of 97.4%, a sensitivity of 74.7%, a specificity of 86.4%, a positive-likelihood ratio of 5.48, a negative-likelihood ratio of 0.29 and an odds ratio of 18.7 (51).

**Digital Rectal Examination (DRE)**

A case-control study by Hamilton et al (2005) found a PPV of 1.5% for an abnormal rectal examination for CRC (72). However, when an abnormal rectal examination was combined in turn with one of six symptoms, four of those symptoms, including rectal bleeding, diarrhea, loss of weight and abdominal tenderness, in combination with the abnormal rectal examination resulted in PPVs greater than 5%. A prospective study of patients with rectal bleeding by Fijten et al found that the PPVs for CRC increased when a rectal palpation found a hemorrhoid (n=2/20, PPV=10%) versus DRE found an abnormal prostate (n=1/2, PPV=50%) versus DRE found a palpable tumour (n=1/1, PPV=100%), although these PPVs were based on small numbers (70). As well, in patients selected for rectal bleeding, a palpable tumour had a PPV of 32% for CRC (89).

**Proctoscopy and Blood Work**

Fijten et al found that an abnormal proctoscopy had a sensitivity of 0%, a specificity of 30%, a PPV of 0%, and an NPV of 87% for the detection of CRC (70). However, proctoscopy was performed by FP s in only 17% (n=45) of the patients, and only two had CRC. They also found that the hemoglobin, ESR, and white blood cell count had low sensitivity in detecting CRC (cited in NICE and NZGG) for the 225 patients with laboratory test results (3,4,70). However, the PPV for low hemoglobin was 14%; for low ESR, 9%; for high ESR, 17%; and for high white blood cell count, 12%.

**Ultrasound**

Martinez-Ares et al (2005) compared abdominal ultrasound with colonoscopy in 145 consecutive symptomatic patients and found a sensitivity of 79% and a specificity of 92% (27). Multivariate analysis including age, sex, hemoglobin, hematocrit, and MCV counts, clinical presence of low digestive hemorrhage, constitutional syndrome, altered bowel habit, and results of the sonography in the model found only positive ultrasonography (OR, 9.26; 95% CI, 4.8 to 17.5) and the presence of microcytosis in blood tests (OR, 2.16; 95% CI, 1.34 to 3.46) were independent factors predicting CRC. Similar results were obtained in a subsequent study by Martinez-Ares et al (2009) (49). The accuracy of ultrasonography for diagnosing CRC among patients suspected of having CRC was 83%, the sensitivity 83.3%, specificity 82.7%, PPV 78.5% and NPV 86.7%.

Chen et al (2006) investigated 511 consecutive patients with abdominal distension and compared ultrasonography to colonoscopy or CT scans (14). They found a sensitivity of 93%, a specificity of 99%, a PPV of 95%, and an NPV of 98%.

**Computed Tomography (CT) Colonography**

Seven studies investigated the diagnostic accuracy of CT colonography for CRC among symptomatic patients (16,35,38,52,58,61,88). One study was performed in a primary care
setting in the UK using the two-week-wait rules (88), and another study had referrals mainly from the two-week-wait clinics (61). The five other studies were performed in secondary care settings, and it was unclear whether the symptomatic patients were referred from primary care (16,35,38,52,58). As well, three studies had less than 10 patients diagnosed with CRC (16,35,88), one had 18 patients (61), one retrospective study had 30 patients (38), one prospective had 56 patients (58), and one reviewed 137 patients with CRC (52). Taylor et al (2003) found that CT colonography detected five of six cancers (83%) compared to colonoscopy (88). Roberts-Thomson et al (2008) found that five of nine (56%) cancers confirmed histologically were considered probable cancers with CT colonography, and three of 193 (NPV=98%) lesions were false positives for CRC (35). In Sofic et al 2010, all 56 cases of CRC were found using CT colonography that had a sensitivity, specificity and PPV of 100% (58). Duff et al (2006) investigated 112 symptomatic patients who could not undergo colonoscopy or barium enema (16). Patients were followed for 12 months. They found a sensitivity of 87.5% and a specificity of 97.1% for the detection of CRC. The White et al (2009) prospective study found a sensitivity of 100% and specificity of 99.2% for virtual colonoscopy compared to colonoscopy (61). Tolan et al (2007) retrospectively reviewed 400 consecutive symptomatic patients older than 70 years and undergoing CT colonography over a 14-month period (38). The sensitivity of CT colonography for the detection of CRC was 93%. Using computer-aided detection for CT colonography, Robinson et al 2011 also found a sensitivity of 93.6% for CRC among symptomatic patients (52).

**Minimal-Preparation Computed Tomography (CT)**

One meta-analysis that did not systematically review the literature found a pooled sensitivity of 83% and a pooled specificity of 90% from six studies with symptomatic patients for the detection of CRC using minimal-preparation CT (22).

**Barium Enema and/or Sigmoidoscopy**

There were twelve studies that examined the diagnostic validity of barium enema or sigmoidoscopy (37,43,58,63,66,68,73-75,81,87,91). One study included patients referred from primary care (68), five from secondary care (37,58,63,73,75), three from both primary and secondary care (43,66,87), one from secondary and tertiary care (91), and two undetermined (74,81). Tate (1988) found that the diagnostic yield from GP-referred open-access barium enemas (3%) was lower than the diagnostic yield in hospital-referred colonoscopy patients (7%) or open-access colonoscopy patients (11%) (87). Anderson et al 2011 found the diagnostic accuracy of surgical assessment for CRC was significantly better than general practitioners' assessment due to the surgeons' use of rigid sigmoidoscopy (43). Among patients referred for rectal bleeding, air-contrast barium enema had a sensitivity of 75%, a specificity of 43%, a PPV of 71%, and an NPV of 47% for the detection of CRC compared to colonoscopy (68). Ott et al (1989) found that barium enema correctly diagnosed 12 (100%) carcinomas identified with colonoscopy, and Anderson et al (1991) found a sensitivity of 71% for single-contrast barium enema or DCBE compared with colonoscopy (63,81). Sofic et al 2010 found a sensitivity of 94.6% and a specificity and PPV of 100% for barium enema compared to colonoscopy (58). As well, for patients referred for colonoscopy from primary care due to rectal bleeding, the sensitivity was higher for DCBE (92%) than for rigid sigmoidoscopy (77%), performed by the investigators, and highest when both tests were used (100%) (73). Also, Jensen et al 1993 found a higher sensitivity for DCBE than for rigid sigmoidoscopy (75). Rex et al (1990) found no difference in the proportion of patients diagnosed with colon cancer when patients, referred for lower gastrointestinal bleeding, were randomized to air-contrast barium enema and FS versus colonoscopy (91). Similarly, for patients referred for rectal bleeding, DCBE (83%) and a combination of DCBE and FS (83%) had higher sensitivity than did FS alone (67%).
(74). Brewster et al (1994) also found that DCBE (100%) had higher sensitivity than did FS, performed by specialists, when compared against colonoscopy (52%) (66). However, for patients followed for three years, Thompson et al (2008) found that FS (99%), carried out by colorectal surgeons or general practice specialists, had a higher sensitivity than did DCBE (86%) (37).

Carcinoembryonic Antigen (CEA)

A European guideline on the diagnostic use of tumour markers for CRC, cited by NICE and NZGG, included sensitivity and specificity for CEA but only in healthy subjects (3,4,96). No additional primary studies were found that included the diagnostic parameters of CEA among symptomatic patients.

Summary/Interpretation

In summary, based on the review of the evidence of the diagnostic accuracy of investigations for CRC, the Working Group has identified the following tests as having a place in the investigative workup for CRC by FPs and other PCPs: FOBTs, CT colonography, barium enema, and sigmoidoscopy.

3. What major, known risk factors increase the likelihood of CRC in patients presenting with signs and/or symptoms of CRC?

The evidence table for this question can be found in Appendices 14 and 17. The NICE systematic review suggested that ulcerative colitis is a risk factor for CRC, but this was not specific to symptomatic patients (3). In addition, evidence was lacking that a family history of hereditary nonpolyposis colon cancer was a risk factor in symptomatic patients (3). Although the NZGG review listed several risk factors for CRC, the supporting evidence was from screening studies or studies conducted in the general population and not among symptomatic patients (4). Therefore, it cannot be concluded from the NICE or NZGG reports that any of the risk factors should raise the suspicion of CRC in symptomatic patients.

The meta-analysis by Olde Bekkink et al found a pooled positive-likelihood ratio of 1.05, a pooled sensitivity of 15% and a pooled specificity of 85% for patients with a family history of CRC (50). These were based on three studies that selected patients with rectal bleeding (21,70,77). Likewise, Jellema et al included two studies from primary care and four from secondary care and found consistently high specificity (pooled specificity=91%) but variable sensitivity (pooled sensitivity=16%) for a family history of cancer among symptomatic patients (47,77,90). They also reported a pooled PPV of 6% and a pooled NPV of 96%.

One study by Steine et al (1994), which was not found in NICE (2), NZGG (3) or the meta-analyses, examined the risk of a personal or family history of CRC and/or polyps among referred patients (92). Those authors found a low PPV for patients with a first-degree relative with CRC or polyps (1.3%) and a higher PPV with patients with a personal history of CRC or polyps (5.7%) (92).

There were four studies that included risk factors in multiple-regression analysis (34,70,83,92). In the regression models of Fijten et al and Steine et al (1994), a family history of cancer or abdominal disease was not a significant predictor of CRC (70,92). As well, a patient’s report of irritable bowel syndrome was not found to be a predictive factor for CRC in the Robertson et al (2006) regression analysis (34). The Parker et al (2007) multivariate analysis by a Cox proportional hazards model found that smoking and coronary heart disease lowered the rate of CRC among patients with rectal bleeding followed for two years (83). However, it is unclear whether patient CRC status was verified at the end of the two-year period.
**Summary/Interpretation**

Based on the PPVs from the evidence, it seems that a family history of cancer does not increase the risk of CRC among symptomatic patients. However, because there were few studies conducted in primary care among an unselected patient population, and the degree of relatedness of the family history was not always well defined across studies, strong conclusions could not be derived.

4. **Which factors are associated with delayed referral? Which factors influence delay by patient and which, delay by physician? Does a delay in the time to consultation affect patient outcome?**

The NICE guidelines included a systematic review for delay that included one other systematic review and 18 primary observational studies (3). The main findings indicate that patient-related delay in diagnosis is mostly associated with patients’ beliefs about their symptoms, including patients not knowing the importance of bowel symptoms or thinking that bleeding is not serious or is caused by hemorrhoids. The second most common reason for patient delay is the fear that the resultant tests may be unpleasant or embarrassing. Delay was decreased if patients experienced symptoms that produced considerable initial discomfort and embarrassment, or had abdominal pain, nausea, or vomiting. For FP-related delay, not recognizing symptoms suggestive of colon carcinoma and failure to investigate IDA or to perform a rectal examination at the first consultation have been associated with increased delay. In addition, initial referral to a specialist without a gastrointestinal interest increased delay. No relationship was found between socio-economic status (SES), gender, or ethnicity and diagnostic delay.

The NZGG guideline includes a systematic review for delay for all suspected cancers (4). The articles that were specific to CRC supported the NICE evidence-based conclusions.

A systematic review by Mitchell et al (2008) included 169 articles from primary or secondary care settings and also supported many of the conclusions derived in the NICE guideline (28). In addition, this systematic review found other factors that influenced delay. For patient-related delay, those with co-morbidity tended to delay less, and those with rectal cancer delayed more than did those with colon cancer. Although SES was not found to influence delay, social support was found to decrease delay, and rural residence or lower levels of education were found to increase delay. For practitioner-related delay, receiving inaccurate or inadequate tests resulted in increased delay. Patients who visited their FP more frequently after an inconclusive initial visit experienced an increase in delay. Older patients or patients with rectal cancer were generally referred more quickly.

A prospective Danish observational study (n=459, colon cancer; n=289, rectal cancer) found that female colon cancer patients had a longer patient delay than did male cases, but the reverse was seen for rectal cancer patients (23). Secondary analysis of the UK National Survey of NHS Cancer Patients, using general linear modelling, found that single and separated/divorced people had longer pre-hospital delays than did married people (29). For referral delay, females had longer delays than did males, younger people had longer delays than did older people, and Black and South Asian people had longer delays than did Caucasians (29).

A prospective study of 280 consecutive Italian patients from primary care found no significant difference in patient- or physician-related delay between patients with or without CRC (82). Likewise, a prospective Norwegian study of 1852 consecutive patients from primary care found no difference between patient delay and the detection of cancer, but physician delay in patients with CRC was significantly shorter than was delay in patients without CRC (92).
Shabbir et al (2009) conducted a retrospective review of patients under the age of 50 years presenting with CRC (53). They found that only 24% were referred through the two-week-wait clinics, which had the shortest median time from referral to initial consultation. Seventy-five percent of the patients would have been eligible for the two-week-wait clinics if age were not a deciding factor in the NICE recommendations. They suggested removing age as a one of the criterion for referral.

Similar to the NICE conclusions, Damery et al 2011 found that the median time to CRC diagnosis for patients with IDA was shorter if they were referred to relevant surgical and gastroenterological specialists (including colorectal and general surgery) compared to other medical specialties (46).

A retrospective study in the USA of 289 symptomatic and asymptomatic patients with CRC found that abnormal symptoms, laboratory tests or imaging results were associated with shorter delays between referral and diagnosis, and the presence of family history (without symptoms or abnormal screening) had longer delays between referral and diagnosis (40).

Singh et al (2009) retrospectively reviewed records of patients diagnosed with CRC whose primary care physicians were within a tertiary care facility (55). They evaluated missed opportunities to initiate endoscopic evaluation based on a set of predefined clinical signs, symptoms, and diagnostic tests. They found a mean of 4.2 missed opportunities and 5.3 clues per patient for the 161 patients with missed opportunities. Suspected or confirmed IDA was the most common clue associated with missed opportunities. Also, African-Americans or patients with congestive heart failure or coronary artery disease were more likely to experience missed opportunities. In logistic regression analysis, patients greater than 75 years of age or patients with anemia were more likely to experience missed opportunities, and patients with abnormal FS or CT scans were less likely to have missed opportunities.

For missed opportunities related mostly to the primary care physician, Singh et al confirmed the results of the NICE report and the Mitchell et al systematic reviews (3,28,55). Additional factors observed included when diagnostic tests were ordered but not performed and when diagnostic or laboratory tests were inadequately followed up, especially with positive FOBTs or complete blood counts (55).

Another study by Singh et al (2011) reviewed patients with CRC at a tertiary care setting over a six-year period (57). They found shorter wait times from referral to colonoscopy for patients with three diagnostic signs or symptoms compared to one sign or symptom. Referrals marked as urgent or next available had shorter wait times than did those marked as routine. As well, documented verbal discussion between the referring physician and the consultant resulted in shorter wait times. Signs and symptoms associated with wait times greater than 60 days included IDA, abnormal CT scan or barium enema, suspected mass on physical examination, abdominal pain, and obstruction. A positive FOBT, hematochezia, and history of polyps were associated with wait times of less than 60 days.

Five articles were found that discussed wait times in Canada (19,25,31,56,64). Armstrong et al (2008) conducted a week-long audit across Canada of consecutive patients seen for consultation or a procedure by a specialist physician (64). In Ontario, the median wait time to consultation for 2480 audits was 72 days. The median wait time from referral to completion of procedures or tests with a digestive health provider for 774 audits was 110 days. For patients with alarming features (n=316), the median wait time from the patient’s first referral until completion of the procedures or tests was 62 days compared to 153 days for patients without alarming features (n=372). A retrospective study conducted in Manitoba found the median diagnostic delay from the last visit with the referring physician to a diagnosis of CRC increased from 44 to 64 days over a five-year period (2001-2005) (56). Also, the median delay from contact with the referring physician to the first colonoscopy increased from 37 to 54 days over the same time period (56). A retrospective observational study of 350
patients conducted in The Ottawa Hospital found that the median time from referral for symptoms suggestive of CRC to a confirmed diagnosis was 66 days. In addition, patients with CRC had significantly shorter delays between referral and the time when patients were informed of their diagnosis than did patients without CRC (19). No associations were found between age, sex, comorbidity, or referring physician and the interval from referral to patient being informed of their diagnosis.

Consensus recommendations for wait times in Canada were developed by the Canadian Association of Gastroenterology using a modified Delphi approach (31). They recommended that patients with acute gastrointestinal bleeding should be seen by a specialist, and if indicated, endoscoped within 24 hours; patients with a high likelihood of cancer based on imaging or physical examination should be seen by a specialist, and if indicated, endoscoped within two weeks; and patients with bright red rectal bleeding or documented IDA or one or more positive FOBTs or chronic constipation or chronic diarrhea or a new-onset change in bowel habit or chronic unexplained abdominal pain should be seen by a specialist, and if indicated, endoscoped within two months.

A week-long audit of specialists across Canada compared the wait times from the patient’s first referral until the completion of procedures or tests to the target wait times recommended by the Canadian Association of Gastroenterology (25). In Ontario, the median wait time for patients with a high likelihood of cancer based on imaging or physical examination was 28 days; for patients with documented IDA, 56 days; for patients with one or more positive FOBTs, 83 days; and for patients with unexplained diarrhea or chronic constipation, 139 days. Fifteen to 52% of people were seen within the target wait time in Ontario.

Two meta-analyses by Ramos et al (2007, 2008) suggest there is no association between diagnostic delay and survival in patients with CRC (n=8 studies, 3680 patients) or disease stage at the time that the diagnosis is made (n=17 studies, 2509 patients) (32,33). However, when colon and rectal cancer are analyzed separately (n=4 studies, 1001 patients with colon cancer, 799 with rectal cancer), a shorter delay is associated with more advanced disease for patients with colon cancer, but the opposite was seen for patients with rectal cancer (32,33).

This is supported by Wattercheril et al (2008), who found no association between the delay between referral and CRC diagnosis and mortality when the reason for the referral, the stage of CRC at diagnosis, or the type of CRC treatment were included in the model (40). Similarly, no relationship was found between diagnostic delay and early stage CRC but for late stage CRC, specifically Dukes D tumours, a shorter delay was associated with shorter survival (59). As well, Rupassara et al (2006) found patients who waited 50 days or more between referral and diagnosis had better cancer-specific five-year survival (p=0.007) than did patients waiting less than 50 days during that interval (84). A retrospective observational study by Comber (2005) found survival was better for patients with longer wait times than for those waiting less than a month (15). Torring et al 2011 also found mortality decreased with increasing diagnostic intervals but only until approximately five weeks, after which time mortality increased (60).

**Summary/Interpretation**

Patient-related factors that were found to have the most influence on delay were patients not recognizing the significance of their symptoms as suggestive of CRC or the fear of the possible tests or interventions that might occur. Patients with more severe symptoms or other co-morbidities were found to have a decrease in delay. As well, those patients with social support had shorter delays. FP-related factors included physicians not recognizing the symptoms of CRC in their patients or not investigating IDA or performing a rectal examination.
In addition, referral to a specialist without a gastrointestinal interest or receiving inadequate test results lead to a delay. Although SES overall appeared not to have a significant effect on delay, several papers found that a lower level of education, living in a rural area, being single/divorced, female, Black or South Asian, or younger led to an increase in delay.

DISCUSSION

Signs and symptoms that may raise suspicions of CRC were evaluated and compared to the predictability of the FOBT used in the Ontario population-based CRC screening program, ColonCancerCheck (PPV=10.9%) (2). The following symptoms yielded median PPVs greater than 10% in primary care settings: dark rectal bleeding, rectal bleeding mixed with stool, rectal bleeding in the absence of perianal symptoms, rectal bleeding combined with change in bowel habits, rectal bleeding combined with weight loss, and IDA. All studies examining abdominal or rectal mass had PPVs greater than 10%. A combination of the symptoms or signs with other symptoms generally increased the PPVs. As well, increasing age elevated PPVs. Signs or symptoms also tended to have higher PPVs in males than in females.

For diagnostic tests for CRC, colonoscopy is considered the gold standard and would be performed by a specialist. However, if there is a delay to consultation with a specialist, there is some evidence to suggest that CT colonography, barium enema, or sigmoidoscopy may be good alternative techniques in the interim. The sensitivities and/or specificities were over 83% when CT colonography or barium enema were compared to colonoscopy (16,35,37,38,52,58,61,63,66,73,74,81,88). FS also showed good sensitivity for detecting CRC, especially when combined with DCBE (37,66,74,91). There were few studies examining the diagnostic accuracy of abdominal CT, abdominal or pelvic ultrasound, DRE, proctoscopy, a CBC, or CEA among symptomatic patients. Also, the potential risks of these alternative techniques were not considered in this review.

The evidence also suggests that the FOBT is a good predictor of CRC based on the studies conducted mainly in secondary care settings with symptomatic patients. In patients presenting with suspicious signs or symptoms of CRC, a meta-analysis showed good diagnostic performance for both immunochemical and guaiac-based FOBTs (47). For those patients that have symptoms of CRC leading to referral, a FOBT may not be useful if it does not influence the specialist’s urgency for consultation with the patient. However, in patients presenting with signs or symptoms that are recommended as not requiring urgent or semi-urgent referral, FOBTs may be useful in helping to determine if the patient has occult bleeding in addition to other signs or symptoms that could lead to a referral.

Two meta-analyses found high specificity but low sensitivity for CRC for symptomatic patients with a family history of cancer (47,50). Jellema et al reported a pooled PPV of 6% for patients with a family history of cancer, and Steine et al found a PPV of 5.7% for patients with a personal history of CRC or polyps (47,92). It appears that the PPV for patients with a family history of cancer may not be substantially higher than with other signs or symptoms. However, these patients would normally participate in a CRC surveillance program, which includes regular colonoscopies.

In addition to factors associated with delay reported in NICE or NZGG, this review also found that patients with social support had shorter delays, and physicians receiving inadequate or inaccurate results led to a delay (3,4,28). Furthermore, although NICE reported that there was no relationship found between SES, gender, or ethnicity and diagnostic delay, this review found evidence that a lower level of education, living in a rural area, being single/divorced, female, Black or South Asian, or younger led to an increase in delay (3,23,28,29,55).

Three papers report that the wait times in Ontario for patients with symptoms or signs of CRC are longer than the proposed wait times suggested by the Canadian Association of
Gastroenterology (19,25,31,64). Leddin et al (2008) found only 15% to 52% of symptomatic patients in Ontario were seen within the target wait times (25). Although the evidence suggests that delay in referral does not have an impact on patient survival, the psychological morbidity on patients and their families should be considered.

CONCLUSIONS

Using a PPV of 10% as a threshold, patients with an abdominal or rectal mass should be referred urgently, and dark rectal bleeding, rectal bleeding mixed with stool, rectal bleeding in the absence of perianal symptoms, rectal bleeding combined with change in bowel habits, rectal bleeding combined with weight loss, or IDA should be referred to a specialist competent in endoscopy semi-urgently (2). The target wait times for endoscopy set by the Canadian Association of Gastroenterology can be used as a guide for referral (31).

FOBTs showed good diagnostic performance for CRC among symptomatic patients and may be ordered in cases where symptoms do not lead to urgent or semi-urgent referral and there is a low suspicion of CRC (47). For symptomatic patients who are waiting a substantial amount of time for a consultation with a specialist, CT colonography, barium enema, or sigmoidoscopy may be alternative investigative measures to consider. The results of any interim tests should be made available to the specialists to help them prioritize patients.

To reduce the delay in referral, there should be appropriate education of patients and FPs and PCPs in the signs and symptoms of CRC. FPs and PCPs should assess patients for signs and symptoms of CRC at periodic health examinations and should counsel patients to address common fears and concerns. Special efforts should be made to address challenges in groups with known delays in CRC diagnosis.

CONFLICT OF INTEREST

In accordance with the PEBC Conflict of Interest (COI) Policy, the guideline authors, the Colorectal Cancer Referral Expert Panel members, and internal and external reviewers were asked to disclose potential conflicts of interest. Suzie Joanisse received a grant from CCO to develop a program to increase breast, colorectal, and cervical screening in Aboriginal communities. Sara Kaune provides guidance to FPs and other PCPs in the referral of patients for colonoscopy and has received funding from CCO for the start-up and operation of a gastrointestinal diagnostic assessment program. All other authors declared no conflicts of interest.

ACKNOWLEDGEMENTS

The Colorectal Cancer Referral Working Group would like to thank the following individuals for their assistance in developing this report:

- Sheila McNair and Hans Messersmith, Assistant Directors, PEBC, for providing feedback on draft versions.
- Samia Qadir, Student-Project Assistant, PEBC, for her involvement in developing one-page algorithms of the recommendations and for auditing the data.
- Carol De Vito, Documents Manager, PEBC, for copyediting.
- Erin Kennedy, and Chika Agbassi, Research Coordinators, PEBC, for their comments on the early version of this document.

A complete list of the members of the Working Group, with their affiliations and conflict of interest information, is provided in Section 2. Appendix 1.
REFERENCES


Section 2: Evidentiary Base
42. Adelstein B, Macaskill P, Chan SF, Katelaris PH, Irwig L. Most bowel cancer symptoms do not indicate colorectal cancer and polyps: A systematic review. BMC Gastroenterol. 2011 30 May;11(65).


### Appendix 1. Members of the Colorectal Cancer Referral Working Group, Expert Panel, and Targeted Peer Reviewers.

<table>
<thead>
<tr>
<th>Colorectal Cancer Referral Working Group</th>
<th>Colorectal Cancer Referral Expert Panel</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Chair:</strong> Lisa Del Giudice MD CCFP FCFP</td>
<td><strong>Rob Annis</strong> Provincial Primary Care and Cancer Network Regional Primary Care Lead, ON</td>
</tr>
<tr>
<td><strong>Primary Care Practitioner:</strong> Sunnybrook Family Practice Unit, Toronto, ON</td>
<td><strong>Sara Kaune</strong> Provincial Primary Care and Cancer Network Regional Administrative Lead, ON</td>
</tr>
<tr>
<td><strong>Regional Primary Care Lead:</strong> Amanda Hey MD CCFP FCFP</td>
<td><strong>Marla Ash</strong> Regional Primary Care Lead, Cancer Care Ontario, Central, ON</td>
</tr>
<tr>
<td><strong>Hôpital régional de Sudbury Regional Hospital - Regional Cancer Program, Sudbury, ON</strong></td>
<td><strong>Gregory Knight</strong> Gastrointestinal Disease Site Group, CCO Grand River Regional Cancer Centre, Kitchener, ON</td>
</tr>
<tr>
<td><strong>William Harris MD FRCSC</strong> Surgeon Thunder Bay Regional Health Sciences Centre, Thunder Bay, ON</td>
<td><strong>Praveen Bansal</strong> Regional Primary Care Lead, Cancer Care Ontario, Central West and Mississauga Halton, ON</td>
</tr>
<tr>
<td><strong>Emily Vella PhD</strong> Research Coordinator Program in Evidence-based Care, Cancer Care Ontario, Hamilton, ON</td>
<td><strong>Carole Beals</strong> Provincial Primary Care and Cancer Network Regional Administrative Lead, ON</td>
</tr>
<tr>
<td><strong>Marko Simunovic MD</strong> Surgical Oncologist Juravinski Cancer Centre, Hamilton, ON</td>
<td><strong>Doina Lupea</strong> Program Manager Primary Care Cancer Care Ontario</td>
</tr>
<tr>
<td><strong>William Harris MD FRCSC</strong> Surgeon Thunder Bay Regional Health Sciences Centre, Thunder Bay, ON</td>
<td><strong>Christine Brezden-Masley</strong> Gastrointestinal Disease Site Group, CCO St. Michael’s Hospital, ON</td>
</tr>
<tr>
<td><strong>Gregory Knight</strong> Gastrointestinal Disease Site Group, CCO Grand River Regional Cancer Centre, Kitchener, ON</td>
<td><strong>Heather McLean</strong> Provincial Primary Care and Cancer Network Regional Primary Care Lead, ON</td>
</tr>
<tr>
<td><strong>Hugh Langley</strong> Provincial Primary Care and Cancer Network Regional Primary Care Lead, ON</td>
<td><strong>Sandy Buchman</strong> Provincial Primary Care and Cancer Network Regional Primary Care Lead, ON</td>
</tr>
<tr>
<td><strong>Alison McMullen</strong> Provincial Primary Care and Cancer Network Regional Administrative Lead, ON</td>
<td><strong>Lynn Chappell</strong> Provincial Primary Care and Cancer Network Regional Administrative Lead, ON</td>
</tr>
<tr>
<td><strong>Michael Mills</strong> Provincial Primary Care and Cancer Network Regional Primary Care Lead, ON</td>
<td><strong>Charles Cho</strong> Gastrointestinal Disease Site Group, CCO Southlake Regional Health Centre, ON</td>
</tr>
<tr>
<td><strong>Julia Niblett</strong> Provincial Primary Care and Cancer Network Regional Administrative Lead, ON</td>
<td><strong>John Day</strong> Provincial Primary Care and Cancer Network Regional Primary Care Lead, ON</td>
</tr>
<tr>
<td><strong>Jason Pantarotto</strong> Gastrointestinal Disease Site Group, CCO The Ottawa Hospital Regional Cancer Centre, ON</td>
<td><strong>Lee Donohue</strong> Provincial Primary Care and Cancer Network Regional Primary Care Lead, ON</td>
</tr>
<tr>
<td><strong>Raimond Wong</strong> Associate Professor, McMaster University Department of Oncology - Division of Radiation Oncology</td>
<td><strong>Danusia Gzik</strong> Provincial Primary Care and Cancer Network Regional Primary Care Lead, ON</td>
</tr>
<tr>
<td><strong>Sophie Wilson</strong> Provincial Primary Care and Cancer Network Regional Primary Care Lead, ON</td>
<td><strong>Sheila-Mae Young</strong> Provincial Primary Care and Cancer Network Regional Primary Care Lead, ON</td>
</tr>
<tr>
<td><strong>Sheila-Mae Young</strong> Provincial Primary Care and Cancer Network Regional Primary Care Lead, ON</td>
<td><strong>Carole Beals</strong> Provincial Primary Care and Cancer Network Regional Administrative Lead, ON</td>
</tr>
<tr>
<td><strong>Doina Lupea</strong> Program Manager Primary Care Cancer Care Ontario</td>
<td><strong>Christine Brezden-Masley</strong> Gastrointestinal Disease Site Group, CCO St. Michael’s Hospital, ON</td>
</tr>
<tr>
<td><strong>Heather McLean</strong> Provincial Primary Care and Cancer Network Regional Primary Care Lead, ON</td>
<td><strong>Sandy Buchman</strong> Provincial Primary Care and Cancer Network Regional Primary Care Lead, ON</td>
</tr>
<tr>
<td><strong>Lynn Chappell</strong> Provincial Primary Care and Cancer Network Regional Administrative Lead, ON</td>
<td><strong>Charles Cho</strong> Gastrointestinal Disease Site Group, CCO Southlake Regional Health Centre, ON</td>
</tr>
<tr>
<td><strong>Julia Niblett</strong> Provincial Primary Care and Cancer Network Regional Administrative Lead, ON</td>
<td><strong>John Day</strong> Provincial Primary Care and Cancer Network Regional Primary Care Lead, ON</td>
</tr>
<tr>
<td><strong>Lee Donohue</strong> Provincial Primary Care and Cancer Network Regional Primary Care Lead, ON</td>
<td><strong>Danusia Gzik</strong> Provincial Primary Care and Cancer Network Regional Primary Care Lead, ON</td>
</tr>
<tr>
<td><strong>Sheila-Mae Young</strong> Provincial Primary Care and Cancer Network Regional Primary Care Lead, ON</td>
<td><strong>Suzie Joanisse</strong> Provincial Primary Care and Cancer Network Regional Administrative Lead, ON</td>
</tr>
<tr>
<td>Name</td>
<td>Position</td>
</tr>
<tr>
<td>---------------------------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>Sindu Kanjeekal</td>
<td>Gastrointestinal Disease Site Group, CCO</td>
</tr>
<tr>
<td>Anna Kobylecky</td>
<td>General Surgeon</td>
</tr>
<tr>
<td>Bob Bluman</td>
<td>Clinical Professor, Department of Family Medicine</td>
</tr>
</tbody>
</table>

**Colorectal Cancer Referral Targeted Peer Reviewers**
Appendix 2. List of sites searched for the environmental scan.

CMA Infobase
The Physicians Query Database (National Cancer Institute)
National Guideline Clearing House
NICE (UK) - NICE Guidance
SIGN (UK) - SIGN Guidelines
ASCO (US) - ASCO Guidelines
NCCN (US) - NCCN home (consensus-based)
National Health and Medical Research Council (Aus) - Cancer Guidelines
New Zealand Guidelines Group - Guidelines
Appendix 3. Literature search strategies.

Signs MEDLINE
(2004-2007 using NICE terms)
Database: Ovid MEDLINE(R) <1996 to June Week 2 2009> Search Strategy:
--------------------------------------------------------------------------------
1 exp "sensitivity and specificity"/ (239327)
2 false negative reactions/ or false positive reactions/ (12654)
3 (sensitivity or specificity or accuracy).ab,ti. (441413)
4 diagnos$.ab,ti. (629674)
5 predictive value$.ab,ti. (31069)
6 reference value$.ab,ti. (4999)
7 ROC.ab,ti. (8755)
8 (likelihood adj ratio$1).ab,ti. (4069)
9 monitoring.tw. (125815)
10 (false adj (negative$1 or positive$1)).ab,ti. (22852)
11 double-blind method/ or single-blind method/ (65827)
12 (randomized controlled trial or controlled clinical trial).pt. (205799)
13 consensus development conference$.pt. (4866)
14 practice guideline.pt. (10940)
15 review.pt. (914918)
16 review.ab. (312258)
17 (meta-analysis or metaanalysis).ab. (14991)
18 meta-analysis.pt. (18597)
19 meta-analysis.ti. (9102)
20 (cohort adj study$).ab,ti. (35083)
21 exp cohort studies/ (449951)
22 (single blind$3 or double blind$3 or triple blind$3).ab,ti. (51879)
23 or/1-22 (2463187)
24 letter.pt. (344350)
25 editorial.pt. (157352)
26 comment.pt. (290185)
27 or/24-26 (554903)
28 23 not 27 (2398165)
29 (loss adj2 appetite).tw. (1161)
30 Anorexia/ (1903)
31 "nausea and vomiting"/ or nausea/ or vomiting/ (9965)
32 gastrointestinal hemorrhage/ or melena/ (9795)
33 (pruritus ani or (itch$ adj3 anus) or (pain adj 3 diarrhea$)).tw. (35)
34 (intestinal obstruction or acute intestinal obstruction or (obstruct$ adj intestine$) or (perforat$ adj intestine$)).tw. (2538)
35 ((rect$ or anal) and (bleed$ or blood$ or haemo$ or hemo$)).tw. (8023)
36 ((mucus or pass$ mucus) adj stool$).tw. (5)
37 stips$.tw. (6)
38 exp Diarrhea/ (13033)
39 frequency of defecation.tw. (86)
40 ((foecal or fecal) and incontinence$).tw. (1700)
41 continence$.tw. (11740)
42 constipation$.tw. (6619)
43 (soil$ or diarrhoea$ or steatorrhea$ or loose stool$ or loose motion$ or loose bowel motion$).tw. (44616)
44 sign$.tw. (1991139)
45 symptom$.tw. (314869)
46 or/29-45 (2236624)
exp abdominal neoplasms/ or anal gland neoplasms/ or digestive system neoplasms/ or gastrointestinal neoplasms/ or gastrointestinal stromal tumors/ or exp intestinal neoplasms/ or exp liver neoplasms/ or peritoneal neoplasms/ or pelvic neoplasms/ (120262)

(rect§ or colorectal§ or alimentary or colon§ or gallbladder§ or duoden§ or gastrointestinal§ or anal or intestinal§ or liver or digestive or abdomen§) adj2 (tumor§ or tumour§ or cancer§ or neoplasm§ or carcinoma§)).tw. (74388)

or/47-48 (137774)

(200406: or 200407: or 200408: or 200409: or 20041: or 2005: or 2006: or 200701: or 200702: or 200703: or 200704: or 200705: or 200706: or 200707:).ed. (1964383)

50 and 28 and 49 and 46 (7279)

limit 51 to (english language and humans) (6264)

(2007-2009 including NICE and NZ terms)

Database: Ovid MEDLINE(R) <1996 to June Week 1 2009> Search Strategy:

1 exp "sensitivity and specificity"/ (238835)
2 false negative reactions/ or false positive reactions/ (12638)
3 (sensitivity or specificity or accuracy).ab,ti. (440620)
4 diagnosis.ab,ti. (628511)
5 predictive value$.ab,ti. (31012)
6 reference value$.ab,ti. (4992)
7 ROC.ab,ti. (8735)
8 (likelihood adj ratio$1).ab,ti. (4062)
9 monitoring.tw. (125521)
10 (false adj (negative$1 or positive$1)).ab,ti. (22820)
11 double-blind method/ or single-blind method/ (65711)
12 (randomized controlled trial or controlled clinical trial).pt. (205454)
13 consensus development conference$.pt. (4846)
14 practice guideline.pt. (10918)
15 review.pt. (913358)
16 review.ab. (311457)
17 (meta-analysis or metaanalysis).ab. (14956)
18 meta-analysis.pt. (18546)
19 meta-analysis.ti. (9069)
20 (cohort adj study$).ab,ti. (34992)
21 exp cohort studies/ (449028)
22 (single blind$3 or double blind$3 or triple blind$3).ab,ti. (51792)
23 or/1-22 (2458631)
24 letter.pt. (343817)
25 editorial.pt. (156938)
26 comment.pt. (289558)
27 or/24-26 (553839)
28 23 not 27 (2393743)
29 exp body weight changes/ (24344)
30 (weight adj1 loss$).tw. (22311)
31 exp "signs and symptoms, digestive"/ (45562)
32 cachexia.tw. (2258)
33 (loss adj2 appetite).tw. (1160)
34 early satiety.tw. (346)
35 Anorexia/ (1903)
36 anorexia.tw. (8602)
37 "nausea and vomiting"/ or nausea/ or vomiting/ (9941)
38 nausea.tw. (18123)
39 vomiting.tw. (19020)
40 gastrointestinal hemorrhage/ or melena/ (9783)
((abdomen or stomach or back or flank) adj3 pain).tw. (30542)

(pruritus ani or (itch adj3 anus) or (pain adj 3 defec$)).tw. (35)

((abdomen or stomach or rect$ or colorectal or renal or intestin$ or gastrointestinal) adj3 mass$).tw. (6304)

(intestinal obstruction or acute intestinal obstruction or (obstruct$ adj intestin$) or (perforat$ adj intestin$)).tw. (2534)

obstruction$.tw. (40441)

((gastrointestina$ or intestin$) adj (bleed$ or hemorrhag$ or haemorrhag$)).tw. (6160)

gastrointestinal hemorrhage/ or melena/ (9783)

((rect$ or colorect$) adj3 (bleed$ or hemorrhag$ or haemorrhag$)).tw. (1475)

((rect$ or anal) and (bleed$ or blood$ or haemo$ or hemo$)).tw. (8012)

((mucus or pass$ mucus) adj stool$).tw. (5)

stips$.tw. (6)

(melena or maelena).tw. (587)

Hematuria/ (2822)

(hematuria or haematuria).tw. (5863)

(hematochezia or haematochezia).tw. (472)

exp anemia/ (36706)

(anemia or anaemia).tw. (35322)

(ir on adj deficiency adj (anemia or anaemia)).tw. (2519)

exp Jaundice/ (1908)

jaundice.tw. (7205)

exp Diarrhea/ (13014)

(diarrhea or diarrhoea).tw. (26781)

change$ in bowel habit$.tw. (137)

bowl habit change$.tw. (11)

frequency of defecation.tw. (86)

((foecal or fecal) and incontinen$).tw. (1699)

continen$.tw. (11718)

constipat$.tw. (6606)

((soil$ or diarrhoea$ or steatorrhoea$ or loose stool$ or loose motion$ or loose bowel motion$).tw. (44538)

exp Cholecystitis./ (2615)

cholecystitis.tw. (3053)

Ascites/ (3480)

ascites.tw. (8958)

Hepatomegaly/ (1060)

hepatomegaly or hepato megaly).tw. (2125)

(alarm adj1 (symptom$ or sign$)).tw. (382)

sign$.tw. (1987256)

symptom$.tw. (314320)

or/29 (2353258)

exp abdominal neoplasms/ or anal gland neoplasms/ or digestive system neoplasms/ or gastrointestinal neoplasms/ or gastrointestinal stromal tumors/ or exp intestinal neoplasms/ or exp liver neoplasms/ or peritoneal neoplasms/ or pelvic neoplasms/ (120049)

((rect$ or colorectal$ or alimentary or colon$ or gallbladder$ or duoden$ or gastrointestinal or anal or intestin$ or (liver or digestive or abdomen$) adj2 (tumor$ or tumour$ or cancer$ or neoplasm$ or carcinoma$)).tw. (74248)

or/80-81 (137527)

or 28 and 82 and 79 (27248)

limit 83 to (english language and humans) (22545)

(200708: or 200709: or 20071: or 2008: or 2009:).ed. (1266739)

84 and 85 (4692)
Signs EMBASE
(2004 - 2006 using NICE terms)
Database: EMBASE <1996 to 2009 Week 25>
Search Strategy:

1 "sensitivity and specificity"/ (52914)
2 false negative result/ or false positive result/ (4811)
3 (sensitivity or specificity or accuracy).ab,ti. (413725)
4 diagnosis.ab,ti. (610737)
5 predictive value$.ab,ti. (30258)
6 reference value$.ab,ti. (4919)
7 ROC.ab,ti. (8247)
8 (likelihood adj ratio$1).ab,ti. (3807)
9 monitoring.tw. (122864)
10 (false adj (negative$1 or positive$1)).ab,ti. (21684)
11 double blind procedure/ or single blind procedure/ or triple blind procedure/ (60280)
12 exp controlled clinical trial/ (151465)
13 exp practice guideline/ (146078)
14 review.pt. (724011)
15 review.ab. (301585)
16 (meta-analysis or metaanalysis).ab. (14125)
17 Meta Analysis/ (31966)
18 meta-analysis.ti. (8926)
19 (cohort adj study).ab,ti. (33709)
20 cohort analysis/ (52287)
21 (single blind$3 or double blind$3 or triple blind$3).ab,ti. (53250)
22 or/1-21 (1951870)
23 letter.pt. (307811)
24 editorial.pt. (182743)
25 or/23-24 (490554)
26 22 not 25 (1951870)
27 (pruritus ani or (itch$ adj3 anus) or (pain adj 3 defec$)).tw. (52)
28 (intestinal obstruction or acute intestinal obstruction or (obstruct$ adj intestinal) or (perforat$ adj intestinal)).tw. (2246)
29 (gastrointestinal$ or intestinal$) adj (bleed$ or hemorrhag$ or haemorrhag$)).tw. (6129)
30 (rect$ or anal) and (bleed$ or blood$ or hemo$ or haemo$)).tw. (7834)
31 (mucus or pass$ mucus) adj stool$.tw. (5)
32 stips$.tw. (9)
33 frequency of defecation.tw. (76)
34 ((foecal or fecal) and incontinen$).tw. (1673)
35 continen$.tw. (10491)
36 constipat$.tw. (7090)
37 (soil$ or diarrhoea$ or steatorrhoea$ or loose stool$ or loose motion$ or loose bowel motion$).tw. (43746)
38 sign$.tw. (1869627)
39 symptom$.tw. (320359)
40 or/27-39 (2103782)
41 digestive system tumor/ or gastrointestinal stromal tumor/ or gastrointestinal tumor/ or digestive system cancer/ or exp liver cancer/ or exp intestine cancer/ or exp liver tumor/ or exp intestine tumor/ (134075)
42 ((rect$ or colorectal$ or alimentary or colon$ or gallbladder$ or duoden$ or gastrointestin$ or anal or intestin$ or liver or digestive or abdom$) adj2 (tumor$ or tumour$ or cancer$ or neoplasm$ or carcinoma$)).tw. (72376)
43 or/41-42 (145005)
(2007-2009 including NICE and NZ terms)

Database: EMBASE <1996 to 2009 Week 23

Search Strategy:

1. "sensitivity and specificity"/ (52544)
2. false negative result/ or false positive result/ (4754)
3. (sensitivity or specificity or accuracy).ab,ti. (411971)
4. diagnosis.ab,ti. (608490)
5. predictive value.ab,ti. (30140)
6. reference value.ab,ti. (4900)
7. ROC.ab,ti. (8205)
8. (likelihood adj ratio).ab,ti. (3777)
9. monitoring.tw. (122377)
10. (false adj (negative$ or positive$)).ab,ti. (21610)
11. double blind procedure/ or single blind procedure/ or triple blind procedure/ (60063)
12. exp controlled clinical trial/ (150877)
13. exp practice guideline/ (145627)
14. review.pt. (722049)
15. review.ab. (300216)
16. (meta-analysis or metaanalysis).ab. (14046)
17. Meta Analysis/ (31900)
18. meta-analysis.ti. (8854)
19. (cohort adj study).ab,ti. (33473)
20. cohort analysis/ (52003)
21. (single blind$ or double blind$ or triple blind$).ab,ti. (53059)
22. or/1-21 (1989882)
23. letter.pt. (306429)
24. editorial.pt. (182039)
25. or/23-24 (488468)
26. 22 not 25 (1944903)
27. weight reduction/ (34934)
28. (weight adj1 loss$).tw. (21269)
29. Cachexia/ (3115)
30. cachexia.tw. (2199)
31. (loss adj2 appetite).tw. (1092)
32. early satiety.tw. (361)
33. Anorexia/ (18392)
34. anorexia.tw. (8440)
35. "nausea and vomiting"/ or nausea/ or vomiting/ (89020)
36. nausea.tw. (18994)
37. vomiting.tw. (19441)
38. abdominal pain/ or lower abdominal pain/ (36335)
39. digestive system hemorrhage/ or exp gastrointestinal hemorrhage/ or exp duodenum bleeding/ (22783)
40. (abdom$ or stomach or back or flank) adj3 pain).tw. (31655)
41. (pruritus ani or (itch$ adj3 anus) or (pain adj3 defec$)).tw. (52)
42. ((abdom$ or stomach or rect$ or colorectal or renal or intestinal$ or gastrointestinal$) adj3 mass$).tw. (5938)
43. (intestinal obstruction or acute intestinal obstruction or (obstruct$ adj intestinal$) or (perforat$ adj intestinal$)).tw. (2241)
44 obstruction$.tw. (39665)
45 ((gastrointestinal$ or intestinal$) adj (bleed$ or hemorrhag$ or haemorrhag$)).tw. (6114)
46 ((rect$ or colorectal$) adj3 (bleed$ or hemorrhag$ or haemorrhag$)).tw. (1478)
47 ((rect$ or anal) and (bleed$ or blood$ or haemo$ or hemo$)).tw. (7792)
48 ((mucus or pass$ mucus) adj stool$).tw. (5)
49 stips$.tw. (9)
50 (melena or maelena).tw. (678)
51 Hematuria/ (9476)
52 (hematuria or haematuria).tw. (5393)
53 (hematochezia or haematochezia).tw. (453)
54 exp anemia/ (74850)
55 (anemia or anaemia).tw. (33350)
56 (iron adj deficiency adj (anemia or anaemia)).tw. (2314)
57 exp Jaundice/ (10589)
58 jaundice.tw. (6721)
59 exp Diarrhea/ (64037)
60 (diarrhea or diarrhoea).tw. (24888)
61 change$ in bowel habit$.tw. (129)
62 bowel habit change$.tw. (8)
63 frequency of defecation.tw. (76)
64 (((faecal or fecal) and incontinen$)).tw. (1672)
65 continen$.tw. (10452)
66 constipat$.tw. (7072)
67 (soil$ or diarrhoea$ or steatorrhoea$ or loose stool$ or loose motion$ or loose bowel motion$).tw. (43580)
68 exp Cholecystitis/ (3891)
69 cholecystitis.tw. (2556)
70 exp Ascites/ (9664)
71 ascites.tw. (8490)
72 Hepatomegaly/ (4068)
73 (hepatomegaly or hepato megaly).tw. (1988)
74 (alarm adj1 (symptom$ or sign$)).tw. (398)
75 sign$.tw. (1861833)
76 symptom$.tw. (319234)
77 or/27-76 (2304715)
78 digestive system tumor/ or gastrointestinal stromal tumor/ or gastrointestinal tumor/ or digestive system cancer/ or exp liver cancer/ or exp intestine cancer/ or exp liver tumor/ or exp intestine tumor/ (133493)
79 ((rect$ or colorectal$ or alimentary or colon$ or gallbladder$ or duoden$ or gastrointestinal$ or anal or intestinal$ or liver or digestive or abdom$) adj2 (tumor$ or tumour$ or cancer$ or neoplasm$ or carcinoma$)).tw. (72080)
80 or/78-79 (144370)
81 (2007: or 2008: or 2009:).ew. (5941853)
82 77 and 80 and 26 (27787)
83 81 and 82 (8558)
84 limit 83 to (human and english language) (7568)

Test MEDLINE
(2004-2009)
Database: Ovid MEDLINE(R) <1996 to June Week 1 2009> Search Strategy:
----------------------------------------------------------------------------------------------------------------------------------
1 Primary Health Care/ (24656)
2 Physicians, Family/ (7162)
3 ((family or general) adj practitioner$).mp. (16487)
Section 2: Evidentiary Base

4 gp.mp. (13693)
5 family physician$.mp. (4805)
6 family doctor$.mp. (1767)
7 Family Practice/. (27039)
8 ((family or general) adj practice$).mp. (34800)
9 primary care.mp. (33200)
10 primary health care.mp. (27461)
11 or/1-10 (92878)
12 meta-analysis/ (18546)
13 "review literature".mp. (2793)
14 meta-analy$.mp. (32391)
15 metaanal$.mp. (900)
16 (systematic$ a dj (review$ or overview$)).mp. (17875)
17 meta-analysis.pt. (18546)
18 review.pt. (913358)
19 review.ti. (81648)
20 or/12-19 (954186)
21 Case Reports/. (598333)
22 letter.pt. (343817)
23 historical article.pt. (87049)
24 comment.pt. (289558)
25 editorial.pt. (156938)
26 or/21-25 (1155958)
27 20 not 26 (868875)
28 exp "sensitivity and specificity"/ (238835)
29 (sensitivity or specificity).tw. (284728)
30 exp Diagnostic Errors/. (39443)
31 predictive value$.tw. (31012)
32 "Predictive value of tests"/ (73110)
33 ROC.tw. (8735)
34 (ROC adj (analys$ or area or auc or characteristic$ or curve$)).tw. (7318)
35 (false adj (negative or positive)).tw. (19547)
36 accuracy.tw. (88282)
37 reference value$.tw. (4992)
38 likelihood ratio$.tw. (4074)
39 ((pre-test or pretest) adj probability).tw. (659)
40 post-test probability.tw. (180)
41 Diagnosis, differential/. (148016)
42 Diagnostic tests, routine/. (3202)
43 or/28-42 (683007)
44 exp Blood Cell Count/. (41124)
45 (CBC or FBC or full blood count).tw. (1336)
46 C-reactive protein/ (13872)
47 c-reactive protein$.mp. (20546)
48 Blood sedimentation/ (2072)
49 erythrocyte sedimentation rate.mp. (3612)
50 ferritin.mp. or Ferritins/ (8531)
51 serum iron.mp. (1443)
52 Occult blood/ (1659)
53 stool occult blood.mp. (28)
54 faecal occult blood.mp. (342)
55 (fob or fobt).mp. (746)
56 Carcinoembryonic Antigen/ (3968)
57 Carcinoembryonic Antigen.tw. (3911)
58 Carcinogenic embryonic Antigen.tw. (5)
Section 2: Evidentiary Base

Test EMBASE
(2004-2009)
Database: EMBASE <1996 to 2009 Week 24>
Search Strategy:

1 exp Primary health care/ (38099)
2 general practitioner/ (25890)
3 ((family or general) adj practitioner$).mp. (31879)
4 gp.mp. (21848)
5 Family physician/ (25890)
6 family physician$.mp. (4813)
7 family doctor$.mp. (1342)
8 general practice/ (16883)
9 ((family or general) adj practice$).mp. (22558)
10 primary care.mp. (29683)
11 primary health care.mp. (10136)
12 or/1-11 (101139)
13 Meta Analysis/ (31927)
14 "systematic review"/ (26933)
15 (meta-anal$ or metaanaly$).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name] (41444)
16 (systematic adj (review$ or overview$)).mp. (34716)
17 review.pt. (723099)
18 review.ti. (79028)
19 or/13-18 (786457)
20 letter.pt. (307009)
21 editorial.pt. (182377)
22 or/20-21 (489386)
23  19 not 22 (780355)
24  "sensitivity and specificity"/ (52736)
25  sensitivity.tw. (200481)
26  specificity.tw. (123738)
27  "prediction and forecasting"/ (1429)
28  predictive value$.tw. (30192)
29  predictive value$ of test$.tw. (26)
30  roc curve/ (2196)
31  (ROC adj (analy$l or area or auc or characteristic$ or curve$)).tw. (6890)
32  exp diagnostic error/ (20894)
33  (false adj (positive or negative)).tw. (18639)
34  diagnostic accuracy/ (111198)
35  accuracy.tw. (82007)
36  reference value/ (10114)
37  reference value$.tw. (4908)
38  likelihood ratio$.tw. (3801)
39  ((pre-test or pretest) adj probability).tw. (652)
40  post-test probability.tw. (171)
41  differential diagnosis/ (82196)
42  or/24-41 (522010)
43  exp blood cell count/ (59069)
44  (CBC or FBC or full blood count).tw. (1234)
45  c-reactive protein.mp. or C Reactive Protein/ (29435)
46  erythrocyte sedimentation rate/ (8447)
47  erythrocyte sedimentation rate.mp. (9050)
48  ferritin.tw. or Ferritin blood level/ or Ferritin/ (9751)
49  serum iron.mp. or exp Iron Blood Level/ (3073)
50  occult blood/ (2008)
51  faecal occult blood.tw. (331)
52  (fob or fobt).tw. (748)
53  Carcinoembryonic Antigen.tw. (3767)
54  Carcinogenic embryonic Antigen.tw. (4)
55  Carcinoembryonic Antigen/ (7624)
56  CEA.tw. (6366)
57  virtual colonography.tw. (1)
58  virtual colonography.mp. (24)
59  virtual colonoscopy.mp. (378)
60  computer assisted tomography/ (181559)
61  computed tomographic colonography/ (1344)
62  (ct scan adj2 abdom$).tw. (727)
63  barium enema.mp. or Barium Enema/ (3475)
64  Rectoscopy/ or proctoscopy.tw. (591)
65  anoscopy/ or anoscopy.mp. (99)
66  Ultrasound/ or ultrasound.mp. (89568)
67  Sigmoidoscopy/ or sigmoidoscopy.tw. (3412)
68  Digital rectal examination/ (1461)
69  pr exam$.tw. (2)
70  per rectum exam$.tw. (7)
71  or/43-70 (370153)
72  digestive system tumor/ or gastrointestinal stromal tumor/ or gastrointestinal tumor/ or digestive
system cancer/ or exp intestine cancer/ or exp intestine tumor/ (91716)
73  exp Abdominal Tumor/ (8492)
74  72 or 73 (98646)
75  42 or 23 (1236650)
76  74 and 75 and 71 (6240)
Section 2: Evidentiary Base

Delay MEDLINE
Database: Ovid MEDLINE(R) <1996 to June Week 2 2009> Search Strategy:

1. exp abdominal neoplasms/ or anal gland neoplasms/ or digestive system neoplasms/ or gastrointestinal neoplasms/ or gastrointestinal stromal tumors/ or exp intestinal neoplasms/ or peritoneal neoplasms/ or pelvic neoplasms/ (81821)
2. ((rect$ or colorectal$ or alimentary or colon$ or gallbladder$ or duoden$ or gastrointestinal$ or anal or intestin$ or liver or digestive or abdomen$) adj2 (tumor$ or tumour$ or cancer$ or neoplasm$ or carcinoma$)).tw. (74388)
3. or/1-2 (106394)
4. (delay$ adj3 practitioner$).tw. (31)
5. (delay$ adj3 diagnos$).tw. (7049)
6. (delay$ adj3 patient$).tw. (5005)
7. (diagnos$ adj1 delay$).tw. (2670)
8. (diagnos$ adj earl$).tw. (1436)
9. early diagnosis/ (4663)
10. earl$ diagnosis.tw. (19673)
11. (earl$ adj detect$).tw. (16059)
12. (earl$ adj present$).tw. (487)
13. (earl$ adj symptom$).tw. (992)
14. exp health behavior/ (44373)
15. exp attitude to health/ (145652)
16. Physician-patient relations/ (24283)
17. or/4-16 (222597)
18. "referral and consultation"/ (21157)
19. referral$.tw. (30725)
20. (late$ adj refer$).tw. (338)
21. (earl$ adj refer$).tw. (732)
22. Disease progression/ (58293)
23. Time factors/ (353063)
24. Physician's practice patterns/ (23294)
25. or/18-24 (468457)
26. (200709: or 20071: or 2008: or 2009:).ed. (1221727)
27. 3 and 17 and 25 and 26 (128)
28. limit 27 to (english language and humans) (118)

Delay EMBASE
Database: EMBASE <1996 to 2009 Week 25> Search Strategy:

1. digestive system tumor/ or gastrointestinal stromal tumor/ or gastrointestinal tumor/ or digestive system cancer/ or exp intestine cancer/ or exp intestine tumor/ (91910)
2. ((rect$ or colorectal$ or alimentary or colon$ or gallbladder$ or duoden$ or gastrointestinal$ or anal or intestin$ or liver or digestive or abdomen$) adj2 (tumor$ or tumour$ or cancer$ or neoplasm$ or carcinoma$)).tw. (72376)
3. or/1-2 (110569)
4. Cancer diagnosis/ (40282)
5. early diagnosis/ (32872)
6. (earl$ adj diagnos$).tw. (20455)
7. diagnos$ earl$.tw. (1443)
8. Delayed Diagnosis/ (1221)
9. (delay$ adj3 diagnos$).tw. (7080)
10. (diagnos$ adj1 delay$).tw. (2687)
11. (delay$ adj3 practitioner$).tw. (19)
12. Patient attitude/ (18992)
13. Attitude to health/ or Attitude to illness/ or Illness behavior/ (4525)
14. (delay$ adj3 patient$).tw. (4818)
15. earl$ detection.tw. (14904)
16. (detect$ adj earl$).tw. (2804)
17. (earl$ adj present$).tw. (2)
18. (earl$ adj symptom$).tw. (976)
19. or/4-18 (123986)
20. patient referral/ (25096)
21. referral$.tw. (27880)
22. (earl$ adj refer$).tw. (686)
23. (late$ adj refer$).tw. (300)
24. Time factors/ (49865)
25. exp disease course/ (733980)
26. 25 and (5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 22 or 23)
   (23076)
27. clinical practice/ (79089)
28. or/20-24,26-27 (189950)
29. 3 and 19 and 28 (1782)
31. 29 and 30 (521)
32. limit 31 to (human and english language) (444)

Risk Factors MEDLINE
Database: Ovid MEDLINE(R), EMBASE
Search Strategy:
--------------------------------------------------------------------------------
1. exp colorectal neoplasms/ (62183)
2. exp large intestine tumor/ (77984)
3. ((proximal or ascending or descending or transverse) adj colon adj3 (cancer$ or neoplas$ or
tumour$ or tumor$ or carcino$ or malignan$)).tw. (942)
4. ((colon$ or colorect$ or bowel$ or large bowel$ or intestin$ or pelv$ or abdom$) adj3 (cancer$ or
neoplas$ or tumour$ or tumor$ or carcino$ or malignan$)).tw. (119155)
5. ((sigmoid$ or rectosigmoid$ or jejunum or ileum or ileal or cecum or cecal or ileocecal or ileocecal
junction or ICJ or appendix$) adj3 (cancer$ or neoplas$ or tumour$ or tumor$ or carcino$ or malignan$)).tw. (4076)
6. CRC.tw. (7894)
7. Burkitt$ lymph$.tw. (4684)
8. (hereditary nonpolyposis colon cancer or nonpolyposis colon cancer or HNPCC or Lynch$ syndrome)..tw. (3617)
9. exp primary health care/ (74886)
10. (primary care or primary health care).tw. (70266)
11. Family Practice/ (43871)
12. Physicians, Family/ (33024)
13. (family practi$ or family doctor$ or family physician$ or gp$ or general practi$).tw. (154404)
14. (200406: or 200407: or 200408: or 200409: or 20041: or 2005: or 2006: or 2007: or 2008: or
2009:).ed. (3217656)
15. meta-analysis.pt,sh. (50415)
16. (meta-anal$ or metaanalis$).tw. (43171)
17. (quantitativ$ review$ or quantitativ$ overview$).tw. (627)
Section 2: Evidentiary Base

Risk Factors EMBASE
Database: EMBASE <1996 to 2009 Week 25>
Search Strategy:

1 exp colorectal neoplasms/ (1808)
2 exp large intestine tumor/ (78329)
3 ((proximal or ascending or descending or transverse) adj colon adj3 (cancer$ or neoplas$ or tumour$ or tumor$ or carcino$ or malignan$)).tw. (484)
4 ((colon$ or colorect$ or bowel$ or large bowel$ or intestin$ or pelv$ or abdom$) adj3 (cancer$ or neoplas$ or tumour$ or tumor$ or carcino$ or malignan$)).tw. (58845)
5 ((sigmoid$ or rectosigmoid$ or jejunum or ileum or ileal or cecum or cecal or ileocecal or ileocecal junction or ICJ or appendi$) adj3 (cancer$ or neoplas$ or tumour$ or tumor$ or carcino$ or malignan$)).tw. (2029)
6 CRC.tw. (3937)
7 Burkitt$ lymph$.tw. (2276)
8 (hereditary nonpolyposis colon cancer or nonpolyposis colon cancer or HNPCC or Lynch$ syndrome).tw. (1795)
9 exp primary health care/ (38190)
10 (primary care or primary health care).tw. (33042)
11 Family Practice/ (16893)
12 Physicians, Family/ (25929)
13 (family practi$ or family doctor$ or family physician$ or gp$ or general practi$).tw. (76192)
14 meta-analysis.pt,sh. (31966)
15 (meta-anal$ or metaanal$).tw. (21443)
16 (quantitativ$ review$ or quantitativ$ overview$).tw. (299)
17 (systematic$ review$ or systematic$ overview$).tw. (17079)
18 (methodologic$ review$ or methodologic$ overview$).tw. (113)
19 (integrative research review$ or research integration$).tw. (22)
20 quantitativ$ synthes$.tw. (123)
21 (medline or medlars).tw,sh. or embase.tw. (30387)
22 (scisearch or psychinfo or psycinfo).tw. (1709)
23  (psychlit or psyclit).tw. (430)
24  (hand search$ or manual search$).tw. (2233)
25  (electronic database$ or bibliographic database$).tw. (2890)
26  (pooling or pooled analys$ or mantel haenszel).tw. (5487)
27  (peto or der simonian or dersimonian or fixed effect$).tw. (1899)
28  review.pt.sh. or review$.tw. or overview$.tw. (975354)
29  or/9-13 (126226)
30  or/21-27 (38983)
31  or/14-20 (52986)
32  28 and 30 (27428)
33  31 or 32 (69330)
34  or/1-8 (94839)
35  34 and 33 (1956)
36  limit 35 to english language (1781)
37  limit 36 to humans (1752)
39  38 and 37 (1236)
## Appendix 4. Rectal bleeding (RB) as a single symptom.

<table>
<thead>
<tr>
<th>Index test</th>
<th>Author</th>
<th>Definition of sign/symptom</th>
<th>PPV (%) (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rectal bleeding</td>
<td>Ellis 2005</td>
<td>RB</td>
<td>3.4 (1.9-6.1)</td>
</tr>
<tr>
<td></td>
<td>Fitjen 1995</td>
<td>RB: new or history of RB</td>
<td>3.3 (1.7-6.3)</td>
</tr>
<tr>
<td></td>
<td>Hamilton 2005</td>
<td>RB</td>
<td>2.4 (1.9-3.2)</td>
</tr>
<tr>
<td></td>
<td>Helfand 1997</td>
<td>RB: red blood in stool/on toilet paper past 3 mths</td>
<td>6.5 (3.8-11)</td>
</tr>
<tr>
<td></td>
<td>Mant 1989</td>
<td>RB</td>
<td>10 (6.3-16)</td>
</tr>
<tr>
<td></td>
<td>Panzuto 2003</td>
<td>RB</td>
<td>16 (10-24)</td>
</tr>
<tr>
<td></td>
<td>Robertson 2006</td>
<td>RB</td>
<td>3.6 (2.4-5.5)</td>
</tr>
<tr>
<td></td>
<td>Sanchez 2005</td>
<td>RB</td>
<td>4.8 (2.2-10.2)</td>
</tr>
<tr>
<td></td>
<td>Steine 1994</td>
<td>RB</td>
<td>5.9 (3.7-9.3)</td>
</tr>
<tr>
<td></td>
<td>Wauters 2000</td>
<td>RB: Rectal blood on stool, underwear, toilet paper, irrespective of duration</td>
<td>7.0 (4.6-10)</td>
</tr>
<tr>
<td>First episode</td>
<td>du Toit 2006</td>
<td>RB: New irrespective of diarrhea/duration/anal causes</td>
<td>5.7 (3.4-9.2)</td>
</tr>
<tr>
<td></td>
<td>Ellis 2005</td>
<td>First time bleeding</td>
<td>4.7 (2.0-11)</td>
</tr>
<tr>
<td></td>
<td>Fijten 1995</td>
<td>RB: first time</td>
<td>5.2 (2.7-9.7)</td>
</tr>
<tr>
<td></td>
<td>Heintze 2005</td>
<td>RB: First sign of RB</td>
<td>4.0 (2.5-6.4)</td>
</tr>
<tr>
<td></td>
<td>Jones 2007</td>
<td>RB in three years after first RB</td>
<td>2.2 (2.0-2.5)</td>
</tr>
<tr>
<td></td>
<td>Metcalf 1996</td>
<td>RB: first presentation of less than 1 yr duration</td>
<td>8.1 (4.1-15)</td>
</tr>
<tr>
<td></td>
<td>Norrelund 1996</td>
<td>RB: new</td>
<td>14 (11-19)</td>
</tr>
<tr>
<td></td>
<td>Parker 2007</td>
<td>RB: first-ever consultation</td>
<td>2.2 (2.1-2.4)</td>
</tr>
<tr>
<td>With no perianal symptoms</td>
<td>Barwick 2004</td>
<td>RB and no anal symptoms &gt;65 yrs; pts under 2WW referral</td>
<td>6.9</td>
</tr>
<tr>
<td></td>
<td>Chohan 2005</td>
<td>RB and no anal symptoms &gt;55 yrs, pts under 2WW referral</td>
<td>18 (14-24)</td>
</tr>
<tr>
<td></td>
<td>Ellis 2005</td>
<td>RB &amp; no perianal symptoms</td>
<td>11 (5.4-22)</td>
</tr>
<tr>
<td></td>
<td>Flashman 2004</td>
<td>RB and no anal symptoms &gt;60 yrs; pts under 2WW referral</td>
<td>10.6 (6.7-16)</td>
</tr>
<tr>
<td>Dark/fresh/bright</td>
<td>Ellis 2005</td>
<td>Dark blood</td>
<td>9.7 (3.2-26)</td>
</tr>
<tr>
<td></td>
<td>Ellis 2005</td>
<td>Bright blood</td>
<td>4.0 (2.0-7.8)</td>
</tr>
<tr>
<td></td>
<td>Mant 1989</td>
<td>Dark blood</td>
<td>17 (6.7-38)</td>
</tr>
<tr>
<td></td>
<td>Mant 1989</td>
<td>Bright blood</td>
<td>9.9 (5.7-17)</td>
</tr>
<tr>
<td></td>
<td>Metcalf 1996</td>
<td>Dark blood</td>
<td>9.7 (3.2-26)</td>
</tr>
<tr>
<td></td>
<td>Metcalf 1996</td>
<td>Bright blood</td>
<td>8.6 (3.9-18)</td>
</tr>
<tr>
<td></td>
<td>Robertson 2006</td>
<td>Dark blood</td>
<td>7.4 (3.9-14)</td>
</tr>
<tr>
<td>Mixed with stool</td>
<td>Ellis 2005</td>
<td>Blood mixed with stool</td>
<td>3.0 (0.4-19)</td>
</tr>
<tr>
<td></td>
<td>Ellis 2005</td>
<td>Blood not mixed with stool</td>
<td>4.3 (2.3-7.8)</td>
</tr>
<tr>
<td></td>
<td>Fijten 1995</td>
<td>Blood seen mixed with stool only</td>
<td>14 (3.6-43)</td>
</tr>
<tr>
<td></td>
<td>Fijten 1995</td>
<td>Blood seen on stool or mixed with only</td>
<td>7.4 (2.8-18)</td>
</tr>
<tr>
<td></td>
<td>Mant 1989</td>
<td>Blood seen mixed with feces</td>
<td>21 (11-36) p&lt;0.05</td>
</tr>
<tr>
<td>Index test</td>
<td>Author</td>
<td>Definition of sign/symptom</td>
<td>PPV (%) (95% CI)</td>
</tr>
<tr>
<td>----------------------------------------</td>
<td>--------------</td>
<td>----------------------------------------------------------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>Blood separate from feces</td>
<td>Mant 1989</td>
<td>Blood separate from feces</td>
<td>6.6 (2.8-15)</td>
</tr>
<tr>
<td>Blood mixed with stool</td>
<td>Metcalf 1996</td>
<td>Blood mixed with stool</td>
<td>11 (4.6-24)</td>
</tr>
<tr>
<td>Blood mixed with stool</td>
<td>Robertson 2006</td>
<td>Blood mixed with stool</td>
<td>5.4 (3.4-8.5)</td>
</tr>
<tr>
<td>Blood both dark and mixed with stool</td>
<td>Robertson 2006</td>
<td>Blood both dark and mixed with stool</td>
<td>10 (5.4-19)</td>
</tr>
<tr>
<td>Neither dark nor mixed with stool</td>
<td>Robertson 2006</td>
<td>Neither dark nor mixed with stool</td>
<td>1.9 (0.8-4.6)</td>
</tr>
<tr>
<td>Blood on paper only</td>
<td>Ellis 2005</td>
<td>Blood on paper only</td>
<td>2.4 (0.6-9.2)</td>
</tr>
<tr>
<td>Blood in pan and on paper</td>
<td>Ellis 2005</td>
<td>Blood in pan and on paper</td>
<td>4.9 (2.6-9.1)</td>
</tr>
<tr>
<td>Blood on paper only</td>
<td>Mant 1989</td>
<td>Blood on paper only</td>
<td>9.6 (4.1-21)</td>
</tr>
<tr>
<td>Blood on paper only</td>
<td>Metcalf 1996</td>
<td>Blood on paper only</td>
<td>8.3 (2.1-28)</td>
</tr>
<tr>
<td>Blood &amp; perianal symptoms</td>
<td>Ellis 2005</td>
<td>Blood &amp; perianal symptoms</td>
<td>2.0 (0.7-5.1)</td>
</tr>
<tr>
<td>Large volume of blood</td>
<td>Ellis 2005</td>
<td>Large volume of blood</td>
<td>1.3 (0.2-8.4)</td>
</tr>
<tr>
<td>Small volume of blood</td>
<td>Ellis 2005</td>
<td>Small volume of blood</td>
<td>5.3 (2.9-9.7)</td>
</tr>
<tr>
<td>Not first time bleeding</td>
<td>Ellis 2005</td>
<td>Not first time bleeding</td>
<td>3.8 (1.7-8.1)</td>
</tr>
<tr>
<td>Blood seen - others or combinations</td>
<td>Fijten 1995</td>
<td>Blood seen - others or combinations</td>
<td>0.8 (0.1-5.6)</td>
</tr>
<tr>
<td>Blood seen - unknown</td>
<td>Fijten 1995</td>
<td>Blood seen - unknown</td>
<td>7.4 (2.8-18)</td>
</tr>
<tr>
<td>Previous history of rectal bleeding</td>
<td>Fijten 1995</td>
<td>Previous history of rectal bleeding</td>
<td>0</td>
</tr>
<tr>
<td>RB reported twice</td>
<td>Hamilton 2005</td>
<td>RB reported twice</td>
<td>6.8</td>
</tr>
<tr>
<td>RB &amp; female</td>
<td>Barwick 2004</td>
<td>RB &amp; female</td>
<td>5 (2-12)</td>
</tr>
<tr>
<td>RB &amp; male</td>
<td>Barwick 2004</td>
<td>RB &amp; male</td>
<td>16 (9-28)</td>
</tr>
<tr>
<td>RB &amp; ≥80 yrs</td>
<td>Bat 1992</td>
<td>RB &amp; ≥80 yrs</td>
<td>29</td>
</tr>
<tr>
<td>RB &amp; ≥55 yrs</td>
<td>du Toit 2006</td>
<td>RB &amp; ≥55 yrs</td>
<td>6.1 (3.6-10)</td>
</tr>
<tr>
<td>RB &amp; ≥65 yrs</td>
<td>du Toit 2006</td>
<td>RB &amp; ≥65 yrs</td>
<td>8.6 (5-15)</td>
</tr>
<tr>
<td>RB &amp; ≥75 yrs</td>
<td>du Toit 2006</td>
<td>RB &amp; ≥75 yrs</td>
<td>7.9 (3.6-15)</td>
</tr>
<tr>
<td>RB &amp; ≥60 yrs</td>
<td>Ellis 2005</td>
<td>RB &amp; ≥60 yrs</td>
<td>5.2 (2.6-10)</td>
</tr>
<tr>
<td>RB &amp; &lt;59 yrs</td>
<td>Ellis 2005</td>
<td>RB &amp; &lt;59 yrs</td>
<td>1.8 (0.6-5.5)</td>
</tr>
<tr>
<td>Blood seen</td>
<td>Fijten 1995</td>
<td>Blood seen</td>
<td>20 (10-35)</td>
</tr>
<tr>
<td>Blood, female</td>
<td>Fijten 1995</td>
<td>Blood, female</td>
<td>1 (0.3-5.1)</td>
</tr>
<tr>
<td>Blood, male</td>
<td>Fijten 1995</td>
<td>Blood, male</td>
<td>5.9 (2.9-12)</td>
</tr>
<tr>
<td>RB, &lt;50 yrs; First sign of RB</td>
<td>Heintze 2005</td>
<td>RB, &lt;50 yrs; First sign of RB</td>
<td>1.3 (0.3-5.1)</td>
</tr>
<tr>
<td>RB, ≥50 yrs; First sign of RB</td>
<td>Heintze 2005</td>
<td>RB, ≥50 yrs; First sign of RB</td>
<td>5.6 (3.4-9.1)</td>
</tr>
<tr>
<td>CRC in men in 3 yrs after first RB</td>
<td>Jones 2007</td>
<td>CRC in men in 3 yrs after first RB</td>
<td>2.4 (2.1-2.8)</td>
</tr>
<tr>
<td>CRC in women in 3 yrs after first RB</td>
<td>Jones 2007</td>
<td>CRC in women in 3 yrs after first RB</td>
<td>2.0 (1.7-2.3)</td>
</tr>
<tr>
<td>RB, women &lt;45yr*</td>
<td>Jones 2007</td>
<td>RB, women &lt;45yr*</td>
<td>0.2 (0.1-0.5)</td>
</tr>
<tr>
<td>RB, women 45-54 yr*</td>
<td>Jones 2007</td>
<td>RB, women 45-54 yr*</td>
<td>0.6 (0.3-1.2)</td>
</tr>
<tr>
<td>RB, women 55-64 yr*</td>
<td>Jones 2007</td>
<td>RB, women 55-64 yr*</td>
<td>2.8 (1.9-3.8)</td>
</tr>
<tr>
<td>RB, women 65-74 yr*</td>
<td>Jones 2007</td>
<td>RB, women 65-74 yr*</td>
<td>2.4 (1.6-3.5)</td>
</tr>
<tr>
<td>RB, women 75-84 yr*</td>
<td>Jones 2007</td>
<td>RB, women 75-84 yr*</td>
<td>7.2 (5.6-9.1)</td>
</tr>
<tr>
<td>Index test</td>
<td>Author</td>
<td>Definition of sign/symptom</td>
<td>PPV (%) (95% CI)</td>
</tr>
<tr>
<td>---------------------</td>
<td>--------------</td>
<td>-----------------------------------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>Jones 2007</td>
<td>RB, women ≥85 yr*</td>
<td></td>
<td>2.8 (1.5-4.8)</td>
</tr>
<tr>
<td>Jones 2007</td>
<td>RB, men &lt;45yr*</td>
<td></td>
<td>0.1 (0.02-0.3)</td>
</tr>
<tr>
<td>Jones 2007</td>
<td>RB, men 45-54 yr*</td>
<td></td>
<td>1.6 (1.00-2.3)</td>
</tr>
<tr>
<td>Jones 2007</td>
<td>RB, men 55-64 yr*</td>
<td></td>
<td>3.4 (2.5-4.5)</td>
</tr>
<tr>
<td>Jones 2007</td>
<td>RB, men 65-74 yr*</td>
<td></td>
<td>4.8 (3.7-6.2)</td>
</tr>
<tr>
<td>Jones 2007</td>
<td>RB, men 75-84 yr*</td>
<td></td>
<td>7.7 (5.8-10)</td>
</tr>
<tr>
<td>Jones 2007</td>
<td>RB, men ≥85 yr*</td>
<td></td>
<td>5.1 (2.6-9.8)</td>
</tr>
<tr>
<td>Lawrenson 2005</td>
<td>RB men aged 40-49**</td>
<td></td>
<td>0.92</td>
</tr>
<tr>
<td>Lawrenson 2005</td>
<td>RB men aged 50-59**</td>
<td></td>
<td>2.75</td>
</tr>
<tr>
<td>Lawrenson 2005</td>
<td>RB men aged 60-69**</td>
<td></td>
<td>5.99</td>
</tr>
<tr>
<td>Lawrenson 2005</td>
<td>RB men aged 70-79**</td>
<td></td>
<td>7.69</td>
</tr>
<tr>
<td>Lawrenson 2005</td>
<td>RB men aged 80-89**</td>
<td></td>
<td>9.13</td>
</tr>
<tr>
<td>Lawrenson 2005</td>
<td>RB women aged 40-49**</td>
<td></td>
<td>0.87</td>
</tr>
<tr>
<td>Lawrenson 2005</td>
<td>RB women aged 50-59**</td>
<td></td>
<td>2.16</td>
</tr>
<tr>
<td>Lawrenson 2005</td>
<td>RB women aged 60-69**</td>
<td></td>
<td>3.50</td>
</tr>
<tr>
<td>Lawrenson 2005</td>
<td>RB women aged 70-79**</td>
<td></td>
<td>4.61</td>
</tr>
<tr>
<td>Lawrenson 2005</td>
<td>RB women aged 80-89**</td>
<td></td>
<td>4.89</td>
</tr>
<tr>
<td>Mant 1989</td>
<td>RB &amp; male</td>
<td></td>
<td>9.1 (4.4-18)</td>
</tr>
<tr>
<td>Mant 1989</td>
<td>RB &amp; female</td>
<td></td>
<td>13 (7.0-24)</td>
</tr>
<tr>
<td>Norrelund 1996</td>
<td>RB &amp; &gt;69</td>
<td></td>
<td>31 (22-40)</td>
</tr>
<tr>
<td>Norrelund 1996</td>
<td>RB &amp; female</td>
<td></td>
<td>13 (9-18)</td>
</tr>
<tr>
<td>Parker 2007</td>
<td>RB: first-ever consultation &amp; ≥55 yrs</td>
<td></td>
<td>4.0 (3.7-4.3)</td>
</tr>
<tr>
<td>Parker 2007</td>
<td>RB: first-ever consultation &amp; ≥65 yrs</td>
<td></td>
<td>4.6 (4.2-5.1)</td>
</tr>
<tr>
<td>Parker 2007</td>
<td>RB: first-ever consultation &amp; ≥75 yrs</td>
<td></td>
<td>4.9 (4.3-5.6)</td>
</tr>
<tr>
<td>Robertson 2006</td>
<td>RB &amp; ≥50 yrs</td>
<td></td>
<td>5.7 (3.7-8.7)</td>
</tr>
<tr>
<td>Robertson 2006</td>
<td>RB &amp; ≥70 yrs</td>
<td></td>
<td>7.5 (3.8-14)</td>
</tr>
<tr>
<td>Robertson 2006</td>
<td>RB &amp; female</td>
<td></td>
<td>2.7 (1.4-5.1)</td>
</tr>
<tr>
<td>Robertson 2006</td>
<td>RB &amp; male</td>
<td></td>
<td>4.8 (2.8-8.0)</td>
</tr>
<tr>
<td>Sanchez 2005</td>
<td>RB &amp; &gt;50 yrs</td>
<td></td>
<td>9.5 (4.3-19.6)</td>
</tr>
<tr>
<td>Wauters 2000</td>
<td>RB &amp; &lt;50 yrs</td>
<td></td>
<td>0.7 (0.1-4.9)</td>
</tr>
<tr>
<td>Wauters 2000</td>
<td>RB &amp; ≥50 yrs</td>
<td></td>
<td>11 (7-15)</td>
</tr>
<tr>
<td>Wauters 2000</td>
<td>RB &amp; ≥60 yrs</td>
<td></td>
<td>13 (9-19)</td>
</tr>
<tr>
<td>Wauters 2000</td>
<td>RB &amp; ≥70 yrs</td>
<td></td>
<td>15 (9-22)</td>
</tr>
</tbody>
</table>

**Abbreviations:** CI = confidence intervals; CRC = colorectal cancer; mth(s) = month(s); pts = patients; PPV = positive-predictive value; 2WW = two-week wait; yr(s) = year(s).

* CRC diagnosed within 3 yrs after first rectal bleed.

**Diagnosed within 12 mths of initial bleeding per 100 pts presenting (men & women).
Appendix 5. Change in bowel habits (CBH) as a single symptom.

<table>
<thead>
<tr>
<th>Index test</th>
<th>Author</th>
<th>Definition of sign/symptom</th>
<th>PPV (%) (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CBH</td>
<td>Panzuto 2003</td>
<td>CBH: Diarrhea or constipation or altered stool in previous 3 mths</td>
<td>15 (7.2-26)</td>
</tr>
<tr>
<td></td>
<td>Steine 1994</td>
<td>CBH</td>
<td>3.0 (2.1-4.5)</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>Chohan 2005</td>
<td>CBH (looser and/or more frequent) &gt; 6 wks, pts under 2WW referral</td>
<td>14 (9.5-19)</td>
</tr>
<tr>
<td></td>
<td>Hamilton 2005</td>
<td>Diarrhea</td>
<td>0.94 (0.7-1.1)</td>
</tr>
<tr>
<td></td>
<td>Panzuto 2003</td>
<td>Diarrhea</td>
<td>12 (6.4-21)</td>
</tr>
<tr>
<td>Constipation</td>
<td>Hamilton 2005</td>
<td>Constipation</td>
<td>0.42 (0.3-0.5)</td>
</tr>
<tr>
<td></td>
<td>Panzuto 2003</td>
<td>Constipation in previous 3 mths</td>
<td>16 (10-23)</td>
</tr>
<tr>
<td>Other</td>
<td>Flashman 2004</td>
<td>CBH &amp; no RB for 6 wks &gt;60 yrs, pts under 2WW referral</td>
<td>6.1 (3.8-9.6)</td>
</tr>
<tr>
<td></td>
<td>Hamilton 2005</td>
<td>diarrhea and constipation</td>
<td>1.1 (0.6-1.8)</td>
</tr>
<tr>
<td></td>
<td>Hamilton 2005</td>
<td>Diarrhea reported twice</td>
<td>1.5 (1.0-2.2)</td>
</tr>
<tr>
<td></td>
<td>Hamilton 2005</td>
<td>Constipation reported twice</td>
<td>0.81 (0.5-1.3)</td>
</tr>
<tr>
<td>By Age/Gender</td>
<td>Lawrenson 2005</td>
<td>CBH men aged 40-49*</td>
<td>0.89</td>
</tr>
<tr>
<td></td>
<td>Lawrenson 2005</td>
<td>CBH men aged 50-59*</td>
<td>4.07</td>
</tr>
<tr>
<td></td>
<td>Lawrenson 2005</td>
<td>CBH men aged 60-69*</td>
<td>6.89</td>
</tr>
<tr>
<td></td>
<td>Lawrenson 2005</td>
<td>CBH men aged 70-79*</td>
<td>8.48</td>
</tr>
<tr>
<td></td>
<td>Lawrenson 2005</td>
<td>CBH men aged 80-89*</td>
<td>7.73</td>
</tr>
<tr>
<td></td>
<td>Lawrenson 2005</td>
<td>CBH women aged 40-49*</td>
<td>0.64</td>
</tr>
<tr>
<td></td>
<td>Lawrenson 2005</td>
<td>CBH women aged 50-59*</td>
<td>1.64</td>
</tr>
<tr>
<td></td>
<td>Lawrenson 2005</td>
<td>CBH women aged 60-69*</td>
<td>2.42</td>
</tr>
<tr>
<td></td>
<td>Lawrenson 2005</td>
<td>CBH women aged 70-79*</td>
<td>3.25</td>
</tr>
<tr>
<td></td>
<td>Lawrenson 2005</td>
<td>CBH women aged 80-89*</td>
<td>4.09</td>
</tr>
</tbody>
</table>

**Abbreviations:** CI = confidence intervals; mth(s) = month(s); pts = patients; PPV = positive-predictive value; 2WW = two-week wait; wks = weeks; yrs = years

*Diagnosed within 12 mths of initial change in bowel habits per 100 pts presenting (men & women)
### Appendix 6. Rectal bleeding (RB) and change in bowel habits (CBH).

<table>
<thead>
<tr>
<th>Index test</th>
<th>Author</th>
<th>Definition of sign/symptom</th>
<th>PPV (%) (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>RB &amp; CBH</td>
<td>Chohan 2005</td>
<td>CBH &amp; any RB, pts under 2WW referral</td>
<td>19 (14-26)</td>
</tr>
<tr>
<td>RB &amp; CBH</td>
<td>Ellis 2005</td>
<td>RB &amp; CBH</td>
<td>9.2 (5.2-16)</td>
</tr>
<tr>
<td>RB &amp; no CBH</td>
<td>Ellis 2005</td>
<td>RB &amp; no CBH</td>
<td>0</td>
</tr>
<tr>
<td>RB &amp; CBH (loose &amp;/or frequent)</td>
<td>Ellis 2005</td>
<td>RB &amp; CBH (loose &amp;/or frequent)</td>
<td>12 (6.6-21)</td>
</tr>
<tr>
<td>RB &amp; CBH (hard &amp;/or frequent)</td>
<td>Ellis 2005</td>
<td>RB &amp; CBH (hard &amp;/or frequent)</td>
<td>2.8 (0.4-17)</td>
</tr>
<tr>
<td>RB &amp; abdominal pain</td>
<td>Ellis 2005</td>
<td>RB &amp; abdominal pain</td>
<td>9.0 (4.1-19)</td>
</tr>
<tr>
<td>RB &amp; no abdominal pain</td>
<td>Ellis 2005</td>
<td>RB &amp; no abdominal pain</td>
<td>9.6 (4.1-21)</td>
</tr>
<tr>
<td>RB &amp; CBH (loose &amp;/or frequent)</td>
<td>Fijten 1995</td>
<td>RB &amp; CBH (loose &amp;/or frequent)</td>
<td>9.0 (4.3-18)</td>
</tr>
<tr>
<td>RB &amp; CBH (loose &amp;/or frequent) for 6 wks, pts under 2WW referral</td>
<td>Flashman 2004</td>
<td>RB &amp; CBH (loose &amp;/or frequent) for 6 wks, pts under 2WW referral</td>
<td>13.9 (9.7-19)</td>
</tr>
<tr>
<td>RB and constipation</td>
<td>Hamilton 2005</td>
<td>RB and constipation</td>
<td>2.4 (1.4-4.4)</td>
</tr>
<tr>
<td>RB and Diarrhea</td>
<td>Hamilton 2005</td>
<td>RB and Diarrhea</td>
<td>3.4 (2.1-6.0)</td>
</tr>
<tr>
<td>RB &amp; CBH; Within 3 mths</td>
<td>Mant 1989</td>
<td>RB &amp; CBH; Within 3 mths</td>
<td>11 (4.9-22)</td>
</tr>
<tr>
<td>RB &amp; Feeling of incomplete evacuation of rectum</td>
<td>Mant 1989</td>
<td>RB &amp; Feeling of incomplete evacuation of rectum</td>
<td>12 (5.0-26)</td>
</tr>
<tr>
<td>RB &amp; CBH</td>
<td>Metcalf 1996</td>
<td>RB &amp; CBH</td>
<td>10 (3.9-24)</td>
</tr>
<tr>
<td>RB &amp; diarrhea</td>
<td>Metcalf 1996</td>
<td>RB &amp; diarrhea</td>
<td>7.4 (1.9-25)</td>
</tr>
<tr>
<td>RB &amp; constipation</td>
<td>Metcalf 1996</td>
<td>RB &amp; constipation</td>
<td>2.6 (0.4-16)</td>
</tr>
<tr>
<td>RB &amp; CBH</td>
<td>Norrelund 1996</td>
<td>RB &amp; CBH</td>
<td>27 (19-36)</td>
</tr>
<tr>
<td>RB &amp; increased frequency/loose motions</td>
<td>Robertson 2006</td>
<td>RB &amp; increased frequency/loose motions</td>
<td>4.8 (2.8-8.1)</td>
</tr>
<tr>
<td>&gt;69 yrs &amp; RB &amp; CBH</td>
<td>Norrelund 1996</td>
<td>&gt;69 yrs &amp; RB &amp; CBH</td>
<td>41 (28-56)</td>
</tr>
</tbody>
</table>

**Abbreviations:** CI = confidence intervals; mth = month; pts = patients; PPV = positive-predictive value; 2WW = two-week wait; wks = weeks; yrs = years.
## Appendix 7a. Anemia or iron-deficiency anemia (IDA) as single signs.

<table>
<thead>
<tr>
<th>Index test</th>
<th>Author</th>
<th>Definition of sign/symptom</th>
<th>PPV (%)</th>
<th>(95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anemia</td>
<td>Hamilton 2005</td>
<td>Low Hb 100-130 g/L</td>
<td>0.97</td>
<td>(0.8-1.3)</td>
</tr>
<tr>
<td></td>
<td>Hamilton 2005</td>
<td>Low Hb &lt;100 g/L</td>
<td>2.3</td>
<td>(1.6-3.1)</td>
</tr>
<tr>
<td></td>
<td>Hamilton 2008</td>
<td>Hb 100-129 g/L</td>
<td>0.3</td>
<td>(0.2-0.3)</td>
</tr>
<tr>
<td></td>
<td>Hamilton 2008</td>
<td>Hb &lt;99 g/L</td>
<td>2.0</td>
<td>(1.7-2.3)</td>
</tr>
<tr>
<td>IDA</td>
<td>Barwick 2004</td>
<td>IDA Hb &lt;100g/L, pts under 2WW referral</td>
<td>11</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chohan 2005</td>
<td>IDA Hb &lt;100g/L, pts under 2WW referral</td>
<td>34</td>
<td>(21-50)</td>
</tr>
<tr>
<td></td>
<td>Flashman 2004</td>
<td>IDA: Hb ≤110 g/L for males, ≤100 g/L for females &gt;50 yrs, pts under 2WW referral</td>
<td>10.9</td>
<td>(5.0-22)</td>
</tr>
<tr>
<td></td>
<td>Panzuto 2003</td>
<td>IDA: Hb &lt;140 g/L for males, &lt;120 g/L for females, ferritin &lt;30 µg/L and MCV &lt;80 fl</td>
<td>41</td>
<td>(30-52)</td>
</tr>
<tr>
<td></td>
<td>Stellon 1997</td>
<td>IDA: Hb &lt;120 g/L and/or MCV &lt;80 fl and ferritin ≤ 16 ng/L</td>
<td>7.7</td>
<td>(1.9-26)</td>
</tr>
<tr>
<td></td>
<td>Yates 2004</td>
<td>IDA: &gt;20 yrs male or &gt;50 yrs female; Hb ≤120 g/L for males, ≤110 g/L for females; MCV &lt;82 fl or &lt;78 fl; red cell count &lt;5.5 x 10¹²/L</td>
<td>8.6</td>
<td>(6.3-12)</td>
</tr>
<tr>
<td>Anaemia by Age/Gender</td>
<td>Hamilton 2008</td>
<td>age 60-69, anemia: Hb &lt;110 g/L for men</td>
<td>1.4</td>
<td>(0.9-2.3)</td>
</tr>
<tr>
<td></td>
<td>Hamilton 2008</td>
<td>age 60-69, anemia: Hb &lt;100g/L for women</td>
<td>1.2</td>
<td>(0.7-2.0)</td>
</tr>
<tr>
<td></td>
<td>Lawrenson 2005</td>
<td>Anemia men aged 40-49*</td>
<td>1.07</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lawrenson 2005</td>
<td>Anemia men aged 50-59*</td>
<td>1.86</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lawrenson 2005</td>
<td>Anemia men aged 60-69*</td>
<td>3.02</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lawrenson 2005</td>
<td>Anemia men aged 70-79*</td>
<td>3.38</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lawrenson 2005</td>
<td>Anemia men aged 80-89*</td>
<td>2.98</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lawrenson 2005</td>
<td>Anemia women aged 40-49*</td>
<td>0.08</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lawrenson 2005</td>
<td>Anemia women aged 50-59*</td>
<td>0.56</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lawrenson 2005</td>
<td>Anemia women aged 60-69*</td>
<td>1.38</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lawrenson 2005</td>
<td>Anemia women aged 70-79*</td>
<td>1.99</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lawrenson 2005</td>
<td>Anemia women aged 80-89*</td>
<td>2.01</td>
<td></td>
</tr>
<tr>
<td>IDA by Age/Gender</td>
<td>Hamilton 2008</td>
<td>age 60-69, IDA Hb &lt;110 g/L for men MCV &lt;80.0 fl or ferritin &lt;20 ng/ml</td>
<td>6.5</td>
<td>(2.0-19)</td>
</tr>
<tr>
<td></td>
<td>Hamilton 2008</td>
<td>age 60-69, IDA, Hb &lt;100 g/L for women MCV &lt;80.0 fl or ferritin &lt;20 ng/ml</td>
<td>2.4</td>
<td>(1.0-5.7)</td>
</tr>
<tr>
<td></td>
<td>Hamilton 2008</td>
<td>&gt;60 yrs, IDA ; Hb &lt;110g/L for men MCV &lt;80.0 fl or ferritin &lt;20 ng/ml</td>
<td>13.3</td>
<td>(9.7-18)</td>
</tr>
<tr>
<td></td>
<td>Hamilton 2008</td>
<td>&gt;60 yrs, IDA ; Hb &lt;100g/L for women MCV &lt;80.0 fl or ferritin &lt;20 ng/ml</td>
<td>7.7</td>
<td>(5.7-11)</td>
</tr>
</tbody>
</table>

**Abbreviations:** CI = confidence intervals; fl = fluid ounce; g = grams; Hb = haemoglobin; L = litre; MCV = mean corpuscular volume; µg = microgram; mth(s) = month(s); ng = nanograms; pts = patients; PPV = positive-predictive value; 2WW = two-week wait; wks = weeks; yrs = years.

*Diagnosed within 12 mths of initial anaemia per 100 patients presenting (men & women).
### Appendix 7b. Anemia or iron-deficiency anemia (IDA) as single signs.

<table>
<thead>
<tr>
<th>Hamilton 2008</th>
<th>Sign &amp; Gender</th>
<th>Age group</th>
<th>Hb levels (g/dL) (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>&lt;90</td>
<td>90-99</td>
</tr>
<tr>
<td>Hamilton 2008</td>
<td>Anemia men</td>
<td>30-59 yrs</td>
<td>1.3 (0.4-4.3)</td>
</tr>
<tr>
<td>Hamilton 2008</td>
<td>Anemia men</td>
<td>60-69 yrs</td>
<td>7.6 (3.4-16)</td>
</tr>
<tr>
<td>Hamilton 2008</td>
<td>Anemia men</td>
<td>70-79 yrs</td>
<td>8.8 (5.4-14)</td>
</tr>
<tr>
<td>Hamilton 2008</td>
<td>Anemia men</td>
<td>≥ 80 yrs</td>
<td>6.8 (4.2-11)</td>
</tr>
<tr>
<td>Hamilton 2008</td>
<td>Anemia women</td>
<td>30-59 yrs</td>
<td>0.9 (0.3-2.9)</td>
</tr>
<tr>
<td>Hamilton 2008</td>
<td>Anemia women</td>
<td>60-69 yrs</td>
<td>&gt;5</td>
</tr>
<tr>
<td>Hamilton 2008</td>
<td>Anemia women</td>
<td>70-79 yrs</td>
<td>8.6 (5.4-14)</td>
</tr>
<tr>
<td>Hamilton 2008</td>
<td>Anemia women</td>
<td>≥ 80 yrs</td>
<td>7.1 (4.5-11)</td>
</tr>
<tr>
<td>Hamilton 2008</td>
<td>IDA men</td>
<td>60-69 yrs</td>
<td>&gt;5</td>
</tr>
<tr>
<td>Hamilton 2008</td>
<td>IDA men</td>
<td>70-79 yrs</td>
<td>18 (8.7-34)</td>
</tr>
<tr>
<td>Hamilton 2008</td>
<td>IDA men</td>
<td>≥ 80 yrs</td>
<td>15 (7.3-28)</td>
</tr>
<tr>
<td>Hamilton 2008</td>
<td>IDA women</td>
<td>30-59 yrs</td>
<td>0.6 (0.2-2.2)</td>
</tr>
<tr>
<td>Hamilton 2008</td>
<td>IDA women</td>
<td>60-69 yrs</td>
<td>&gt;5</td>
</tr>
<tr>
<td>Hamilton 2008</td>
<td>IDA women</td>
<td>70-79 yrs</td>
<td>10 (5.2-19)</td>
</tr>
<tr>
<td>Hamilton 2008</td>
<td>IDA women</td>
<td>≥ 80 yrs</td>
<td>10 (5.6-17)</td>
</tr>
</tbody>
</table>

**Abbreviations:** CI = confidence intervals; IDA = iron-deficiency anemia; yrs = years.
### Appendix 8. Perianal symptoms, weight loss, abdominal pain and other symptoms or signs as single symptoms or signs.

<table>
<thead>
<tr>
<th>Index test</th>
<th>Author</th>
<th>Definition of sign/symptom</th>
<th>PPV (%) (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weight loss</td>
<td>Barwick 2004</td>
<td>Weight loss, pts under 2WW referral</td>
<td>5</td>
</tr>
<tr>
<td>Hamilton 2005</td>
<td></td>
<td>Weight loss</td>
<td>1.2 (0.9-1.6)</td>
</tr>
<tr>
<td>Hamilton 2005</td>
<td></td>
<td>Wt loss reported twice</td>
<td>1.4 (0.8-2.6)</td>
</tr>
<tr>
<td>Panzuto 2003</td>
<td></td>
<td>Weight loss - Decrease &gt;3 kg in 3 mths prior to visit</td>
<td>36 (23-51)</td>
</tr>
<tr>
<td>Steine 1994</td>
<td></td>
<td>Weight loss</td>
<td>4.8 (3.0-7.6)</td>
</tr>
<tr>
<td>Nausea/vomiting</td>
<td>Steine 1994</td>
<td>Nausea</td>
<td>1.8 (1.0-3.3)</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>Barwick 2004</td>
<td>Abdominal pain, pts under 2WW referral</td>
<td>7</td>
</tr>
<tr>
<td>Hamilton 2005</td>
<td></td>
<td>abdominal pain</td>
<td>1.1 (0.9-1.3)</td>
</tr>
<tr>
<td>Hamilton 2005</td>
<td></td>
<td>abdominal pain reported twice</td>
<td>3.0 (1.8-5.2)</td>
</tr>
<tr>
<td>Muris 1993</td>
<td></td>
<td>abdominal pain (selected pt)</td>
<td>0.5 (0.2-1.6)</td>
</tr>
<tr>
<td>Panzuto 2003</td>
<td></td>
<td>Abdominal pain</td>
<td>13 (9.6-19)</td>
</tr>
<tr>
<td>Steine 1994</td>
<td></td>
<td>Abdominal pain</td>
<td>2.1 (1.4-3.0)</td>
</tr>
<tr>
<td>Abdominal tenderness/bloating</td>
<td>Hamilton 2005</td>
<td>Abdominal tenderness</td>
<td>1.1 (0.8-1.5)</td>
</tr>
<tr>
<td>Hamilton 2005</td>
<td></td>
<td>Abdominal tenderness reported twice</td>
<td>1.7 (0.8-3.7)</td>
</tr>
<tr>
<td>Hamilton 2005</td>
<td></td>
<td>Abdominal tenderness and abdominal pain</td>
<td>1.4 (0.3-2.2)</td>
</tr>
<tr>
<td>Panzuto 2003</td>
<td></td>
<td>bloating</td>
<td>13 (8.8-19)</td>
</tr>
<tr>
<td>Steine 1994</td>
<td></td>
<td>Abdominal distension</td>
<td>2.6 (1.9-3.6)</td>
</tr>
<tr>
<td>Fatigue</td>
<td>Steine 1994</td>
<td>Fatigue</td>
<td>1.9 (1.2-2.9)</td>
</tr>
</tbody>
</table>

**Abbreviations:** CI = confidence intervals; kg = kilograms; mths = months; pts = patients; PPV = positive-predictive value; 2WW = two-week wait; wks = weeks; yrs = years.
## Appendix 9. Combination of rectal bleeding (RB) and other symptoms.

<table>
<thead>
<tr>
<th>Index test</th>
<th>Author</th>
<th>Definition of sign/symptom</th>
<th>PPV (%) (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Perianal symptoms</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fijten 1995</td>
<td>RB &amp; perianal eczema</td>
<td>18 (5.8-43)</td>
</tr>
<tr>
<td></td>
<td>Mant 1989</td>
<td>RB &amp; anal itch</td>
<td>2.8 (0.4-17)</td>
</tr>
<tr>
<td></td>
<td>Mant 1989</td>
<td>RB &amp; anal protrusion</td>
<td>3.3 (0.5-20)</td>
</tr>
<tr>
<td></td>
<td>Mant 1989</td>
<td>RB &amp; pain on defecation</td>
<td>6.7 (1.7-23)</td>
</tr>
<tr>
<td></td>
<td>Robertson 2006</td>
<td>RB &amp; hemorrhoids</td>
<td>3.1 (1.7-5.7)</td>
</tr>
<tr>
<td></td>
<td>Robertson 2006</td>
<td>RB &amp; hemorrhoids and bright red blood not mixed with stool</td>
<td>1.9 (0.6-5.7)</td>
</tr>
<tr>
<td></td>
<td>Robertson 2006</td>
<td>RB &amp; hemorrhoids and no other symptoms except bright non-mixed bleeding</td>
<td>3.3 (1.1-9.8)</td>
</tr>
<tr>
<td></td>
<td>Wauters 2000</td>
<td>RB &amp; spasms</td>
<td>5.4 (2.0-11)</td>
</tr>
<tr>
<td><strong>Abdominal Pain</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fijten 1995</td>
<td>RB &amp; abdominal pain</td>
<td>2.2 (0.7-6.7)</td>
</tr>
<tr>
<td></td>
<td>Fijten 1995</td>
<td>RB &amp; pain at night</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Hamilton 2005</td>
<td>Abdominal pain and RB</td>
<td>3.1 (1.9-5.3)</td>
</tr>
<tr>
<td></td>
<td>Mant 1989</td>
<td>RB &amp; abdominal pain last 3 mths</td>
<td>9.3 (3.5-22)</td>
</tr>
<tr>
<td></td>
<td>Metcalf 1996</td>
<td>RB &amp; abdominal pain</td>
<td>7.1 (2.3-20)</td>
</tr>
<tr>
<td></td>
<td>Norrelund 1996</td>
<td>RB &amp; abdominal pain</td>
<td>23 (16-33)</td>
</tr>
<tr>
<td></td>
<td>Robertson 2006</td>
<td>RB &amp; abdominal pain</td>
<td>1.7 (0.6-4.5)</td>
</tr>
<tr>
<td></td>
<td>Wauters 2000</td>
<td>RB &amp; pain</td>
<td>0 (0-10)</td>
</tr>
<tr>
<td><strong>Abdominal tenderness</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hamilton 2005</td>
<td>Abdominal tenderness and RB</td>
<td>4.5</td>
</tr>
<tr>
<td><strong>Weight loss</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fijten 1995</td>
<td>RB &amp; weight loss</td>
<td>9.5 (3.6-23)</td>
</tr>
<tr>
<td></td>
<td>Hamilton 2005</td>
<td>Weight loss and RB</td>
<td>4.7</td>
</tr>
<tr>
<td></td>
<td>Mant 1989</td>
<td>RB &amp; weight loss</td>
<td>14 (3.6-43)</td>
</tr>
<tr>
<td></td>
<td>Metcalf 1996</td>
<td>RB &amp; weight loss</td>
<td>13 (3.4-41)</td>
</tr>
<tr>
<td></td>
<td>Norrelund 1996</td>
<td>RB &amp; weight loss</td>
<td>23 (13-37)</td>
</tr>
<tr>
<td></td>
<td>Robertson 2006</td>
<td>RB &amp; weight loss</td>
<td>4.8 (1.6-14)</td>
</tr>
<tr>
<td></td>
<td>Wauters 2000</td>
<td>RB &amp; Weight loss</td>
<td>16 (4.5-36)</td>
</tr>
<tr>
<td><strong>Other</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fijten 1995</td>
<td>RB &amp; decreased appetite</td>
<td>2.4 (0.3-15)</td>
</tr>
<tr>
<td></td>
<td>Fijten 1995</td>
<td>RB &amp; nausea</td>
<td>1.5 (0.2-9.7)</td>
</tr>
<tr>
<td></td>
<td>Fijten 1995</td>
<td>RB &amp; pale conjunctivae</td>
<td>17 (2.3-63)</td>
</tr>
<tr>
<td></td>
<td>Fijten 1995</td>
<td>RB &amp; family history of abdominal disease</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Mant 1989</td>
<td>RB &amp; first-degree relative with CRC</td>
<td>10 (2.5-32)</td>
</tr>
<tr>
<td></td>
<td>Metcalf 1996</td>
<td>RB &amp; associated slime</td>
<td>11 (3.5-28)</td>
</tr>
<tr>
<td></td>
<td>Wauters 2000</td>
<td>RB &amp; fatigue</td>
<td>7.1 (8.3-16)</td>
</tr>
</tbody>
</table>

**Abbreviations:** CI = confidence intervals; mths = months; PPV = positive-predictive value; yrs = years.
### Appendix 10. Combination of change in bowel habits (CBH) and other symptoms.

<table>
<thead>
<tr>
<th>Index test</th>
<th>Author</th>
<th>Definition of sign/symptom</th>
<th>PPV (%) (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abdominal pain or tenderness</td>
<td>Hamilton 2005</td>
<td>abdominal pain and constipation</td>
<td>1.5 (1.0-2.2)</td>
</tr>
<tr>
<td></td>
<td>Hamilton 2005</td>
<td>abdominal tenderness and constipation</td>
<td>1.7 (0.9-3.4)</td>
</tr>
<tr>
<td></td>
<td>Hamilton 2005</td>
<td>abdominal pain and diarrhea</td>
<td>1.9 (1.4-2.7)</td>
</tr>
<tr>
<td></td>
<td>Hamilton 2005</td>
<td>abdominal tenderness and diarrhea</td>
<td>2.4 (1.3-4.8)</td>
</tr>
<tr>
<td>Weight loss</td>
<td>Hamilton 2005</td>
<td>wt loss and constipation</td>
<td>3.0 (1.7-5.4)</td>
</tr>
<tr>
<td></td>
<td>Hamilton 2005</td>
<td>wt loss and diarrhea</td>
<td>3.1 (1.8-5.5)</td>
</tr>
<tr>
<td>Anemia</td>
<td>Hamilton 2005</td>
<td>Hb 100-130 g/L and constipation</td>
<td>1.2 (0.6-2.7)</td>
</tr>
<tr>
<td></td>
<td>Hamilton 2005</td>
<td>Hb &lt;100 g/L and constipation</td>
<td>2.6</td>
</tr>
<tr>
<td></td>
<td>Hamilton 2005</td>
<td>Hb 100-130 g/L and diarrhea</td>
<td>2.2 (1.2-4.3)</td>
</tr>
<tr>
<td></td>
<td>Hamilton 2005</td>
<td>Hb &lt;100 g/L and diarrhea</td>
<td>2.9</td>
</tr>
</tbody>
</table>

**Abbreviations:** CI = confidence intervals; g = grams; Hb = hemoglobin; L = litre; mth = month; PPV = positive-predictive value.

### Appendix 11. Combination of anaemia and other symptoms.

<table>
<thead>
<tr>
<th>Index test</th>
<th>Author</th>
<th>Definition of sign/symptom</th>
<th>PPV (%) (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abdominal pain or tenderness</td>
<td>Hamilton 2005</td>
<td>Hb &lt;100 g/L and abdominal tenderness</td>
<td>&gt;10</td>
</tr>
<tr>
<td></td>
<td>Hamilton 2005</td>
<td>Hb&lt;100 g/L and abdominal pain</td>
<td>6.9</td>
</tr>
<tr>
<td></td>
<td>Hamilton 2005</td>
<td>Hb 100-130 g/L and abdominal tenderness</td>
<td>2.7</td>
</tr>
<tr>
<td></td>
<td>Hamilton 2005</td>
<td>Hb 100-130 g/L and abdominal pain</td>
<td>2.2 (1.1-4.5)</td>
</tr>
<tr>
<td>Weight loss</td>
<td>Hamilton 2005</td>
<td>Hb &lt;100 g/L and weight loss</td>
<td>4.7</td>
</tr>
<tr>
<td></td>
<td>Hamilton 2005</td>
<td>Hb 100-130 g/L and weight loss</td>
<td>1.3 (0.7-2.6)</td>
</tr>
<tr>
<td>Rectal bleeding</td>
<td>Hamilton 2005</td>
<td>Hb &lt;100 g/L and RB</td>
<td>3.2</td>
</tr>
<tr>
<td></td>
<td>Hamilton 2005</td>
<td>Hb 100-130 g/L and RB</td>
<td>3.6</td>
</tr>
</tbody>
</table>

**Abbreviations:** CI = confidence intervals; g = grams; Hb = hemoglobin; L = litre; PPV = positive-predictive value; RB = rectal bleeding.

### Appendix 12. Combination of other symptoms.

<table>
<thead>
<tr>
<th>Index test</th>
<th>Author</th>
<th>Definition of sign/symptom</th>
<th>PPV (%) (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Various</td>
<td>Hamilton 2005</td>
<td>abdominal pain and weight loss</td>
<td>3.4 (2.1-6.0)</td>
</tr>
<tr>
<td></td>
<td>Hamilton 2005</td>
<td>abdominal tenderness and weight loss</td>
<td>6.4</td>
</tr>
<tr>
<td></td>
<td>Hamilton 2005</td>
<td>abdominal tenderness and abdominal pain</td>
<td>1.4 (0.3-2.2)</td>
</tr>
</tbody>
</table>

**Abbreviations:** CI = confidence intervals; PPV = positive-predictive value.
Appendix 13. Abdominal or rectal mass.

<table>
<thead>
<tr>
<th>Index test</th>
<th>Author</th>
<th>Definition of sign/symptom</th>
<th>PPV (%) (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abdominal mass</td>
<td>Chohan 2005</td>
<td>abdominal mass; 2WW referral</td>
<td>41 (21-65)</td>
</tr>
<tr>
<td></td>
<td>Flashman 2004</td>
<td>Right-sided abdominal mass; 2WW referral</td>
<td>16.3 (8.0-30)</td>
</tr>
<tr>
<td>Rectal mass</td>
<td>Chohan 2005</td>
<td>rectal mass; 2WW referral</td>
<td>80 (57-92)</td>
</tr>
<tr>
<td></td>
<td>Flashman 2004</td>
<td>rectal mass; 2WW referral</td>
<td>22.6 (13-36)</td>
</tr>
<tr>
<td>Abdominal or rectal</td>
<td>Barwick 2004</td>
<td>abdominal or rectal mass; 2WW referral</td>
<td>16.7</td>
</tr>
</tbody>
</table>

Abbreviations: CI = confidence intervals; PPV = positive predictive value; 2WW = two-week wait.
### Appendix 14. Multiple regression.

<table>
<thead>
<tr>
<th>Study</th>
<th>Included in model</th>
<th>Significant predictors</th>
<th>Level of significance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fijten 1995</td>
<td>Blood seen mixed with stool only, blood seen on stool or mixed with only, blood seen - others or combinations, Blood seen - unknown, abdominal pain, change in bowel habit (loose &amp;/or frequent), pain at night, decreased appetite, nausea, weight loss, family history of abdominal disease, previous history of rectal bleeding, pale conjunctivae, perianal eczema, rectal palpation (hemorrhoid), rectal palpation (tumour), rectal palpation (abnormal prostate), proctoscopy abnormal, age, gender</td>
<td>Age, change in bowel habit, blood mixed with stool or on stool</td>
<td>p&lt;0.05</td>
</tr>
<tr>
<td>Hamilton 2008</td>
<td>Hb stratified into 6 bands: &lt;9, 9, 10, 11, 12, 13 g/dL, age stratified into 4 bands: 30-59, 60-69, 70-79, 80+, microcytosis &lt;80.0 fl, low ferritin &lt;20 ng/mL</td>
<td>Anemia, microcytosis, low ferritin, antagonistic interaction between microcytosis and low ferritin</td>
<td>p&lt;0.001</td>
</tr>
<tr>
<td>Hamilton 2005</td>
<td>Included 56 variables in model, only reported some of the variables: Rectal bleeding, loss of weight, number of episodes of abdominal pain, constipation, number of episodes of diarrhea, rectal disease on rectal examination, tenderness on palpation of abdomen, FOBT+, low hemoglobin category, no low hemoglobin, haemoglobin 12.0-12.9 g/dL, haemoglobin 10.0-11.9 g/dL, haemoglobin &lt;10 g/dL, blood sugar &gt;10 mmol/L, age, gender</td>
<td>These were reported: Rectal bleeding, loss of weight, number of episodes of abdominal pain, constipation, number of episodes of diarrhea, rectal disease on rectal examination, tenderness on palpation of abdomen, positive faecal occult blood, low hemoglobin category, blood sugar &gt;10 mmol/L, age; antagonistic interactions: hemoglobin subcategory with age group, abdominal pain with tenderness, FOBT+ with hemoglobin &lt;10 g/dL</td>
<td>p&lt;0.05</td>
</tr>
<tr>
<td>Norrelund 1996</td>
<td>Gender, age, patient thought bleeding due to cancer, weight loss, abdominal pain, change in bowel habits, discomfort, rectal bleeding</td>
<td>Age, change in bowel habits</td>
<td>p&lt;0.05</td>
</tr>
<tr>
<td>Panzuto 2003</td>
<td>Age &gt;50 yrs, weight loss, IDA</td>
<td>Age &gt;50 yrs, IDA</td>
<td>p&lt;0.05</td>
</tr>
<tr>
<td>Park 2009</td>
<td>Age, sex, lifestyle factors (BMI, waist-to-hip ratio, smoking status, energy intake, alcohol intake, dietary fibre intake, meat intake), bowel movement (frequency, consistency, quantity, discomfort), laxative use</td>
<td>Loose vs. soft stools (adjusted for age and sex, or lifestyle factors or age, sex, lifestyle factors, bowel movement and laxative use)</td>
<td>p=0.003</td>
</tr>
<tr>
<td>Parker 2007</td>
<td>Age, sex, area deprivation level, BMI, smoking status, blood pressure, comorbidities</td>
<td>Age, sex, smoking status, coronary heart disease (each variable was adjusted for all other variables in model)</td>
<td>p&lt;0.05</td>
</tr>
<tr>
<td>Robertson 2006</td>
<td>Age group, sex, dark blood, blood mixed in stool</td>
<td>Age, blood mixed in stool</td>
<td>p&lt;0.05</td>
</tr>
<tr>
<td>Study (1994)</td>
<td>Symptoms/Signs Reported</td>
<td>Signs of Interest</td>
<td>p-value</td>
</tr>
<tr>
<td>-------------</td>
<td>--------------------------</td>
<td>------------------</td>
<td>--------</td>
</tr>
<tr>
<td>Steine</td>
<td>Increased or looser stools, patient reported IBS</td>
<td>Age, sex, rectal bleeding, loss of weight, abdominal pain, fatigue, abdominal distension, nausea</td>
<td>p&lt;0.05</td>
</tr>
</tbody>
</table>

**Abbreviations:**
BMI = body mass index; CRC = colorectal cancer; dL = decalitre; fL = femtolitre; FOBT = fecal occult blood test; g = grams; Hb = hemoglobin; IBS = irritable bowel syndrome; IDA = iron-deficiency anemia; L = litre; mmol = millimoles; ng = nanograms; yrs = years.
Appendix 15. Summary of pooled diagnostic measures from meta-analyses.

<table>
<thead>
<tr>
<th>Index test</th>
<th>Author</th>
<th>Pooled sensitivity (95% CI)</th>
<th>Pooled specificity (95% CI)</th>
<th>Pooled PPV % (95% CI)</th>
<th>Pooled positive-likelihood ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>RB</td>
<td>Astin 2011</td>
<td>8.1 (6.0-10.8)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ford 2008</td>
<td>64 (55-73)</td>
<td>52 (42-63)</td>
<td>1.32 (1.19-1.47)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jellema 2010</td>
<td>44</td>
<td>66</td>
<td>7 (5-10)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Shapley 2010</td>
<td>4.57 (3.68-5.46)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dark RB</td>
<td>Ford 2008</td>
<td>15 (3-34)</td>
<td>96 (93-98)</td>
<td>3.83 (2.62-5.61)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jellema 2010</td>
<td>35</td>
<td>85</td>
<td>14 (9-21)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Olde Bekkink 2010</td>
<td>22 (13-34)</td>
<td>84 (69-93)</td>
<td>1.37 (0.59-3.30)</td>
<td></td>
</tr>
<tr>
<td>RB mixed with stool</td>
<td>Jellema 2010</td>
<td>51</td>
<td>71</td>
<td>6 (4-10)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Olde Bekkink 2010</td>
<td>40 (4-93)</td>
<td>81 (23-98)</td>
<td>1.91 (0.75-5.51)</td>
<td></td>
</tr>
<tr>
<td>Previous history of RB</td>
<td>Olde Bekkink 2010</td>
<td>30 (5-41)</td>
<td>66 (63-71)</td>
<td>0.58 (0.14-1.41)</td>
<td></td>
</tr>
<tr>
<td>RB &amp; age ≥70</td>
<td>Shapley 2010</td>
<td>5.54 (3.91-7.17)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RB &amp; abdominal pain</td>
<td>Astin 2011</td>
<td>33 (24.0-42.5)</td>
<td>63 (60.1-65.3)</td>
<td>7.58 (3.00-19.2)</td>
<td>1.03 (0.63-1.69)</td>
</tr>
<tr>
<td></td>
<td>Astin 2011</td>
<td>19 (12.3-27.9)</td>
<td>89 (86.7-90.2)</td>
<td>13.4 (8.15-21.9)</td>
<td>1.88 (1.25-2.83)</td>
</tr>
<tr>
<td>RB &amp; weight loss</td>
<td>Astin 2011</td>
<td>58 (49.0-67.3)</td>
<td>63 (60.4-65.1)</td>
<td>11.8 (6.78-20.4)</td>
<td>1.81 (1.33-2.46)</td>
</tr>
<tr>
<td>CBH</td>
<td>Ford 2008</td>
<td>41 (23-60)</td>
<td>69 (58-78)</td>
<td>1.29 (1.05-1.59)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jellema 2010</td>
<td>52</td>
<td>61</td>
<td>9</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Olde Bekkink 2010</td>
<td>62 (18-94)</td>
<td>68 (53-80)</td>
<td>1.92 (0.54-3.57)</td>
<td></td>
</tr>
<tr>
<td>Diarrhea</td>
<td>Jellema 2010</td>
<td>20 (14-29)</td>
<td>73 (67-78)</td>
<td>6 (2-15)</td>
<td>0.74 (0.34-1.62)</td>
</tr>
<tr>
<td>Constipation</td>
<td>Jellema 2010</td>
<td>13</td>
<td>72</td>
<td>6 (2-18)</td>
<td></td>
</tr>
<tr>
<td>Anemia</td>
<td>Astin 2011</td>
<td>9.70 (3.52-26.8)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ford 2008</td>
<td>17 (5.5-33)</td>
<td>90 (87-92)</td>
<td>1.43 (0.75-2.74)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Olde Bekkink 2010</td>
<td>17 (5-35)</td>
<td>95 (93-96)</td>
<td>3.67 (1.30-10.35)</td>
<td></td>
</tr>
<tr>
<td>Iron-deficiency anemia</td>
<td>Ford 2008</td>
<td>23 (2-57)</td>
<td>87 (83-91)</td>
<td>1.38 (0.48-3.94)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jellema 2010</td>
<td>13</td>
<td>92</td>
<td>13</td>
<td></td>
</tr>
<tr>
<td>Weight loss</td>
<td>Ford 2008</td>
<td>22 (14-31)</td>
<td>89 (81-95)</td>
<td>1.96 (1.25-3.08)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jellema 2010</td>
<td>20</td>
<td>89</td>
<td>9</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Olde Bekkink 2010</td>
<td>17 (6-37)</td>
<td>91 (83-96)</td>
<td>1.89 (1.03-3.07)</td>
<td></td>
</tr>
<tr>
<td>Pain on defecation</td>
<td>Olde Bekkink 2010</td>
<td>22 (13-36)</td>
<td>41 (22-78)</td>
<td>0.49 (0.25-0.97)</td>
<td></td>
</tr>
<tr>
<td>Itch/eczema</td>
<td>Olde Bekkink 2010</td>
<td>17 (7-33)</td>
<td>81 (73-95)</td>
<td>1.31 (0.25-6.21)</td>
<td></td>
</tr>
<tr>
<td>Hemorrhoid</td>
<td>Olde Bekkink 2010</td>
<td>24 (9-45)</td>
<td>73 (46-91)</td>
<td>0.51 (0.09-2.97)</td>
<td></td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>Astin 2011</td>
<td>3.29 (0.69-15.6)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jellema 2010</td>
<td>35</td>
<td>59</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Olde Bekkink 2010</td>
<td>25 (4-62)</td>
<td>73 (52-89)</td>
<td>0.94 (0.19-1.59)</td>
<td></td>
</tr>
<tr>
<td>Index test</td>
<td>Author</td>
<td>Pooled sensitivity (95% CI) %</td>
<td>Pooled specificity (95% CI) %</td>
<td>Pooled PPV % (95% CI)</td>
<td>Pooled positive-likelihood ratio (95% CI)</td>
</tr>
<tr>
<td>---------------------</td>
<td>-------------------------</td>
<td>------------------------------</td>
<td>------------------------------</td>
<td>-----------------------</td>
<td>------------------------------------------</td>
</tr>
<tr>
<td>Abdominal mass</td>
<td>Ford 2008</td>
<td>5 (2-9)</td>
<td>97 (96-98)</td>
<td></td>
<td>1.47 (0.68-3.19)</td>
</tr>
<tr>
<td>Age &lt;40</td>
<td>Olde Bekkink 2010</td>
<td>3 (0-16)</td>
<td>73 (69-76)</td>
<td></td>
<td>0.32 (0.05-2.21)</td>
</tr>
<tr>
<td>Age 40-59</td>
<td>Olde Bekkink 2010</td>
<td>9 (4-19)</td>
<td>79 (70-86)</td>
<td></td>
<td>0.41 (0.18-0.90)</td>
</tr>
<tr>
<td>Age ≥60</td>
<td>Olde Bekkink 2010</td>
<td>66 (45-83)</td>
<td>76 (68-83)</td>
<td></td>
<td>2.79 (2.00-3.90)</td>
</tr>
<tr>
<td>Age &gt;50 v &lt;50</td>
<td>Jellema 2010</td>
<td>91</td>
<td>36</td>
<td>10 (7-13)</td>
<td></td>
</tr>
<tr>
<td>Age &gt;60 v &lt;60</td>
<td>Jellema 2010</td>
<td>83</td>
<td>55</td>
<td>9 (8-10)</td>
<td></td>
</tr>
<tr>
<td>Age &gt;70 v &lt;70</td>
<td>Jellema 2010</td>
<td>50</td>
<td>79</td>
<td>13</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>Olde Bekkink 2010</td>
<td>62</td>
<td>55</td>
<td>7 (5-12)</td>
<td></td>
</tr>
<tr>
<td>Family history</td>
<td>Jellema 2010</td>
<td>16</td>
<td>91</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>FOBT (guaiac)</td>
<td>Jellema 2010</td>
<td>75</td>
<td>86</td>
<td>28</td>
<td></td>
</tr>
<tr>
<td>FOBT (immunochemical)</td>
<td>Jellema 2010</td>
<td>95</td>
<td>84</td>
<td>21</td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations:** CBH = change in bowel habits; CI = confidence intervals; FOBT = fecal occult blood test; PPV = positive-predictive value; RB = rectal bleeding.
### Appendix 16. Diagnostic investigations.

<table>
<thead>
<tr>
<th>Author</th>
<th>Test</th>
<th>PPV (95% CI)</th>
<th>Other parameters (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bjerregaard 2009</td>
<td>Hemoccult Sensa® FOBT</td>
<td>10.5 (6.8-14.3)</td>
<td>SE=75 (69.7-80.3); SP=79.4 (74.5-84.4); NPV=99 (97.8-100)</td>
</tr>
<tr>
<td>McSherry 1969</td>
<td>FOBT+; in 1228 patients</td>
<td></td>
<td>SE=73.3</td>
</tr>
<tr>
<td>Oono 2010</td>
<td>Immunochemical FOBT</td>
<td>33.7 (27.5-40.5)</td>
<td>SE=74.7 (64.8-82.6); SP=86.4 (84.1-83.4); NPV=97.4 (96.1-98.2); POS LR=5.48 (4.49-6.67); NEG LR=0.29 (0.21-0.42); OR=18.7 (11.3-31.1)</td>
</tr>
<tr>
<td>Shaw 2008</td>
<td>Hemoccult® FOBT</td>
<td>7.7 (1.9-26)</td>
<td></td>
</tr>
<tr>
<td>Viiala 2007</td>
<td>FOBT+</td>
<td>14.3</td>
<td>OR=5.9 (1.2-29.7)</td>
</tr>
<tr>
<td>Fijten 1995</td>
<td>RB &amp; rectal palpation (hemorrhoid)</td>
<td>10 (2.5-32)</td>
<td>SE=22; SP=93; NPV=97; OR=3.8</td>
</tr>
<tr>
<td>Fijten 1995</td>
<td>RB &amp; rectal palpation (abnormal prostate)</td>
<td>50 (5.9-94)</td>
<td>SE=11; SP=99.6; NPV=97; OR=31.8</td>
</tr>
<tr>
<td>Fijten 1995</td>
<td>RB &amp; rectal palpation (tumour)</td>
<td>100</td>
<td>SE=11; SP=89; NPV=97; OR=undefined</td>
</tr>
<tr>
<td>Fijten 1995</td>
<td>RB &amp; proctoscopy abnormal</td>
<td>0</td>
<td>SE=0; SP=30; NPV=87; OR=0.2</td>
</tr>
<tr>
<td>Fijten 1995</td>
<td>RB &amp; Hb low (female &lt; 7.5 mmol/L, male &lt;8.5 mmol/L)</td>
<td>14 (3.6-43)</td>
<td>SE=33; SP=95; NPV=98; OR=8.8</td>
</tr>
<tr>
<td>Fijten 1995</td>
<td>RB &amp; ESR high (female &gt;28 mm/h, male &gt;12 mm/h)</td>
<td>8.7 (2.2-29)</td>
<td>SE=40; SP=91; NPV=98; OR=6.3</td>
</tr>
<tr>
<td>Fijten 1995</td>
<td>RB &amp; ESR high &gt;30 mm/h</td>
<td>17 (4.2-48)</td>
<td>SE=40; SP=96; NPV=99; OR=14</td>
</tr>
<tr>
<td>Fijten 1995</td>
<td>RB &amp; White blood cell count high &gt;10^7/L</td>
<td>12 (3.9-31)</td>
<td>SE=75; SP=90; NPV=99.5; OR=26.3</td>
</tr>
<tr>
<td>Hamilton 2005</td>
<td>Abnormal rectal exam</td>
<td>1.5 (1.0-2.2)</td>
<td></td>
</tr>
<tr>
<td>Hamilton 2005</td>
<td>Abnormal rectal exam and RB</td>
<td>8.5</td>
<td></td>
</tr>
<tr>
<td>Hamilton 2005</td>
<td>Abnormal rectal exam and constipation</td>
<td>2.6</td>
<td></td>
</tr>
<tr>
<td>Hamilton 2005</td>
<td>Abnormal rectal exam and diarrhea</td>
<td>11</td>
<td></td>
</tr>
<tr>
<td>Hamilton 2005</td>
<td>Abnormal rectal exam and abdominal pain</td>
<td>3.3</td>
<td></td>
</tr>
<tr>
<td>Hamilton 2005</td>
<td>Abnormal rectal exam and abdominal tenderness</td>
<td>5.8</td>
<td></td>
</tr>
<tr>
<td>Author</td>
<td>Test</td>
<td>PPV (95% CI)</td>
<td>Other parameters (95% CI)</td>
</tr>
<tr>
<td>------------------</td>
<td>-------------------------------------------</td>
<td>--------------</td>
<td>------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Hamilton 2005</td>
<td>Abnormal rectal exam and wt loss</td>
<td>7.4</td>
<td>SE=25 (10-51); SP=46 (37-54); POS LR=0.46 (0.19-1.09); NEG LR=1.64 (1.17-2.30); NPV=83 (73-90); OR=0.28 (0.09-0.92)</td>
</tr>
<tr>
<td>Mant 1989</td>
<td>RB &amp; hemorrhoids identified by FP</td>
<td>5.4 (2.0-14)</td>
<td>p&lt;0.05 SE=93 (86-97); SP=99 (97-99); POS LR=76.8 (32.1-184); NEG LR=0.07 (0.04-0.15); NPV=98 (97-99); OR=1051 (326-3389)</td>
</tr>
<tr>
<td>Wauters 2000</td>
<td>RB &amp; palpable tumour</td>
<td>32 (13-57)</td>
<td></td>
</tr>
<tr>
<td>Chen 2006</td>
<td>Ultrasonography</td>
<td>95 (88-98)</td>
<td>SE=93 (86-97); SP=99 (97-99); POS LR=76.8 (32.1-184); NEG LR=0.07 (0.04-0.15); NPV=98 (97-99); OR=1051 (326-3389)</td>
</tr>
<tr>
<td>Martinez-Ares 2005</td>
<td>Abdominal ultrasound</td>
<td>81 (66-90)</td>
<td>SE=79 (64-89); SP=92 (85-96); POS LR=10.1 (5.09-20); NEG LR=0.23 (0.13-0.41); NPV=91 (84-95); OR=44.4 (15.8-124) adjusted OR= 9.26 (4.8-17.5); Regression=P&lt;0.05</td>
</tr>
<tr>
<td>Martinez-Ares 2009</td>
<td>Abdominal ultrasound</td>
<td>78.5</td>
<td>SE=83.3; SP=82.7; NPV=86.7; accuracy=83</td>
</tr>
<tr>
<td>Duff 2006</td>
<td>CT colonography</td>
<td>70 (38-90)</td>
<td>SE=88 (46-98); SP=97 (91-99); POS LR=30.3 (9.65-95.4); NEG LR=0.13 (0.02-0.81); NPV=99 (93-99.8); OR=236 (21.6-2570)</td>
</tr>
<tr>
<td>Roberts-Thomson 2008</td>
<td>CT colonography</td>
<td>63 (28-87)</td>
<td>SE=56 (25-82); SP=98 (95-99); POS LR=35.7 (10.1-127); NEG LR=0.45 (0.22-0.94); NPV=98 (95-99); OR=79.2 (13.9-451)</td>
</tr>
<tr>
<td>Robinson 2011</td>
<td>CT colonography</td>
<td></td>
<td>SE=93.6</td>
</tr>
<tr>
<td>Sofic 2010</td>
<td>CT colonography</td>
<td>100</td>
<td>SE=100; SP=100</td>
</tr>
<tr>
<td>Taylor 2003</td>
<td>CT colonography</td>
<td></td>
<td>SE=83</td>
</tr>
<tr>
<td>Tolan 2007</td>
<td>CT colonography</td>
<td></td>
<td>SE=93 (77-98)</td>
</tr>
<tr>
<td>White 2009</td>
<td>CT colonography</td>
<td></td>
<td>SE=100; SP=99.2</td>
</tr>
<tr>
<td>Koo 2005</td>
<td>Minimal-preparation computed tomography</td>
<td></td>
<td>SE=Pooled 83 (76-88); SP=Pooled 90 (85-94)</td>
</tr>
<tr>
<td>Brewster 1994</td>
<td>FS</td>
<td></td>
<td>SE=52 (32-72)</td>
</tr>
<tr>
<td>Thompson 2008</td>
<td>FS</td>
<td></td>
<td>SE=99 (98-99)</td>
</tr>
<tr>
<td>Irvine 1988</td>
<td>FS</td>
<td></td>
<td>SE=67</td>
</tr>
<tr>
<td>Anderson 2011</td>
<td>RS</td>
<td></td>
<td>Diagnostic accuracy of surgical assessment for CRC significantly better than general practitioner assessment due to surgeons’ use of RS</td>
</tr>
<tr>
<td>Helfand 1997</td>
<td>RS</td>
<td></td>
<td>SE=77 (48-92)</td>
</tr>
<tr>
<td>Helfand 1997</td>
<td>RS &amp; DCBE</td>
<td></td>
<td>SE=100</td>
</tr>
<tr>
<td>Jensen 1993</td>
<td>Rectosigmoidoscopy</td>
<td></td>
<td>SE=40</td>
</tr>
<tr>
<td>Irvine 1988</td>
<td>FS &amp; DCBE</td>
<td></td>
<td>SE=83</td>
</tr>
<tr>
<td>Rex 1990</td>
<td>FS &amp; ACBE</td>
<td></td>
<td>Chi-squared NS p&gt;0.05</td>
</tr>
<tr>
<td>Anderson 1991</td>
<td>SCBE or DCBE</td>
<td></td>
<td>SE=71</td>
</tr>
<tr>
<td>Brewster 1994</td>
<td>DCBE</td>
<td></td>
<td>SE=100</td>
</tr>
<tr>
<td>Helfand 1997</td>
<td>DCBE</td>
<td></td>
<td>SE=92 (61-99)</td>
</tr>
<tr>
<td>Irvine 1988</td>
<td>DCBE</td>
<td></td>
<td>SE=83</td>
</tr>
<tr>
<td>Jensen 1993</td>
<td>DCBE</td>
<td></td>
<td>SE=60</td>
</tr>
<tr>
<td>Author</td>
<td>Test</td>
<td>PPV CI</td>
<td>Other parameters (95% CI)</td>
</tr>
<tr>
<td>------------</td>
<td>----------------------------------</td>
<td>--------------</td>
<td>------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Sofic 2010</td>
<td>Barium enema</td>
<td>100</td>
<td>SE=94.6; SP=100</td>
</tr>
<tr>
<td>Tate 1988</td>
<td>FP-referred DCBE</td>
<td></td>
<td>Diagnostic yield=3</td>
</tr>
<tr>
<td>Thompson 2008</td>
<td>DCBE</td>
<td></td>
<td>SE=86 (78-92)</td>
</tr>
<tr>
<td>Church 1991</td>
<td>Air-contrast barium enema</td>
<td>71 (56-83)</td>
<td>SE=75 (59-86); SP=43 (24-64); Pos LR=1.31 (0.87-1.98); Neg LR=0.58 (0.28-1.21); NPV=47 (27-69); OR=2.25 (0.73-6.91)</td>
</tr>
<tr>
<td>Ott 1989</td>
<td>Single- or double-contrast barium enema</td>
<td></td>
<td>SE=100</td>
</tr>
</tbody>
</table>

**Abbreviations**: CBH = change in bowel habits; CI = confidence intervals; CT = computed tomography; DCBE = double-contrast barium enema; ESR = erythrocyte sedimentation rate; FS = flexible sigmoidoscopy; FOBT = fecal occult blood test; FP = family physician; h = hour; Hb = haemoglobin; L = litre; LR = likelihood ratio; mm = millimetre; mmol = millimoles; Neg = negative; NPV = negative-predictive value; OR = odds ratio; Pos = positive; PPV = positive-predictive value; RB = rectal bleeding; RS = rigid sigmoidoscopy; SCBE = single-contrast barium enema; SE = sensitivity; SP = specificity.
### Appendix 17. Personal or family history as single risk factors.

<table>
<thead>
<tr>
<th>Index test</th>
<th>Author</th>
<th>Definition of sign/symptom</th>
<th>PPV (%) (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Personal history</td>
<td>Steine 1994</td>
<td>Personal history of CRC/polyp</td>
<td>5.7 (2.6-12)</td>
</tr>
<tr>
<td>Family history</td>
<td>Steine 1994</td>
<td>Family history of CRC/polyp</td>
<td>1.3 (0.4-3.9)</td>
</tr>
</tbody>
</table>

**Abbreviations:** CI = confidence intervals; CRC = colorectal cancer; PPV = positive-predictive value.
References for Appendices 4-17.


• Tate JJ, Royle GT. Open access colonoscopy for suspected colonic neoplasia. Gut. 1988 October 1;29(10):1322-5.


• Tolan DJ, Armstrong EM, Chapman AH. Replacing barium enema with CT colonography in patients older than 70 years: the importance of detecting extracolonic abnormalities. AJR. 2007;American(5):1104-11.


Evidence-Based Series 24-1: Section 3 - Development Methods, Recommendations
Development and External Review Process

Referral of Patients with Suspected Colorectal Cancer
by Family Physicians and Other Primary Care Providers:
EBS Development Methods and External Review Process

L. Del Giudice, E. Vella, A. Hey, W. Harris, M. Simunovic, C. Levitt,
and the Colorectal Cancer Referral Expert Panel

A Quality Initiative of the
Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO)

Report Date: April 24, 2012

The 2012 guideline recommendations have been ENDORSED, which means that the recommendations are still current and relevant for decision making. Below are the original methods and review from 2012. Please see Section 4: Document Review Summary and Tool for a summary of updated evidence published between 2009 and 2015 and for details on how this Clinical Practice Guideline was ENDORSED.

THE PROGRAM IN EVIDENCE-BASED CARE
The Program in Evidence-based Care (PEBC) is an initiative of the Ontario provincial cancer system, Cancer Care Ontario (CCO) (1). The PEBC mandate is to improve the lives of Ontarians affected by cancer, through the development, dissemination, implementation, and evaluation of evidence-based products designed to facilitate clinical, planning, and policy decisions about cancer care.

The PEBC supports a network of disease-specific panels, termed Disease Site Groups (DSGs), as well as other groups or panels called together for a specific topic, all mandated to develop the PEBC products. These panels are comprised of clinicians, other health care providers and decision makers, methodologists, and community representatives from across the province.

The PEBC is well known for producing evidence-based guidelines, known as Evidence-Based Series (EBS) reports, using the methods of the Practice Guidelines Development Cycle (1,2). The EBS report consists of an evidentiary base (typically a systematic review), an
interpretation of and consensus agreement on that evidence by our Groups or Panels, the resulting recommendations, and an external review by Ontario clinicians and other stakeholders in the province for whom the topic is relevant. The PEBC has a formal standardized process to ensure the currency of each document, through the periodic review and evaluation of the scientific literature and, where appropriate, the integration of that literature with the original guideline information.

The Evidence-Based Series
Each EBS is comprised of three sections:

- **Section 1: Guideline Recommendations.** Contains the clinical recommendations derived from a systematic review of the clinical and scientific literature and its interpretation by the Group or Panel involved and a formalized external review in Ontario by review participants.
- **Section 2: Evidentiary Base.** Presents the comprehensive evidentiary/systematic review of the clinical and scientific research on the topic and the conclusions reached by the Group or Panel.
- **Section 3: EBS Development Methods and External Review Process.** Summarizes the EBS development process and the results of the formal external review of the draft version of Section 1: Guideline Recommendations and Section 2: Evidentiary Base.

DEVELOPMENT OF THIS EVIDENCE-BASED SERIES
Development and Internal Review
This EBS was developed by the Provincial Primary Care and Cancer Network of the CCO PEBC. The series is a convenient and up-to-date source of the best available evidence on primary care referral for suspected colorectal cancer, developed through the review of the evidentiary base, evidence synthesis, and input from external review participants in Ontario.

Development of the Recommendations for Referral
Estimated positive-predictive values (PPVs) of each possible sign and symptom of CRC were extracted from the peer-reviewed literature. The recommendations for urgency of referral associated with the PPV of each sign and symptom were aligned with the same relative urgency as a positive FOBT in Ontario’s CRC screening program, ColonCancerCheck (3). The PPV for the detection of CRC using Hema Screen, the FOBT used in the Ontario ColonCancerCheck screening program, in single (one-time) testing of asymptomatic adults was estimated to be 10.9% (4). Therefore, the Colorectal Cancer Referral Working Group believed that signs or symptoms with PPVs greater than 10% should lead to a higher index of suspicion of CRC and more urgent referral.

The Working Group agreed that the urgency of referral for signs and/or symptoms of CRC should be comparable to current published Canadian guidelines by Paterson et al (2006) (5). Where not available, the urgency of referral was based on comparable PPVs for CRC of established target wait times: in particular, the target wait time of eight weeks for colonoscopy for a positive FOBT from the ColonCancerCheck Program in Ontario (3).

The signs and symptoms leading to referral demonstrated PPVs of 10% or greater. The term ‘unexplained’ was used to emphasize that clinical judgement is necessary to rule out other possible causes for rectal bleeding or IDA. The cutoff value for hemoglobin to assess anemia was taken from the two-week referral guideline developed by the National Institute for Health and Clinical Excellence (NICE) in 2005 and endorsed by the New Zealand Guidelines Group (NZGG) in 2009 (6,7). Although median PPVs were not calculated for rectal or abdominal masses because there were less than four studies found for each sign, the Working
Group chose to include these signs to prompt referrals because all PPVs for each study were over 10% and because of their own clinical experience with these signs.

**Expert Panel Review**

Key issues raised by the guideline Expert Panel and the Working Group responses (italicized) included the following:

- Change the title to “Referral of Patient with Suspected Colorectal Cancer by Primary Care Practitioners”
  - The title was changed.
- The guideline does address symptomatic people with a strong family history?
  - Under Target Population, the sentence “These recommendations are not intended to provide recommendations for patients who should be in a surveillance program such as those with inflammatory bowel disease, a personal history of CRC, or patients with a strong family history of CRC.” was changed to “Patients at increased risk of CRC such as a personal history of CRC, inflammatory bowel disease or a first-degree family member with CRC should be in a CRC surveillance program involving regular colonoscopies. Clinical judgement about the need for referral should be exercised if these patients present with interim new or worsening symptoms.”
- I don’t think I like the suggestion “be vigilant” in a guideline - it’s something that we always have to do, kind of like “develop a differential diagnosis” or “be caring.”
  - Under Target Population, the sentence “Ongoing vigilance during the diagnostic assessment by the primary care provider can be expected to minimize the impact of unexpected situations such as missed or inaccurate diagnostic tests.” was changed to “During the process of referral and the diagnostic assessment pathway, FPs and other PCPs should apply the College of Physicians and Surgeons of Ontario’s policy on Test Results Management to ensure that an appropriate response to test results are met (8).”
- A focused physical exam could include the following manoeuvres” would seem like more appropriate wording, to me.
  - The recommendation “A focused physical examination should at the very least include the following manoeuvres; as their sole or combined presence and/or absence can inform the primary care provider.” was changed to “To supplement the history, a focused physical examination could include the following manoeuvres:”
- Digital rectal exam and/or proctoscopy: this implies proctoscopy alone is OK.
  - The recommendation “Digital rectal examination and/or proctoscopy” was changed to “Digital rectal examination followed by proctoscopy if indicated and available”
- “The following tests may be helpful to complete the assessment...” urine test for blood is included. Later on you say the urine test is needed if there is anemia, to rule out a urinary tract cause of anemia. It seems that this recommendation should be clarified. That is, if there is no anemia, a urinary test for blood isn’t required.
  - The recommendation “Urine test for blood” was removed because positive results would not increase the urgency of referral.
- I see why this (FOBT) is included due the Jellema meta-analysis yet when I have participated in CIRT calls I’ve often heard that we should not be seeing FOBT testing for symptomatic patients (9). On page 14, it explains in clearer detail that FOBT testing is recommended as an interim test while the patient is waiting for colonoscopy
so this is something that may need to be added to the CIRT decision tree? I also think it may be good in this section to be more explicit in the reason for an FOBT test in a symptomatic patient (as an interim test) as explained clearly on pg 15: ‘Since IDA or rectal bleeding mixed with stool have PPV values greater than 10%, and FOBTs showed good diagnostic performance for CRC among symptomatic patients (9), a complete blood count and FOBT can be ordered but should not delay referral. The results of these tests should be made available to specialists to help them prioritize patients.’
- The recommendation “The following tests* may be helpful to complete the assessment but should not delay referral” was changed to “The following may be helpful ancillary tests* but their completion should not delay referral”. Also, “Positive results may increase the urgency of referral.” was added.
- I strongly disagree with FOBT as a diagnostic test. Although a positive test may encourage one to speed the referral, a negative test might harm the process by relaxing time for appropriate workup. There is a high risk of a negative FOBT delaying referral in my opinion.
  - See previous response.
- Patients should expect to see their primary care provider within 1 week of the initial phone call, when they complain of any symptom that could suggest CRC. (you’re letting primary care get off way too easy by only emphasizing time from referral to consultation, the true wait time is time from the initial phone call. What’s the point of a 2 week referral guideline if it takes 8 weeks to see the GP? There is some evidence that primary care waits correlate with worse mortality, and that open access scheduling improves primary care capacity, diagnosis of new conditions, and improved chronic disease management.
  - This recommendation was added to the delay section “FPs and other PCPs should consider implementing systems (e.g., open-access booking) to expedite initial appointments for patients calling with signs and/or symptoms suggestive of CRC.”
- Under referral section: will there be a reference here to any DAP’s if available in your Region as should be upcoming? not necessarily as part of the CCC but in alignment with that program
  - The DAP was added to the recommendations as a source for referral.
- My main concern within the recommendations, if I understand them correctly, is the suggestion that in the event that there is a delay in the workup of a patient with a likely colorectal cancer, that tests with unacceptable false-negative results (DCBE, CT colonography, sigmoidoscopy) be performed while awaiting a definitive colonoscopy. I’m not certain of the value in performing these tests (which have unacceptable false-negative results) as a positive or negative test will not alter the ultimate investigations required by the patient but only expose the patient to additional procedures and risks at additional costs, and may in fact delay the definitive investigations. How do these tests make excess wait times any less of a problem? If negative or positive, the same work up will be done by the specialist.
  - The statement “Normal or negative results should not lead to a cancellation of the consult with the CRC DAP or specialist. Positive results may facilitate more timely investigation of a patient” was added.
- Recommendations to Reduce Diagnostic Delay (I think, in this section, you should say something about endoscopists developing appropriate triage protocols)
  - The recommendation “CRC DAPs and specialists competent in endoscopy should develop triage protocols to avoid delays in the diagnosis of CRC in patients with suspicious signs and/or symptoms.” was added.
During the periodic or annual health exam, primary care providers, should at minimum, ask patients about rectal bleeding and about change in bowel habits and family history of CRC.

- The recommendation “During the periodic or annual health examination, primary care providers, should at minimum, ask patients about rectal bleeding and about change in bowel habits.” was changed to “During the periodic health examination, FPs and other PCPs, should at a minimum, ask patients who are 50 years or older about rectal bleeding, about change in bowel habits, and about a family history for CRC.” Annual health examinations were deleted to promote periodic health examinations instead. An age of 50 and older was included to mirror the risk assessment approach for CRC screening in Ontario for average-risk, asymptomatic patients.

Internal Review: PEBC Director

Prior to the submission of this EBS draft report for External Review, the report was reviewed and approved by the Director of the PEBC, Dr. Melissa Brouwers, with expertise in methodological issues. The key issues raised by the Director and the Working Group responses (italicized) were the following:

- In the recommendations, it states with some of the investigations, if the investigation comes up negative but do not let that outcome delay referral. What is their purpose then? If it will not differentiate course of action it is very unclear why one would recommend them. Similarly, there are two procedures recommended in the case of a long delay - what are their purposes? A justification is required.
  - A justification is presented under Key Evidence.
- I think a summary at the end of each question would be helpful.
  - A summary is included at the end of each question.
- Most of the investigations data focus on PPV, NPV, sensitivity and specificity data - there is nothing about risks of the procedures. Are these data not available or were not searched? That might be worth a point in the discussion.
  - This is addressed in the Discussion.
- A bit more interpretation of the data (rather than a summary of the evidence) in the discussion would be useful - for example, first and third points could be addressed there.
  - The first and third points are addressed in the Discussion.

External Review by Ontario Clinicians and Other Experts

The PEBC external review process is two-pronged and includes a targeted peer review that is intended to obtain direct feedback on the draft report from a small number of specified content experts and a professional consultation that is intended to facilitate dissemination of the final guidance report to Ontario practitioners.

Following the review and discussion of Section 1: Recommendations and Section 2: Evidentiary Base of this EBS and the review and approval of the report by the PEBC’s Director, the Colorectal Cancer Referral Working Group circulated Sections 1 and 2 to external review participants for review and feedback. Box 1 summarizes the draft recommendations and supporting evidence developed by the Colorectal Cancer Referral Working Group.

BOX 1:
DRAFT RECOMMENDATIONS (approved for external review June 20, 2011)

QUESTIONS
Overall Question
In patients presenting to family physicians (FPs) and other primary care providers (PCPs) with signs and/or symptoms of colorectal cancer (CRC), what should the referral process include? The following questions are the factors considered in answering the overall question:

1. What signs, symptoms, and other clinical features are predictive of CRC?
2. What is the diagnostic accuracy of investigations for CRC?
3. What major, known risk factors are predictive of CRC?
4. Which factors are associated with delayed referral? Which delay factors can be attributed to patients, and which factors can be attributed to providers?
5. Does a delay in the time to consultation affect patient outcome?

TARGET POPULATION

Patients at average risk for CRC presenting in primary care settings comprise the target population. Patients at increased risk of CRC such as those with a personal history of CRC, inflammatory bowel disease or a first-degree family member with CRC should be in a CRC surveillance program involving regular colonoscopies. Clinical judgement about the need for referral should be exercised if these patients present with interim new or worsening symptoms. In addition, this guideline does not provide recommendations for patients who present with emergency alarm features such as anemia resulting in symptoms and signs of hemodynamic instability, acute gastrointestinal hemorrhaging, acute intestinal obstructions, or unremitting abdominal pain. These patients should be referred for emergency assessment. During the process of referral and along the diagnostic assessment pathway, FPs and other PCPs should apply the College of Physicians and Surgeons of Ontario’s policy on Test Results Management to ensure that an appropriate response to test results are met (1).

INTENDED USERS

This guideline is targeted to FPs, general practitioners, emergency room physicians, other PCPs (nurse practitioners, registered nurses, and physician assistants), surgeons and gastroenterologists. For the purposes of this document, we have referred to FPs, general practitioners, emergency room physicians, and other PCPs as ‘FPs and other PCPs’.

RECOMMENDATIONS

<table>
<thead>
<tr>
<th>Clinical Presentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>A focused history and physical examination should be performed if patients present with one or more of the following signs or symptoms that could inform the FPs and other PCPs in the diagnosis of CRC:</td>
</tr>
<tr>
<td>• Palpable rectal mass</td>
</tr>
<tr>
<td>• Palpable abdominal mass</td>
</tr>
<tr>
<td>• Anemia (especially iron-deficiency anemia [IDA])</td>
</tr>
<tr>
<td>• Rectal bleeding</td>
</tr>
<tr>
<td>• Change in bowel habits</td>
</tr>
<tr>
<td>• Weight loss</td>
</tr>
<tr>
<td>• Abdominal discomfort</td>
</tr>
<tr>
<td>• Perianal symptoms</td>
</tr>
</tbody>
</table>
### The focused history should determine the following details:

- **Age and gender**
- **Rectal bleeding, and if yes,**
  - Colour (dark versus bright red)
  - Location of blood relative to stool (mixed in with stool versus separate from stool, on the toilet paper)
- **Change in bowel habit over recent months/years, and if yes,**
  - Increased loose or watery stools or diarrhea
  - Increased constipation or difficulty passing stools
  - Feeling of incomplete emptying
  - Increased urgency
  - Incontinence of stools or soiling
- **Weight loss**
- **Abdominal discomfort (pain, tenderness, bloating)**
- **Perianal symptoms such as prolapsed lump, pruritus, pain, hemorrhoids**
- **Family history of first-degree relative and the age of onset**
- **Symptoms of anemia (fatigue, weakness, dyspnea on exertion/poor exercise tolerance, palpitations/tachycardia, dizziness, anorexia, headache, and/or cold intolerance)**
- **History of unexplained IDA**
  - If the patient's presenting sign (complaint) is unexplained anemia or IDA, the patient’s history should also include questions about diet, prescribed and non-prescribed medications (especially non-steroidal anti-inflammatory drugs [NSAIDs]), menstrual history, frank bleeding (injury or epistaxis), recent surgery, blood donation, and a personal or family history of a blood disorder.

### To supplement the history, a focused physical examination could include the following manoeuvres:

- **Digital rectal examination (DRE) followed by proctoscopy if indicated and available**
- **Abdominal examination**
  - Signs of anemia such as skin and/or conjunctival pallor, loss of skin tone, tachycardia, increased pulse pressure, systolic ejection murmurs, or postural hypotension
- **Weight (and comparison to previous weights if possible)**

### Diagnostic Investigations

The following may be helpful ancillary tests* but their completion should not delay referral:

- **Fecal Occult Blood Test (FOBT), in the absence of current active rectal bleeding**
- **Complete blood count (CBC), and if low mean cell or corpuscular volume (MCV) (i.e., microcytic anemia), ferritin**
- **Imaging for abdominal masses**

*Normal or negative results should not deter or delay referral. Positive results may increase the urgency of referral.

### Referral
Wait times for a referral have been developed for the following indications by using evidence citing the relative predictability of the listed single or combined signs, symptoms, or diagnostic investigations for CRC and weighing this with the predictability for CRC of a positive FOBT in the Ontario CRC Screening Program (2). The referral wait times also align with the recommendations developed by the Canadian Association of Gastroenterology (3). In many jurisdictions, organized Diagnostic Assessment Programs (DAPs), with centralized referral access, facilitate timely tests and specialist appointments.

4. Referring physicians should send a referral to a CRC DAP or a specialist competent in endoscopy within 24 hours, expect a consultation within 2 weeks, and expect a definitive diagnostic workup to be completed within 2 weeks of consultation, if a patient has at least one of the following:
   - Palpable rectal mass suspicious for CRC
   - Abnormal abdominal imaging result suspicious for CRC

5. Based on a detailed history, physical examination, and investigations, along with clinical judgement, referring physicians should send a referral to a CRC DAP or a specialist competent in endoscopy within 24 hours, expect a consultation within 4 weeks, and expect a definitive diagnostic work up to be completed within 8 weeks of referral, if a patient has at least one of the following:
   - Unexplained rectal bleeding in patients with at least one of the following characteristics or combinations of symptoms:
     - Dark rectal bleeding
     - Rectal bleeding mixed with stool
     - Rectal bleeding in the absence of perianal symptoms
     - Rectal bleeding and change in bowel habits
     - Rectal bleeding and weight loss
   - Unexplained IDA and a hemoglobin of ≤110 g/L for males or ≤100 g/L for non-menstruating females

For patients where the decision to refer to a CRC DAP or a specialist has been made based on the above criteria, the following may increase the risk of CRC and may be taken into consideration to assist the specialist assessment in prioritizing patients.
   - Patients aged 60 years and older with any of the above mentioned signs or symptoms
   - Male patients with any of the above mentioned signs or symptoms
   - A combination of any of the above mentioned signs or symptoms
   - Patients with any of the above mentioned signs or symptoms and a first-degree family history of CRC

In situations where wait times may exceed these timelines, referring physicians may order (depending on locally available resources):
   - Computed tomographic (CT) colonography
   - Double-contrast barium enema (DCBE)

This is best done in coordination with the CRC DAP or specialist, if possible. Normal or negative results should not lead to a cancellation of the consult with the CRC DAP or specialist. Positive results may facilitate more timely investigation of a patient.
6. If the signs or symptoms of patients do not meet the criteria for referral but, based on clinical judgement, there remains a suspicion of CRC, then any of the following strategies may be appropriate:

- Watch, wait, and review
- Order CT colonography or DCBE
- Confer with a specialist competent in endoscopy to obtain guidance
- Refer to a CRC DAP or a specialist competent in endoscopy

### Recommendations to Reduce Diagnostic Delay

- There should be appropriate educational tools developed and disseminated that highlight the signs and symptoms of CRC cancer for FPs and other PCPs.
- Educational tools should be developed on obtaining a proper detailed history, physical examination, appropriate investigations, and referral in patients presenting with suspicious signs and symptoms of CRC for FPs and other PCPs.
- During the periodic health examination, FPs and other PCPs should, at a minimum, ask patients who are 50 years of age or older about rectal bleeding, changes in bowel habits, and a family history for CRC.
- While discussing colorectal cancer screening with patients, FPs and other PCPs should ask about the signs and symptoms predictive of CRC.
- FPs and other PCPs should investigate unexplained anemia, especially IDA.
- For signs and symptoms suggestive of CRC with lower positive predictive values (PPVs) that may not have prompted initial referral, FPs and other PCPs should consider reassessment and further workup if the presentation does not resolve.
- FPs and other PCPs should consider implementing systems (e.g., open-access booking) to expedite initial appointments for patients calling with signs and/or symptoms suggestive of CRC.
- CRC DAPs and specialists competent in endoscopy should develop triage protocols to avoid delays in the diagnosis of CRC in patients with suspicious signs and/or symptoms.
- Sustainable public education about the signs and symptoms of CRC, the importance of early detection and management, as well as common fears and concerns that may delay referral, should be developed and implemented.
- Special efforts should be made to reduce delays in presentation often observed among women, single patients, younger patients, visible minorities, and patients with co-morbidities, decreased social support, lower levels of education, or a rural residence.
Colorectal Cancer Guideline Recommendations

Does the patient have one or more of the following signs/symptoms?

- Palpable rectal mass
- Palpable abdominal mass
- Anemia (especially iron deficiency anemia)
- Rectal bleeding
- Change in bowel habit
- Weight loss
- Abdominal discomfort
- Perianal symptoms

If Yes, perform a more focused history and physical exam

A focused history should include the following details:

- Age and gender
- Rectal bleeding, and if yes,
  - Colour (dark versus bright red)
  - Location of blood relative to stool (mixed in/separate to toilet paper)
- Change in bowel habit over recent months/years, and if yes,
  - Increased loose or watery stools
  - Increased constipation or difficulty passing stools
  - Feeling of incomplete emptiness
  - Increased urgency
  - Incontinence of stools or soiling
- Weight loss
- Abdominal discomfort (pain, tenderness, bloating)
- Perianal symptoms (lump, pruritus, pain, haemorrhoids)
- Family history of first degree relative and the age of onset
- Symptoms of Anemia
- History of unexplained iron deficiency anemia (IDA)

A focused physical exam could include the following maneuvers:

- Digital rectal exam followed by proctoscopy if indicated and available
- Abdominal exam
- Signs of anemia
- Weight

The following may be helpful ancillary tests but their completion should not delay referral:

- Fecal Occult Blood Test, in the absence of current active rectal bleeding
- Complete Blood Count, ferritin (low MCV)
- Abdominal imaging

*Normal or negative results should not deter or delay referral. Positive results may increase the urgency of referral.

If a patient has at least one of the following:

- Suspicious palpable rectal mass
- Suspicious abnormal abdominal imaging

If a patient has at least one of the following:

- Unexplained rectal bleeding in patients of any age with at least one of the following characteristics or combinations of symptoms:
  - Dark rectal bleeding
  - Rectal bleeding mixed with stool
  - Rectal bleeding in the absence of perianal symptoms
  - Rectal bleeding and change in bowel habits
  - Rectal bleeding and weight loss
- Unexplained IDA and a haemoglobin of ≤110 g/L for males or ≤100 g/L for non-menstruating females

Referring physicians should send a referral to a CRC Diagnostic Assessment Program (DAP) or a specialist competent in endoscopy within 24 hours, expect a consultation within 2 weeks, and expect a definitive diagnostic work up to be completed within 2 weeks of consultation.*

If the signs or symptoms of patients do not meet the criteria for referral but, based on clinical judgement, there remains a suspicion of CRC

Any of the following strategies may be appropriate:

- Watch, wait, and review
- Order computed tomographic colonography or double contrast barium enema
- Consult with a specialist competent in endoscopy to obtain guidance
- Refer to a CRC DAP or a specialist competent in endoscopy

* Wait times for referral align with Ontario’s Colon Cancer Check Screening Program and the Canadian Association of Gastroenterology

The following may increase the risk of CRC and may be considered to assist specialist assessment in prioritizing patients:

- Patients aged ≥60 years with any of the mentioned signs or symptoms
- Male patients with any of the above mentioned signs or symptoms
- A combination of any of the above mentioned signs or symptoms
- Patients with any of the above mentioned signs or symptoms and a first-degree family history of CRC

In situations where wait times may exceed these timelines, referring physicians may order (depending on locally available resources):

- CT Colonography
- Barium Enema

This is best done in coordination with a CRC DAP or specialist, if possible. Normal or negative results should not lead to a cancellation of the consult with the CRC DAP or specialist. Positive results may facilitate a more timely investigation of a patient.
KEY EVIDENCE

Clinical Presentation

The Working Group believe that the signs and symptoms listed under clinical presentation should inform FPs and other PCPs about the suspicion of CRC. The signs or symptoms listed met one of two criteria: the sign or symptom presented in at least 5% of patients with confirmed CRC, or the sign or symptom was a statistically significant predictor of CRC. The exception to this is perianal symptoms. The absence of perianal symptoms with rectal bleeding strengthens the PPV for CRC rather than the presence of perianal symptoms. The studies included in calculating median PPVs or that contained multiple regression analyses can be found in Section 2 of this report.

The signs and symptoms of anemia as well as the questions to ask patients presenting with unexplained anemia were derived from an evidence-based guideline for the management of anemia used by family physicians in the Working Group (4).

There was a paucity of studies examining the diagnostic accuracy of DRE and proctoscopy for predicting CRC in symptomatic patients. Therefore, these tests were included based on consensus, because a DRE is a simple manoeuvre, can be easily performed in primary care, and, if a suspicious rectal mass is felt, provide valuable information leading to expedited referral. Proctoscopy is also commonly used in the primary care setting.

Diagnostic Investigations

The following diagnostic investigations that were chosen by the Working Group may be helpful in completing an assessment: FOBT, complete blood count, and imaging for abdominal masses. These investigations may be ordered because a patient presents with certain signs or symptoms (i.e., signs of anemia and/or symptoms of an abdominal mass) that would lead to a referral, or these tests may be ordered to determine if other suspected signs or symptoms of CRC are present (i.e., FOBT). The results of these tests would be made available to the specialists.

The meta-analysis by Jellema et al (2010) found good diagnostic performance for both guaiac and immunological-based FOBT tests in symptomatic patients (5). Since a combination of symptoms or signs increases the likelihood of CRC (6), the Working Group believe patients with one sign or symptom and a concurrent positive FOBT (in the absence of current active rectal bleeding) should be triaged more urgently than should patients with only a single sign or symptom. Likewise, patients with single symptoms or signs who subsequently are found to have anemia or IDA should also be triaged more urgently than should patients with a single symptom.

Because there were very few studies examining the diagnostic accuracy of carcinoembryonic antigen (CEA) and erythrocyte sedimentation rate (ESR) for predicting CRC in symptomatic patients, they were not recommended. There were very few studies examining the diagnostic accuracy of a CBC alone, but there was consensus that this should be ordered to assist in the evaluation of whether anemia, and especially IDA, is present.

It is common practice to image abdominal masses found during a physical examination. Imaging may help to determine whether the mass is intra-colonic or extra-colonic and direct the workup of the mass, as well as indicate appropriate specialty referral.

Referral
The Working Group chose to include signs or symptoms with median PPVs greater than 10%, identified in studies in Section 2 of this report, as indicators for referral. The development of these recommendations can be found in Section 3 of this report.

The following combinations of clinical features have been found to increase the index of suspicion for CRC:

- Increasing age (most studies used a cutoff of greater than or equal to 60 years) and rectal bleeding or change in bowel habits or anemia (especially IDA)
- Male patients with rectal bleeding or change in bowel habits or anemia (especially IDA)
- A combination of signs or symptoms

Meta-analyses by Olde Bekkink et al and Jellema et al found high specificity but low sensitivity for a family history of CRC in symptomatic patients (5,7). Also, Jellema et al reported a pooled PPV of 6% for a family history of CRC in symptomatic patients (5). Based on the consensus of the Working Group, the decision was that patients with a first-degree family history of CRC might be at higher risk of CRC and should be priority triaged when referred according to the criteria described above. Regardless of symptoms, the current recommendation was that patients with a personal history of polyps or a first-degree family history of CRC should participate in a CRC screening surveillance program that includes regular colonoscopies.

If the time to referral exceeds the recommended wait times, the Working Group recommended that the referring physician order CT colonography or DCBE, depending on locally available resources. This would ensure that as much information as possible would be made available to the specialist during the consultation. There is some evidence to suggest that CT colonography or DCBE may have good diagnostic properties in symptomatic patients. The sensitivities and/or specificities were over 83% when CT colonography or DCBE were compared to colonoscopy alone (8-18). Flexible sigmoidoscopy (FS) also showed good sensitivity for detecting CRC, especially when combined with DCBE (9,12,16,19). However, the Working Group preferred that the entire colon be visualized. There were few studies examining the diagnostic accuracy of abdominal CT or abdominal or pelvic ultrasound among symptomatic patients.

Factors Contributing to Diagnostic Delay

Evidence from prospective and retrospective studies described in Section 2 of this report suggest that the following may delay the diagnosis of CRC:

- FP and other PCP-related delays (20-24)
  - failure to recognize signs and symptoms were suggestive of CRC
  - failure to investigate IDA
  - failure to perform DRE
  - initial referral to a specialist without a gastrointestinal interest
  - receiving inaccurate or inadequate tests
  - frequent visits following an inconclusive first visit
  - patients with colon cancer referred less quickly than patients with rectal cancer
- younger patients
- gender (females had longer delays than males)
- visible minorities

- Patient-related delays (20-23,25)
  - patient’s lack of appreciation regarding the association of symptoms with CRC
  - fear that tests might be unpleasant or embarrassing
  - uncomfortable with or embarrassed about symptoms, including pain, nausea, and vomiting
  - decreased social support
  - presence of co-morbidity
  - rural residency
  - lower education level
  - single/separated/divorced
  - female colon cancer patients had longer delays than male
  - male rectal cancer patients had longer delays than females

**FUTURE RESEARCH**

Further studies should be designed to determine which educational initiatives would be best at decreasing practitioner or patient-related delay. Also, more studies to determine the diagnostic performance of signs and symptoms for CRC are needed in the primary care setting.

**Methods**

*Targeted Peer Review:* During the guideline development process, six targeted peer reviewers from Ontario and British Columbia considered to be clinical and/or methodological experts on the topic were identified by Colorectal Cancer Referral Working Group. Several weeks prior to completion of the draft report, the nominees were contacted by email and asked to serve as reviewers. Two reviewers agreed and the draft report and a questionnaire were sent via email for their review. The questionnaire consisted of items evaluating the methods, results, and interpretive summary used to inform the draft recommendations and whether the draft recommendations should be approved as a guideline. Written comments were invited. The questionnaire and draft document were sent out on June 20, 2011. Follow-up reminders were sent at two weeks (email) and at four weeks (telephone call). The Colorectal Cancer Referral Working Group reviewed the results of the survey.

*Professional Consultation:* Feedback was obtained through a brief online survey of health care professionals who are the intended users of the guideline. All health care professionals with an interest in colorectal cancer including family physicians, gastroenterologists, radiologists and surgeons in the PEBC database were contacted by email to inform them of the survey. Also, members of the Canadian Cancer Society, the Nurses Practitioner Association of Ontario, the Ontario College of Family Physicians, the Ontario Hospital Association, the Ontario Medical Association, and the Uniting Primary Care and Oncology Leads at Cancer Care Manitoba were invited to review this guideline. Participants were asked to rate the overall quality of the guideline (Section 1) and whether they would use and/or recommend it. Written comments were invited. Participants were contacted by email and directed to the survey website where they were provided with access to the survey, the guideline recommendations (Section 1) and the evidentiary base (Section 2). The notification email
was sent on June 20, 2011. The consultation period ended on August 16, 2011. The Colorectal Cancer Referral Working Group reviewed the results of the survey.

Results

Targeted Peer Review: Two responses were received from two reviewers. The key results of the feedback survey are summarized in Table 2.

Table 2. Responses to nine items on the targeted peer reviewer questionnaire.

<table>
<thead>
<tr>
<th>Question</th>
<th>Reviewer Ratings (N=2)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Lowest Quality (1)</td>
</tr>
<tr>
<td>1. Rate the guideline development methods.</td>
<td>0</td>
</tr>
<tr>
<td>2. Rate the guideline presentation.</td>
<td>0</td>
</tr>
<tr>
<td>3. Rate the guideline recommendations.</td>
<td>0</td>
</tr>
<tr>
<td>4. Rate the completeness of reporting.</td>
<td>0</td>
</tr>
<tr>
<td>5. Does this document provide sufficient information to inform your decisions? If not, what areas are missing?</td>
<td>0</td>
</tr>
<tr>
<td>6. Rate the overall quality of the guideline report.</td>
<td>0</td>
</tr>
<tr>
<td>7. I would make use of this guideline in my professional decisions.</td>
<td>Strongly Disagree (1)</td>
</tr>
<tr>
<td>8. I would recommend this guideline for use in practice.</td>
<td>0</td>
</tr>
</tbody>
</table>

9. What are the barriers or enablers to the implementation of this guideline report?

The target peer reviewers felt the document was laid out well and the literature review was complete. One reviewer felt that education for primary care providers as well as resources for application and implementation should be considered. One reviewer mentioned that a primary care provider other than a family physician was not included in the working group. One reviewer mentioned they would have liked to have seen this guideline integrated with CRC screening guidelines.

Table 3. Summary of written comments by targeted peer reviewers and modifications/actions taken.

<table>
<thead>
<tr>
<th>Summary of Written Comments</th>
<th>Modifications/Actions/Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. The information on symptoms and signs of anemia are not generally practical and questionably useful.</td>
<td>The Working Group decided to shorten the list of signs and symptoms for anemia and refer physicians to (10,11).</td>
</tr>
<tr>
<td>2. I would have liked a comparison of the value of an in office digital sample for FOBT vs lab-ordered FOBT.</td>
<td>There is lack of evidence for this among symptomatic patients.</td>
</tr>
</tbody>
</table>
Professional Consultation: Ninety-eight of 418 (23%) responses were received. Key results of the feedback survey are summarized in Table 4.

Table 4. Responses to four items on the professional consultation survey.

<table>
<thead>
<tr>
<th>General Questions: Overall Guideline Assessment</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Rate the overall quality of the guideline report.</td>
<td>Lowest Quality (1) 2 9 54 32</td>
</tr>
<tr>
<td></td>
<td>Highest Quality (5) Strongly Agree</td>
</tr>
<tr>
<td>2. I would make use of this guideline in my professional decisions.</td>
<td>4 7 13 33 40</td>
</tr>
<tr>
<td>3. I would recommend this guideline for use in practice.</td>
<td>1 2 14 39 42</td>
</tr>
<tr>
<td>4. What are the barriers or enablers to the implementation of this guideline report?</td>
<td></td>
</tr>
<tr>
<td>Some professional consultants believed that the document was well organized and the evidence was extensively reviewed, whereas other reviewers believed the guideline was lengthy. As well, some reviewers believed the flowchart was useful, and others believed it was too complex. One reviewer suggested that an enabler would include province-wide organized diagnostic assessment programs with specific personnel available to answer questions about signs/symptoms/referral. Barriers included lack of resources, availability of specialists, and access to endoscopy and diagnostic investigations. Some reviewers believed that dissemination and education to a wide range of primary care givers is a challenge. Also, patients find it difficult to discuss any matters relating to excretory function. One reviewer felt an integrated provincial eReferral &amp; reporting system is required to optimize system performance and patient outcomes. Although these guidelines will help move clinical practice in the right direction, without systematic infrastructural support, adoption will be limited.</td>
<td></td>
</tr>
</tbody>
</table>

Table 5. Summary of written comments by professional consultants and modifications/actions taken.

<table>
<thead>
<tr>
<th>Summary of Written Comments</th>
<th>Modifications/Actions/Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. A stronger comment or disclaimer that this guideline is NOT about asymptomatic screening, or screening with ONLY a positive family history.</td>
<td>Under target population “In addition, this guideline does not address CRC screening for asymptomatic patients.” was added.</td>
</tr>
<tr>
<td>2. Screening symptom of ‘change in bowel habit and ‘abdominal discomfort’ seem v. vague. Focused history and physical seems a lot to fit into a typical 15’ visit- could there be any way of passing this down to key symptoms and/or signs?</td>
<td>The Working Group believe the recommendations give direction as to focusing on key symptoms and signs and is achievable in 15 minutes.</td>
</tr>
<tr>
<td>3. In regards to Q2 I am a CLR surgeon. I think DRE should be included without the “if available and indicated”. You mention that omission of DRE is a reason for delay in dx. FPs/PCP don’t like doing DRE so that line gives then an excuse not to.</td>
<td>The Working Group agreed and removed “if available and indicated”.</td>
</tr>
<tr>
<td>4. Comments about the lack of usefulness of CEA</td>
<td>The Working Group believe the lack of</td>
</tr>
</tbody>
</table>
for screening and initial investigation should be put in the main part of the guideline.

usefulness of CEA is mentioned in the key evidence section and described more fully in section two. The Working Group chose not to make any changes.

5. Perhaps be more specific that abdominal imaging should be based on physical findings, not an option as part of routine work-up.

The Working Group agreed and made the changes suggested.

6. Lack of clarity on use of FOBT as diagnostic test for symptomatic patients.

The Working Group agreed and made changes to the recommendations regarding FOBT. They recommend it may be used in situations where FPs have a low level of suspicion of CRC.

7. I’m concerned re FOBT being used inappropriately. i.e. if negative - no further work-up.

The Working Group included the statement that “A negative result does not rule out CRC”.

8. Many felt the timelines for referral were unrealistic.

These sentences were added under Target Population, “The guidelines are also intended for policymakers to help ensure that resources are in place so that target wait times can be achieved. They are intended to coincide with the introduction of colorectal cancer Diagnostic Assessment Programs (DAPS) in Ontario. DAPs provide a single point of referral, coordination of care using a clinical navigator, fast-tracking of diagnostic tests and a multidisciplinary team approach. They are an Ontario-wide strategic priority designed to improve patient access and outcomes, and are outlined in the Ontario Cancer Plan since 2005-2011 and 2011-2014 (12).”

9. Indicate that the hemoglobin trend, especially with IDA, may be more important than absolute values.

The Working Group believed that this should be part of clinical judgement that influences a low or high index of suspicion.

10. Pg. 4 at top rectangle, 2nd bullet --> why limit to males with signs and symptoms when female sex is a barrier to early detection. These 2 statements are not congruous. Acknowledging that the deficiency is common in women, especially pre-menopausal women, why not add a category of older women with similar signs and symptoms.

The Working group chose not to change the recommendation because it aligns with the evidence. Also, stating that males have higher PPVs in the recommendations is for triaging purposes and not an indication for referral.

11. Expecting consultation before colonoscopy is often unwarranted; in many instances the need for colonoscopy is clear and could be directly booked without consultation. This is often done where there is a close relationship between

This is outside the scope of this document. This document sets what timelines should ideally exist. How a community of practitioners or DAP get there is for discussions locally,
<table>
<thead>
<tr>
<th>Section 3: EBS Development Methods and External Review Process</th>
</tr>
</thead>
<tbody>
<tr>
<td>consultant and FP when need is urgent - why cannot it be expected in all instances. A corollary is that when patients have to travel far distances for their consultation (e.g. northern Ontario) investigations should be coordinated so that repeat trips are not required.</td>
</tr>
<tr>
<td>12. Eliminate DCBE due to poor sensitivity &amp; declining quality/expertise</td>
</tr>
<tr>
<td>The Working Group chose not to change this recommendation because there is evidence in the literature indicating its usefulness and there may be value in ordering DCBE when there are delays to colonoscopy.</td>
</tr>
<tr>
<td>13. In #3 (page 4) &amp; algorithm, “if suspicion for CRC”, I do not suggest “watch, wait, and review” statement unless a reasonable timeframe is suggested (not ‘open ended’).</td>
</tr>
<tr>
<td>The Working Group agreed and made this recommendation more specific.</td>
</tr>
<tr>
<td>14. What is the evidence of educational validity of any educational tool - Please reference What is sustainable education ( I have pursued a MEd and am unfamiliar with this concept ) Please provide a definition of this term. What specific educational methodologies are shown to have significant benefit in achieving this goal? As this is an evidence based guideline, you are obligated to present evidence of the efficacy of such methodologies. Otherwise you should admit that this is a motherhood statement but without adequate literature to actually support the &quot;educational&quot; recommendations.</td>
</tr>
<tr>
<td>The recommendations were changed to “Information regarding the signs and symptoms of CRC, how to obtain a proper detailed history, physical examination, appropriate investigations, and referral of patients presenting with suspicious signs and symptoms should be widely disseminated to FPs and other PCPs using various knowledge translation strategies.”</td>
</tr>
<tr>
<td>15. Pg. 4, under recommendations, 6th bullet, what are the signs and symptoms associated with lower PPV. Not listed ? not have section 2 &amp; 3.</td>
</tr>
<tr>
<td>The recommendation was reworded to “For signs and symptoms suggestive of CRC that may not have prompted initial referral, FPs and other PCPs should reassess and further workup if sign/symptoms do not resolve.”</td>
</tr>
<tr>
<td>16. Under &quot;Recommendation to reduce diagnostic delays&quot; - don't feel that the statement regarding appointment booking system should be included in such a guideline as this should be at the discretion of the physician, a recommendation about office staff triaging suspicious complaints for CRC would be more accurate.</td>
</tr>
<tr>
<td>The recommendation was reworded to “FPs and other PCPs should consider training staff regarding triaging of patients calling with signs and/or symptoms suggestive of CRC to expedite initial appointments.”</td>
</tr>
<tr>
<td>17. Some comment regarding what to do in event of positive screening FOBT on the algorithm would be helpful.</td>
</tr>
<tr>
<td>The Working Group changed the title to “Colorectal Cancer Guideline Recommendations for Symptomatic Patients” to reflect that this guideline is not for screening.</td>
</tr>
<tr>
<td>18. Suggestion - a simple CRC form for referrals with check boxes for history &amp; physical exam - history part can be filled in by patients and PE</td>
</tr>
</tbody>
</table>
| The Working Group agreed with this comment and believed this guideline could be used to development these
part checked in by primary physicians - would get more information from primary physicians and also remind physicians to perform the DRE - most of my colleagues do not perform either a DRE or anoscopy in clinics - form will also increase patient acceptance of the procedure.  

knowledge translation products.

| 19. Quality information from referring practitioners remains a major obstacle in prioritizing referrals on this topic. I wonder if a referral sheet incorporating the features of the guideline recommendations flowchart in a concise fashion would be helpful. Perhaps a tick-off format would make it easy to enter info. Documentation of investigations completed to date with results would be valuable. Inadequate or incomplete info frequently delays assessment. | See #19. |

Review by the CRC Advisory Committee

The CRC Advisory Committee provided feedback to the Working Group during a teleconference on January 17, 2012. Two gastroenterologists from the committee, Drs. Michael Gould and Jill Tinmouth, provided written feedback to the Working Group. The responses to their feedback can be found in Table 6. The Expert Panel approved the changes made by the Working Group.

Table 6. Summary of written comments by CRC Advisory Committee and modifications/actions taken.

<table>
<thead>
<tr>
<th>Summary of Written Comments</th>
<th>Modifications/Actions/Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. The evidence to support FOBTs is largely based on the Jellema et al. 2010 review, which includes studies mainly from secondary care (9). I believe that the patients in these studies differ importantly from typical primary care symptomatic patients as most had already been triaged to colonoscopy. This suspicion is substantiated by the very high prevalence of CRC in these studies: 1-15%, with 11 studies reporting prevalence ≥ 5%. This is much higher than the prevalence of CRC in most primary care settings, even among symptomatic patients. Given that PPV varies with the prevalence of the disease in the population, I would be very hesitant to apply the PPV reported in the Jellema et al. 2010 study to settings that are truly primary care.</td>
<td>The Working Group agreed that the majority of studies in the Jellema et al. 2010 systematic review were conducted in secondary care settings and that this was a concern (9). However, Jellema et al. 2010 selected secondary care studies with a prevalence of CRC of less than 15% because this was the highest prevalence seen in their included primary care studies. It is difficult to know whether this is significantly different than the prevalence of CRC among symptomatic patients in the primary care setting without evidence to support that claim.</td>
</tr>
<tr>
<td>2. Where reported, the mean/median age from the studies in the Jellema et al. 2010 paper suggests that older populations were studied; the reported PPV would be affected by the higher prevalence of CRC in these populations (9). The</td>
<td>Young patients have been found to have delays in diagnosis. This delay would not be offset by participation in CRC screening as they are not invited to participate. The work-up of</td>
</tr>
</tbody>
</table>
PEBC review does not comment on or advise regarding the age of symptomatic patients in whom an FOBT might be considered. I would be concerned that as a result, readers might also use the FOBT in younger symptomatic patients.

<table>
<thead>
<tr>
<th>3. Application of the algorithm states that patients with a rectal mass, rectal bleeding, iron deficiency anemia or abnormal imaging warrant urgent referral. The implication is that FOBT may be useful in the remaining symptomatic patients to “increase the urgency of the referral”. However, 16 of the 19 studies in the Jellema et al 2010 paper took all symptomatic patients (3 excluded patients with visible rectal bleeding) (9). I suspect that many of the patients in these studies had the more worrisome symptoms (as described by the PEBC doc) warranting urgent referral mentioned above - and these patients are likely driving the high PPV reported in the Jellema et al 2010 paper. As a result, I would be cautious about using FOBT in the subset of symptomatic patients (ie symptoms other than rectal mass, rectal bleeding, or iron deficiency anemia) described in the PEBE algorithm in the PEBE review as I do not think the PPV would be as high as reported by Jellema et al 2010.</th>
<th>The Working Group agreed this was a limitation of the studies in the Jellema et al article, however, patients with the remaining unexplained symptoms (ex., change in bowel habits or weight loss) are still at higher risk for CRC than asymptomatic patients (9). According to the evidence, combinations of signs and/or symptoms increase the PPV for CRC (see Section 2 of this report). Having a positive FOBT in addition to another symptom should increase the PPV for CRC. Therefore, the Working Group believed that in cases where FPs had a lower suspicion of CRC for the remaining symptomatic patients, a FOBT could be used to assist the FP in deciding whether to refer (with a positive FOBT) or treat and review (with a negative FOBT).</th>
</tr>
</thead>
<tbody>
<tr>
<td>4. Despite the statement in the PEBC review that a negative FOBT result should not deter or delay referral, I think that it would. Otherwise, why bother doing the test?</td>
<td>The Working Group agreed with this comment and changed the recommendations to include a treat-and-review statement if the FOBT was found to be negative.</td>
</tr>
<tr>
<td>5. Should the family doctor be concerned about symptoms in this small group may reduce delay in diagnosis. The Working Group believed that a younger patient with symptoms of CRC that did not meet the criteria for referral (ex., change in bowel habits) could be offered a FOBT in addition to treating their symptoms if their suspicion for CRC was low. Many of the studies that examined symptomatic patients included younger patients. So, although the prevalence of CRC is lower in younger patients, patients with symptoms have a higher risk for CRC than asymptomatic patients. If a FP has a lower suspicion of CRC for a younger symptomatic patient (ex., with a change in bowel habits), a FOBT could be ordered to assist the FP in deciding whether to refer (with a positive FOBT) or treat and review (with a negative FOBT).</td>
<td>The Working Group agreed with this</td>
</tr>
</tbody>
</table>
symptoms, they should treat the symptoms and then refer if there is concern or no improvement, or just refer the patient. The regular referral pathway when there is heightened concern should be used if the referral needs to be expedited. While I do share the concern about screening patients jumping the queue over symptomatic patients, it requires good family doctor-consultant communication to deal with the issue.

<table>
<thead>
<tr>
<th>6. The CCO colon check program is a population based screening program and not meant to deal with GI symptoms and we should not be using the screening kits for that purpose, and we should be promoting this approach through the CCO colon check program.</th>
</tr>
</thead>
<tbody>
<tr>
<td>The Working Group agreed with this concern and included FOBT (non-ColonCancerCheck) in their recommendations to reflect that the FOBT kits ordered should not be screening kits. The Working Group also included a statement that three stool samples should be taken at three different bowel movements.</td>
</tr>
</tbody>
</table>

| 7. I reviewed the members of the expert panel, absent among the members were any Gastroenterologists who are arguably the experts in this field. I believe this was a significant oversight, which lead you to this place. |
| The Working Group acknowledged this concern and had difficulty in recruiting gastroenterologists to volunteer as expert panel members. The Working Group is appreciative to Drs. Gould and Tinmouth for providing their valuable feedback to make this guideline a better document. |

**Conclusion**

This EBS report reflects the integration of feedback obtained through the external review process with final approval given by the Colorectal Cancer Referral Expert Panel and the Director of the PEBC. Updates of the report will be conducted as new evidence informing the question of interest emerges.
REFERENCES


12. Cancercare.on.ca. [Internet]. Toronto (ON): Cancer Care Ontario (CCO); 2011 [cited 2010 Aug 3].
OVERVIEW
The original version of this guidance document was released by Cancer Care Ontario’s Program in Evidence-based Care in 2012. In January 2015, this document was assessed in accordance with the PEBC Document Assessment and Review Protocol and was determined to require a review. As part of the review, a PEBC methodologist conducted an updated search of the literature. A clinical expert (LDG) reviewed and interpreted the new eligible evidence and proposed the existing recommendations could be endorsed. The Colorectal Cancer Referral Expert Panel members (Appendix 1) endorsed the recommendations found in Section 1 (Guideline Recommendations) on April 10, 2017.

DOCUMENT ASSESSMENT AND REVIEW RESULTS
Questions Considered
1. How should patients presenting to family physicians (FPs) and other primary care providers (PCPs) with signs and/or symptoms of colorectal cancer (CRC) be managed? What signs, symptoms, and other clinical features that present in primary care are predictive of CRC?
2. What is the diagnostic accuracy of investigations commonly considered for patients presenting with signs and/or symptoms of CRC?
3. What major, known risk factors increase the likelihood of CRC in patients presenting with signs and/or symptoms of CRC?
4. Which factors are associated with delayed referral? Which delay factors can be attributed to patients, and which factors can be attributed to providers? Does a delay in the time to consultation affect patient outcome?

Literature Search and New Evidence

PEBC has decided to focus on existing systematic reviews and clinical practice guidelines for this updated literature search. The new search (June 2009 to September 2015) yielded a total of two existing guidelines and three systematic reviews. The results of the included guidelines and systematic reviews can be found in the Document Review Tool below.

Impact on Guidelines and Its Recommendations

The new evidence continues to support current recommendations. However, the new evidence slightly weakens some of the recommendations. For example, median positive predictive values for such specific symptoms as anemia and rectal bleeding may be slightly lower according to new evidence. Compared with the new 2015 NICE guidelines, the recommendations in this guideline are more conservative and have a lower threshold for the gold standard investigation using colonoscopy, based on the same evidence.

During the review process, an issue was raised with respect to the option to test with FOBT in a narrow set of circumstances. In the 2017 version, because of the possible negative impact of the 2012 recommendation regarding FOBT on the organized colorectal cancer screening program in Ontario, it was decided to remove all recommendations associated with FOBT from the guidance for referral, from the summary of key evidence, and from the accompanying algorithm.

With those minor changes, the Colorectal Cancer Referral Expert Panel ENDORSED the 2012 recommendations.

Document Review Tool

<table>
<thead>
<tr>
<th>Number and title of document under review</th>
<th>EBS 24-1: Referral of Patients with Suspected Colorectal Cancer by Family Physicians and Other Primary Care Providers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current Report Date</td>
<td>April 24, 2012</td>
</tr>
<tr>
<td>Clinical Expert</td>
<td>Lisa Del Giudice</td>
</tr>
<tr>
<td>Health Research Methodologists</td>
<td>Xiaomei Yao and Sarah Kellett</td>
</tr>
<tr>
<td>Date Assessed</td>
<td>January 6, 2015</td>
</tr>
<tr>
<td>Current Literature Search Date</td>
<td>September 8, 2015</td>
</tr>
<tr>
<td>Approval Date</td>
<td>April 10, 2017</td>
</tr>
</tbody>
</table>

Original Questions:

1. How should patients presenting to family physicians (FPs) and other primary care providers (PCPs) with signs and/or symptoms of colorectal cancer (CRC) be managed? What signs, symptoms, and other clinical features that present in primary care are predictive of CRC?
2. What is the diagnostic accuracy of investigations commonly considered for patients presenting with signs and/or symptoms of CRC?
3. What major, known risk factors increase the likelihood of CRC in patients presenting with signs and/or symptoms of CRC?
4. Which factors are associated with delayed referral? Which delay factors can be attributed to patients, and which factors can be attributed to providers? Does a delay in the time to consultation affect patient outcome?
consultation affect patient outcome?

Target Population:
Adult patients presenting in primary care settings comprise the target population. This guideline does not provide recommendations for patients who present with alarming emergency symptoms and signs of hemodynamic instability, acute gastrointestinal hemorrhaging, acute intestinal obstructions, or unremitting abdominal pain. These patients should be immediately referred to emergency for assessment and treatment. In addition, this guideline does not address CRC screening for asymptomatic patients.

Study Section Criteria:
Guidelines were included if they addressed at least one of our research questions, were not cited in the NZGG or NICE guidelines, and included recommendations not found or different from those in either the NICE or NZGG guidelines.

Studies, found from reference lists, that were published before the NICE or NZGG guidelines but were not included in their reports were included in this systematic review if they addressed any of the research questions and met the inclusion criteria.

This report focuses on adult patients presenting to primary care with signs or symptoms of CRC. For the clinical question regarding the predictive characteristics of signs or symptoms, all comparative studies of symptom recognition and/or identification for CRC were included. Studies that reported only the main signs or symptoms for each patient, ignoring the presence of additional signs or symptoms, were excluded. Studies where CRC was found in only one patient were also excluded. Studies conducted in secondary care settings were included if they provided predictive information about signs and/or symptoms for suspected CRC; however, they may not have been taken as strongly into consideration as were primary care data when developing the recommendations. Screening studies were excluded because they include asymptomatic patients.

All diagnostic studies were sought in which adult symptomatic primary care patients underwent one or more investigations that included computed tomographic (CT) colonography, barium enema, sigmoidoscopy, ultrasound, CT scan, digital rectal examination (DRE), proctoscopy, rectoscopy, anoscopy, fecal occult blood tests (FOBTs), or complete blood counts (CBC). Studies involving investigations for carcinoembryonic antigen (CEA), C-reactive protein, erythrocyte sedimentation rate (ESR), ferritin, or serum iron were also searched. Studies conducted in secondary care settings were included if they provided diagnostic information for suspected CRC for the specified investigations; however, they may not have been considered as strongly as the primary care data when developing the recommendations. Screening studies were excluded.

For the clinical questions concerning risk factors and delay, a search for practice guidelines, systematic reviews with meta-analyses, and systematic reviews without meta-analyses was performed. If these articles did not definitively answer the particular clinical question, searches for randomized phase III trials and randomized phase II trials, followed by comparative studies, were performed. If the information from systematic reviews definitely answered the question(s), articles from the time of publication of the systematic review and onwards were searched. To develop recommendations with feasible wait times for Ontario, articles assessing wait times in Canada were also included, regardless of study design.

Non-English publications were not eligible due to the lack of translation funding. Non-systematic reviews, abstracts, case studies, letters, editorials, and commentaries were excluded.

Search Details:
Please see the search strategy for Medline and Embase in Appendix 2.

Brief Summary/Discussion of New Evidence:
PEBC decided to focus on existing systematic reviews and clinical practice guidelines for this updated literature search. The flow diagram of existing systematic reviews and clinical practice guidelines considered in this review is shown below:

NICE = National Institute for Health and Care Excellence, SIGN = Scottish Intercollegiate guidelines Network, ASCO = American Society of Clinical Oncology, NZGG = New Zealand Guidelines Group

Two guidelines and three SRs met the inclusion criteria and are summarized in Table 1. There is no SR or guideline eligible for Q3. Nine of 12 eligible studies in the Huggenberger 2015 SR were covered by the Tong 2014 SR for Q1.

Table 1. Systematic Reviews/guideline

<table>
<thead>
<tr>
<th>Q1: Symptoms/signs</th>
</tr>
</thead>
<tbody>
<tr>
<td>References</td>
</tr>
<tr>
<td>------------</td>
</tr>
</tbody>
</table>
| NICE 2015 (guideline) [1] | 31 | Unclear | Pts with symptoms for suspicious CRC in primary care settings | PPV | Refer people using a suspected cancer pathway referral (for an appointment within 2 weeks) for colorectal cancer if:

  * they are aged 40 and over with unexplained weight loss and abdominal pain or
  * they are aged 50 and over with unexplained rectal bleeding or
<table>
<thead>
<tr>
<th>Huggenberger 2015 [2]</th>
<th>12</th>
<th>NR</th>
<th>Unselected population from general practice with a newly recognised alarm symptom</th>
<th>PPV or LR for any of the alarm symptoms</th>
<th>PPV of “rectal bleeding” was high for patients &gt; 60 years (6.6-21.2%), but much lower in younger age groups. For “change in bowel habits” and “significant general symptoms”, the PPV was 3.5-8.5%.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tong 2014 [3]</td>
<td>38</td>
<td>73,174 Pts with RB (5,626 CRC Pts)</td>
<td>24 primary care settings, 9 secondary hospital settings, 5 community settings</td>
<td>SEN, SPE, PPV</td>
<td>Diagnostic values for RB: SEN=47% (CI=45%-48%), SPE=96% (CI=96%-96%), PPV=6% (CI=5%-8%).</td>
</tr>
</tbody>
</table>

**Q2: Investigation tests**

<table>
<thead>
<tr>
<th>References</th>
<th>Study</th>
<th>Sample size</th>
<th>Pts population</th>
<th>Tests</th>
<th>Brief results</th>
</tr>
</thead>
<tbody>
<tr>
<td>NICE 2015 (guideline) [1]</td>
<td>12</td>
<td>Unclear</td>
<td>Pts with symptoms for suspicious CRC in primary care settings</td>
<td>FOBT, Sigm, Double-contrast barium enema</td>
<td>Offer testing for occult blood in feces to assess for colorectal cancer in adults without rectal bleeding who: • are aged 50 and over with unexplained: abdominal pain or weight loss, or • are aged under 60 with changes in their bowel habit or iron-deficiency anemia or • are aged 60 and over and have anemia even in the absence of iron deficiency. [new 2015] The fecal occult blood testing is cost-effective to detect colorectal cancer in people aged 40 years and older with a change in bowel habit in primary care. Barium enema, flexible sigmoidoscopy and computed tomography colonography were all found to be cost-effective compared to colonoscopy however FOBT was the most cost effective for this low risk population. Discuss with people with suspected cancer (and their carers as appropriate, taking account of the need for confidentiality) their preferences for being involved in decision-making about referral options and further investigations including their potential risks and benefits. [new 2015]</td>
</tr>
<tr>
<td>Spada 2015 (ESGE/ESGAR guideline) [4]</td>
<td>NR</td>
<td>NR</td>
<td>Pts with symptoms or without symptoms</td>
<td>CTC</td>
<td>a) ESGE/ESGAR recommend CTC as the radiological examination of choice for the diagnosis of colorectal neoplasia. b) ESGE/ESGAR do not recommend barium enema in this setting (strong recommendation, high quality evidence).</td>
</tr>
</tbody>
</table>

**Q3: Risk factors in symptomatic pts for CRC: no evidence was found**
### Q4: Delay

<table>
<thead>
<tr>
<th>References</th>
<th>Study</th>
<th>Sample size</th>
<th>Inclusion criteria</th>
<th>Brief results</th>
</tr>
</thead>
</table>
| Oberoi 2014* [5] | 32 | 6-1,966 per study | a) Focused on factors associated with delay between the onset of symptom and seeking medical advice. b) Had adequate sample size and provided statistically significant differences with regards to factors associated with delay (quantitative) and those with rigorous methods of data collection and analysis (qualitative) | Factors that increased patient delay:  
**Demographic factors**  
- Educational level (low)  
- Younger age (< 50 years) in men and older age in women  
- Lack of health insurance  
- Low income  
- Living with spouse (rectal cancer)  
- Living in rural areas  
- Inadequate transportation facilities  
- Difficulty in visiting GP or making appointment  
- No screening advice received from the doctor  
- Lack of social support or lay referral networks  
**Health belief factors**  
- Non-specific symptoms  
- Attribution of symptoms to benign conditions and non-recognition of symptom severity  
- Attribution of symptoms to changes in diet and lifestyle  
- Fear of unpleasant investigations  
- Fear of treatment  
- Denial of cancer  
- Lack of trust in the medical system  
- Belief that the symptoms would resolve spontaneously  
- Past history of anxiety and depression or of benign bowel disease  
- Family history of cancer  
- Relief from over-the-counter medications  
| Factors that reduced patient delay:  
**Demographic factors**  
- Age (> 60 years) for males  
- Retirement  
- Educational level (high)  
**Health belief factors**  
- Persistent symptoms  
- Aggravation of symptoms  
- Blood mixed in stool  
- Abdominal pain and discomfort  
- Multiple symptoms occurring together  
- Trust in GP  
- Symptom disclosure to someone significant  
- Knowledge about the cause of symptoms  
- Opportunity to talk to GP about lower bowel symptoms during regular visit  
| Factors that had a mixed impact on delay:  
- Embarrassment about the symptoms  
- Fear of cancer diagnosis  
- Not living with spouse  
- Socioeconomic status |

Abbreviations: AUC=Area under curve, BMI = body mass index, CI = 95% confidence interval, CRC = colorectal cancer, CTC = computed tomographic colonography, ESGE/ESGAR = European society of gastrointestinal endoscopy and European society of gastrointestinal and abdominal radiology, LR = likelihood-ratios, NR = not reported, PPV = positive predictive values, Pts = patients, RB = rectal bleeding, RR = risk ratio, SEN = sensitivity, Sigm = sigmoidoscopy, SPE = specificity

* The blue highlighted factors were not mentioned in 24-1 guideline for patients-related delay factors.

Clinical Expert Interest Declaration:  
No conflict of interest was declared.
### Instructions

For each document, please respond **YES** or **NO** to all the questions below. Provide an explanation of each answer as necessary.

<table>
<thead>
<tr>
<th>Question</th>
<th>Response</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Does any of the newly identified evidence, on initial review, contradict the current recommendations, such that the current recommendations may cause harm or lead to unnecessary or improper treatment if followed?</td>
<td><strong>NO</strong></td>
</tr>
<tr>
<td>2. On initial review,</td>
<td><strong>YES</strong></td>
</tr>
<tr>
<td>a. Does the newly identified evidence support the existing recommendations?</td>
<td><strong>YES</strong></td>
</tr>
<tr>
<td>b. Do the current recommendations cover all relevant subjects addressed by the evidence, such that no new recommendations are necessary?</td>
<td></td>
</tr>
<tr>
<td>3. Is there a good reason (e.g., new stronger evidence will be published soon, changes to current recommendations are trivial or address very limited situations) to postpone updating the guideline? Answer Yes or No, and explain if necessary:</td>
<td><strong>NO</strong></td>
</tr>
<tr>
<td>4. Do the PEBC and the DSG/GDG responsible for this document have the resources available to write a full update of this document within the next year?</td>
<td><strong>UNCERTAIN</strong></td>
</tr>
</tbody>
</table>

### Review Outcome

**ENDORSED**

### DSG/GDG Approval Date

April 10, 2017

### DSG/GDG Commentary

In the future, a review of FIT as a diagnostic test in the evaluation of patients with symptoms suspicious of colorectal cancer should be considered.

### New References Identified:


Appendix 1. Members of the Expert Panel

<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lisa Del Giudice, MD, MSc, CCFP</td>
<td>CCO Regional Primary Care Lead&lt;br&gt;Toronto Central Regional Cancer Program&lt;br&gt;Toronto, Ontario</td>
</tr>
<tr>
<td>Danusia Gzik, MD, MHSc, CCFP</td>
<td>CCO Regional Primary Care Lead&lt;br&gt;North Simcoe Muskoka Regional Cancer Program&lt;br&gt;Huntsville, Ontario</td>
</tr>
<tr>
<td>Praveen Bansal, MD, CCFP</td>
<td>CCO Regional Primary Care Lead&lt;br&gt;Central West Regional Cancer Program&lt;br&gt;Brampton, Ontario</td>
</tr>
<tr>
<td>Hugh Langley, MD, CCFP</td>
<td>CCO Regional Primary Care Lead&lt;br&gt;South East Regional Cancer Program&lt;br&gt;Kingston, Ontario</td>
</tr>
<tr>
<td>Amanda Hey, MD, CCFP, FCFP</td>
<td>CCO Regional Primary Care Lead&lt;br&gt;North East Regional Cancer Program&lt;br&gt;Sudbury, Ontario</td>
</tr>
<tr>
<td>Lee Donohue, MD, MHSc, CCFP</td>
<td>CCO Regional Primary Care Lead&lt;br&gt;Champlain Regional Cancer Program&lt;br&gt;Ottawa, Ontario</td>
</tr>
<tr>
<td>Janice Owen, MD, MSc, CCFP, FCFP</td>
<td>Regional Primary Care Lead&lt;br&gt;South West Regional Cancer Program&lt;br&gt;London, Ontario</td>
</tr>
</tbody>
</table>

Appendix 2. Search Strategies
For Question 1 (Symptoms/signs)
Systematic Reviews Only
Database: Ovid MEDLINE(R)
Search Strategy:

1. exp "sensitivity and specificity"/
2. false negative reactions/ or false positive reactions/
(sensitivity or specificity or accuracy).ab,ti.
diagnostic.ab,ti.
predictive value.ab,ti.
reference value.ab,ti.
ROC.ab,ti.
(likelihood adj ratio1).ab,ti.
monitoring.tw.
(false adj (negative1 or positive1)).ab,ti.
(systematic adj (review: or overview:)).mp.
(meta-analy: or metaanaly:).mp.
(pooled analy: or statistical pooling or mathematical pooling or statistical summar: or mathematical summar: or quantitative syntheses or quantitative overview:).mp.
(exp review literature as topic/ or review.pt. or exp review/) and systematic.tw.
(cochrane or embase or psychlit or psyclit or cinhal or cinahl or science citation index or scisearch or bids or sigle or cancerlit or pubmed or pub-med or medline or med-line).ab.
(reference list: or bibliograph: or hand-search: or handsearch: or relevant journal: or manual search:).ab.
or/1-16
(selection criteria or data extract: or quality assess: or jadad score or jadad scale or methodologic: quality).ab.
(stud: adj1 select:).ab.
(18 or 19) and review.pt.
17 or 20
(guideline or practice guideline).pt.
exp consensus development conference/
consensus/
(guideline: or recommend: or consensus or standards).ti.
22 or 23 or 24 or 25
21 or 26
(comment or letter or editorial or note or erratum or short survey or news or newspaper article or case reports or historical article).pt.
27 not 28
exp body weight changes/
(weight adj1 loss$).tw.
exp "signs and symptoms, digestive"
 cachexia.tw.
(loss adj2 appetite).tw.
early satiety.tw.
Anorexia/
anorexia.tw.
"nausea and vomiting"/ or nausea/ or vomiting/
nausea.tw.
vomiting.tw.
gastrointestinal hemorrhage/ or melena/
((abdom$ or stomach or back or flank) adj3 pain).tw.
(pruritus ani or (itch$ adj3 anus) or (pain adj 3 defec$)).tw.
(((abdomen or stomach or rectum or colorectal or renal or intestinal or gastrointestinal) adj3 mass).tw.
(intestinal obstruction or acute intestinal obstruction or (obstruct adj intestine) or (perforate adj intestine)).tw.
obstruction$.tw.
((gastrointestinal$ or intestine) adj (bleed$ or hemorrhage$ or haemorrhage$)).tw.
gastrointestinal hemorrhage/ or melena/
((rectum or colorectal) adj3 (bleed$ or hemorrhage$ or haemorrhage$)).tw.
((rectum or anal) and (bleed$ or blood$ or haemos$ or hemo$)).tw.
((mucus or pass mucus) adj stool$).tw.
stips$.tw.
(melena or maelena).tw.
Hematuria/
(hematuria or haematuria).tw.
(hematochezia or haematochezia).tw.
exp anemia/
(anemia or anaemia).tw.
(iron adj deficiency adj (anemia or anaemia)).tw.
exp Jaundice/
jaundice.tw.
exp Diarrhea/
(diarrhea or diarrhoea).tw.
change$ in bowel habit$.tw.
bowel habit change$.tw.
frequency of defecation.tw.
((foecal or fecal) and incontinence$).tw.
continence$.tw.
constipation$.tw.
((soil$ or diarrhoea$ or steatorrhoea$ or loose stool$ or loose motion$ or loose bowel motion$).tw.
exp Cholecystitis/
cholecystitis.tw.
Ascites/
ascites.tw.
Hepatomegaly/
(hepatomegaly or hepato megaly).tw.
(alarm adj1 (symptom$ or sign$)).tw.
or/30-77
exp abdominal neoplasms/ or anal gland neoplasms/ or digestive system neoplasms/ or gastrointestinal neoplasms/ or gastrointestinal stromal tumors/ or exp intestinal neoplasms/ or exp liver neoplasms/ or peritoneal neoplasms/ or pelvic neoplasms/
((rectum or colorectal$ or alimentary or colon$ or gallbladder$ or duoden$ or gastrointestinal$ or anal or intestine$ or liver or digestive or abdominal$) adj2 (tumor$ or tumour$ or cancer$ or neoplasm$ or carcinoma$)).tw.
or/79-80
29 and 81 and 78
limit 82 to (english language and humans)
(200906: or 200907: or 200908: or 200909: or 200910: or 200911: or 2010: or 2011:
or 2012: or 2013: or 2014: or 2015:).ed.
83 and 84

Database: EMBASE
Search Strategy:

1  "sensitivity and specificity"/
2  false negative result/ or false positive result/
3  (sensitivity or specificity or accura$).ab,ti.
4  diagnos$.ab,ti.
5  predictive value$.ab,ti.
6  reference value$.ab,ti.
7  ROC.ab,ti.
8  (likelihood adj ratio$1).ab,ti.
9  monitoring.tw.
10 (false adj (negative$1 or positive$1)).ab,ti.
11 (systematic adj (review: or overview:)).mp.
12 (meta-analy: or metaanaly:).mp.
13 (pooled analy: or statistical pooling or mathematical pooling or statistical summar: or
mathematical summar: or quantitative syntheses or quantitative overview:).mp.
14 (exp review literature as topic/ or review.pt. or exp review/) and systematic.tw.
15 (cochrane or embase or psychlit or psyclit or psychinfo or cinhal or cinahl or
science citation index or scisearch or bids or sigle or cancerlit or pubmed or pub-med or
medline or med-line).ab.
16 (reference list: or bibliograph: or hand-search: or handsearch: or relevant journal: or manual
search:).ab.
17 (selection criteria or data extract: or quality assess: or jadad score or jadad scale or
methodologic: quality).ab.
18 (stud: adj1 select:).ab.
19 (17 or 18) and review.pt.
20 or/1-16
21 19 or 20
22 consensus development conference/
23 practice guideline/
24 *consensus development/ or *consensus/
25 *standard/
26 (guideline: or recommend: or consensus or standards).kw.
27 (guideline: or recommend: or consensus or standards).ti.
28 or/22-27
29 (editorial or note or letter or erratum or short survey).pt. or abstract report/ or letter/ or
case study/
30 (21 or 28) not 29
31 weight reduction/
32 (weight adj1 loss$).tw.
33 Cachexia/
34 cachexia.tw.
35 (loss adj2 appetite).tw.
36 early satiety.tw.
37 Anorexia/
38 anorexia.tw.
39 "nausea and vomiting"/ or nausea/ or vomiting/
40 nausea.tw.
41 vomiting.tw.
42 abdominal pain/ or lower abdominal pain/
digestive system hemorrhage/ or exp gastrointestinal hemorrhage/ or exp duodenum bleeding/
((abdom$ or stomach or back or flank) adj3 pain).tw.
(pruritus ani or (itch$ adj3 anus) or (pain adj 3 defec$)).tw.
((abdom$ or stomach or rect$ or colorectal or renal or intestin$ or gastrointestin$) adj3
mass$).tw.
(intestinal obstruction or acute intestinal obstruction or (obstruct$ adj intestin$) or (perforat$
adj intestin$)).tw.
((gastrointestina$ or intestin$) adj (bleed$ or hemorrhag$ or haemorrhag$)).tw.
((rect$ or colorect$) adj3 (bleed$ or hemorrhag$ or haemorrhag$)).tw.
((rect$ or anal) and (bleed$ or blood$ or haemo$ or hemo$)).tw.
((mucus or pass$ mucus) adj stool$).tw.
stips$.tw.
((melena or maeleena).tw.
Hematuria/
(hematuria or haematuria).tw.
(hematochezia or haematochezia).tw.
exp anemia/
(anemia or anaemia).tw.
(iron adj deficiency adj (anemia or anaemia)).tw.
Jaundice/
jaundice.tw.
exp Diarrhea/
(diarrhea or diarrhoea).tw.
change$ in bowel habit$.tw.
bowel habit change$.tw.
frequency of defecation.tw.
((foecal or fecal) and incontinen$).tw.
continen$tw.
constipat$.tw.
(soil$ or diarrhoea$ or steatorrhoea$ or loose stool$ or loose motion$ or loose bowel
motion$).tw.
exp Cholecystitis/
cholecystitis.tw.
exp Ascites/
ascites.tw.
Hepatomegaly/
hepatomegaly or hepato megaly).tw.
(alarm adj1 (symptom$ or sign$)).tw.
or/31-78
digestive system tumor/ or gastrointestinal stromal tumor/ or gastrointestinal tumor/ or
digestive system cancer/ or exp liver cancer/ or exp intestine cancer/ or exp liver tumor/ or
exp intestine tumor/
((rect$ or colorectal$ or alimentary or colon$ or gallbladder$ or duoden$ or gastrointestin$ or
anal or intestin$ or liver or digestive or abdom$) adj2 (tumor$ or tumour$ or cancer$ or
neoplasm$ or carcinoma$)).tw.
or/80-81
(200906: or 200907: or 200908: or 200909: or 200910: or 200911: or 200912: or 2010: or 2011:
or 2012: or 2013: or 2014: or 2015:):ew.
79 and 82 and 30
83 and 84
limit 85 to (human and english language)

For Question 2 (Investigation tests)
Database: Ovid MEDLINE(R)
Search Strategy:

1  Primary Health Care/
2  Physicians, Family/
3  ((family or general) adj practitioner$).mp.
4  gp.mp.
5  family physician$.mp.
6  family doctor$.mp.
7  Family Practice/
8  ((family or general) adj practice$).mp.
9  primary care.mp.
10  primary health care.mp.
11  or/1-10
12  meta-analysis/
13  "review literature".mp.
14  meta-analy$.mp.
15  metaanal$.mp.
16  (systematic$ adj (review$ or overview$)).mp.
17  meta-analysis.pt.
18  review.pt.
19  review.ti.
20  or/12-19
21  Case Reports/
22  letter.pt.
23  historical article.pt.
24  comment.pt.
25  (editorial or abstracts).pt.
26  or/21-25
27  20 not 26
28  exp "sensitivity and specificity"/
29  (sensitivity or specificity).tw.
30  exp Diagnostic Errors/
31  predictive valu$.tw.
32  “Predictive value of tests”/
33  ROC.tw.
34  (ROC adj (analyS or area or auc or characteristic$ or curve$)).tw.
35  (false adj (negative or positive)).tw.
36  accuracy.tw.
37  reference value$.tw.
38  likelihood ratio$.tw.
39  ((pre-test or pretest) adj probability).tw.
40  post-test probability.tw.
41  Diagnosis, differential/
42  Diagnostic tests, routine/
43  or/28-42
44  exp Blood Cell Count/
45  (CBC or FBC or full blood count).tw.
46  C-reactive protein/
47  c-reactive protein$.mp.
48  Blood sedimentation/
49  erythrocyte sedimentation rate.mp.
50  ferritin.mp. or Ferritins/
51  serum iron.mp.
52  Occult blood/
53 stool occult blood.mp.
54 faecal occult blood.mp.
55 (fob or fobt).mp.
56 Carcinoembryonic Antigen/
57 Carcinoembryonic Antigen.tw.
58 Carcinogenic embryonic Antigen.tw.
59 cea.tw.
60 Colonography, computed tomographic/
61 (ct scan adj2 abdom$).tw.
62 virtual colography.mp.
63 virtual colonography.mp.
64 virtual colonoscopy.mp.
65 Proctoscopy/ or proctoscopy.mp.
66 anoscopy.mp.
67 Sigmoidoscopy/ or sigmoidoscopy.mp.
68 barium enema.mp.
69 ultrasonography. or Endosonography/
70 Digital rectal examination/
71 ((per rect$ or pr) adj exam$).tw.
72 or/44-71
73 exp abdominal neoplasms/ or anal gland neoplasms/ or digestive system neoplasms/ or gastrointestinal neoplasms/ or gastrointestinal stromal tumors/ or exp intestinal neoplasms/ or peritoneal neoplasms/ or pelvic neoplasms/
74 ((rect$ or colorectal$ or alimentary or colon$ or gallbladder$ or duoden$ or gastrointestinal$ or anal or intestin$ or digestive or abdom$) adj2 (tumor$ or tumour$ or cancer$ or neoplasm$ or carcinoma$)).tw.
75 73 or 74
76 27 or 43
77 75 and 72 and 76
78 (200906: or 200907: or 200908: or 200909: or 200910: or 200911: or 200912: or 2010: or 2011: or 2012: or 2013: or 2014: or 2015:).ed.
79 77 and 78

Database: EMBASE
Search Strategy:

1 exp Primary health care/
2 general practitioner/
3 ((family or general) adj practitioner$).mp.
4 gp.mp.
5 Family physician/
6 family physician$.mp.
7 family doctor$.mp.
8 general practice/
9 ((family or general) adj practice$).mp.
10 primary care.mp.
11 primary health care.mp.
12 or/1-11
13 Meta Analysis/
14 "systematic review"/
15 (meta-analy$ or metaanaly$).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]
16 (systematic adj (review$ or overview$)).mp.
17 review.pt.
review.ti.
or/13-18
cor/13-18
letter.pt.
editorial.pt.
or/20-21
not 22
"sensitivity and specificity"/
sensitivity.tw.
specificity.tw.
"prediction and forecasting"
predictive value$.tw.
predictive value$ of test$.tw.
roc curve/
(ROC adj (analy$ or area or auc or characteristic$ or curve$)).tw.
exp diagnostic error/
(false adj (positive or negative)).tw.
diagnostic accuracy/
accuracy.tw.
reference value/
reference value$.tw.
likelihood ratio$.tw.
((pre-test or pretest) adj probability).tw.
post-test probability.tw.
differential diagnosis/
or/24-41
exp blood cell count/
(CBC or FBC or full blood count).tw.
c-reactive protein.mp. or C Reactive Protein/
erthrocyte sedimentation rate/
erthrocyte sedimentation rate.mp.
ferritin.tw. or Ferritin blood level/ or Ferritin/
serum iron.mp. or exp Iron Blood Level/
occult blood/
faecal occult blood.tw.
(fob or fobt).tw.
Carcinoembryonic Antigen.tw.
Carcinogenic embryonic Antigen.tw.
Carcinoembryonic Antigen/
CEA.tw.
virtual colography.tw.
virtual colonography.mp.
virtual colonoscopy.mp.
computer assisted tomography/
computed tomographic colonography/
(ct scan adj abdom$).tw.
barium enema.mp. or Barium Enema/
Rectoscopy/ or proctoscopy.tw.
anoscopy/ or anoscopy.mp.
Ultrasound/ or ultrasound.mp.
Sigmoidoscopy/ or sigmoidoscopy.tw.
Digital rectal examination/
pr exam$.tw.
per rectum exam$.tw.
or/43-70
digestive system tumor/ or gastrointestinal stromal tumor/ or gastrointestinal tumor/ or digestive system cancer/ or exp intestine cancer/ or exp intestine tumor/
exp Abdominal Tumor/
72 or 73
74 72 or 73
75 or 23
76 74 and 75 and 71
77 limit 76 to (human and english language)
78 (200906: or 200907: or 200908: or 200909: or 200910: or 200911: or 200912: or 2010: or 2011: or 2012: or 2013: or 2014: or 2015:).ew.
79 77 and 78
For Question 3 (Risk factors)
Database: Ovid MEDLINE(R)
Search Strategy:
--------------------------------------------------------------------------------
1  exp colorectal neoplasms/
2  exp large intestine tumor/
3  ((proximal or ascending or descending or transverse) adj colon adj3 (cancer$ or neoplas$ or tumour$ or tumor$ or carcino$ or malignan$)).tw.
4  ((colon$ or colorect$ or bowel$ or large bowel$ or intestin$ or pelv$ or abdom$) adj3 (cancer$ or neoplas$ or tumour$ or tumor$ or carcino$ or malignan$)).tw.
5  ((sigmoid$ or rectosigmoid$ or jejunum or ileum or ileal or cecum or cecal or ileocecal or ileocecal junction or ICJ or appendi$) adj3 (cancer$ or neoplas$ or tumour$ or tumor$ or carcino$ or malignan$)).tw.
6  CRC.tw.
7  Burkitt$ lymph$.tw.
8  (hereditary nonpolyposis colon cancer or nonpolyposis colon cancer or HNPCC or Lynch$ syndrome).tw.
9  exp primary health care/
10 (primary care or primary health care).tw.
11 Family Practice/
12 Physicians, Family/
13 (family practi$ or family doctor$ or family physician$ or gp$ or general practi$).tw.
14 (200906: or 200907: or 200908: or 200909: or 200910: or 200911: or 200912: or 2010: or 2011: or 2012: or 2013: or 2014: or 2015:).ed.
15 meta-analysis.pt,sh.
16 (meta-anal$ or metaanal$).tw.
17 (quantitativ$ review$ or quantitativ$ overview$).tw.
18 (systematic$ review$ or systematic$ overview$).tw.
19 (methodologic$ review$ or methodologic$ overview$).tw.
20 (integrative research review$ or research integration$).tw.
21 quantitativ$ synthes$.tw.
22 (medline or medlars).tw,sh. or embase.tw.
23 (scisearch or psychinfo or psycinfo).tw.
24 (psychlit or psyclit).tw.
25 (hand search$ or manual search$).tw.
26 (electronic database$ or bibliographic database$).tw.
27 (pooling or pooled analys$ or mantel haenszel$).tw.
28 (peto or der simonian or dersimonian or fixed effect$).tw.
29 review.pt,sh. or review$.tw. or overview$.tw.
30 or/9-13
31 or/22-28
32 or/15-21
33 29 and 31
34  32 or 33  
35  or/1-8  
36  35 and 34  
37  limit 36 to english language  
38  limit 37 to humans  
39  38 and 14  
40  remove duplicates from 39  

**Database: EMBASE**

**Search Strategy:**

1. exp colorectal neoplasms/
2. exp large intestine tumor/
3. ((proximal or ascending or descending or transverse) adj colon adj3 (cancer$ or neoplas$ or tumour$ or tumor$ or carcino$ or malignan$)).tw.
4. ((colon$ or colorect$ or bowel$ or large bowel$ or intestin$ or pelv$ or abdom$) adj3 (cancer$ or neoplas$ or tumour$ or tumor$ or carcino$ or malignan$)).tw.
5. ((sigmoid$ or rectosigmoid$ or jejunum or ileum or ileal or cecum or cecal or ileocecal or ileocecal junction or ICJ or appendi$) adj3 (cancer$ or neoplas$ or tumour$ or tumor$ or carcino$ or malignan$)).tw.
6. CRC.tw.
8. (hereditary nonpolyposis colon cancer or nonpolyposis colon cancer or HNPCC or Lynch$ syndrome).tw.
9. exp primary health care/
10. (primary care or primary health care).tw.
11. Family Practice/
12. Physicians, Family/
13. (family practi$ or family doctor$ or family physician$ or gp$ or general practi$).tw.
14. meta-analysis.pt,sh.
15. (meta-anal$ or metaanal$).tw.
16. (quantitativ$ review$ or quantitativ$ overview$).tw.
17. (systematic$ review$ or systematic$ overview$).tw.
18. (methodologic$ review$ or methodologic$ overview$).tw.
19. (integrative research review$ or research integration$).tw.
20. quantitativ$ synthes$.tw.
21. (medline or medlars).tw,sh. or embase.tw.
22. (scisearch or psychinfo or psychinfo).tw.
23. (psychlit or psyclicl).tw.
24. (hand search$ or manual search$).tw.
26. (pooling or pooled analys$ or mantel haenszel).tw.
27. (peto or der simonian or dersimonian or fixed effect$).tw.
28. review.pt,sh. or review$.tw. or overview$.tw.
29. or/9-13  
30. or/21-27  
31. or/14-20  
32. 28 and 30  
33. 31 or 32  
34. or/1-8  
35. 34 and 33  
36. limit 35 to english language  
37. limit 36 to humans
For Question 4 (Delay)
Database: Ovid MEDLINE(R)
Search Strategy:

1. exp abdominal neoplasms/ or anal gland neoplasms/ or digestive system neoplasms/ or gastrointestinal neoplasms/ or gastrointestinal stromal tumors/ or exp intestinal neoplasms/ or peritoneal neoplasms/ or pelvic neoplasms/ and ((rect$ or colorectal$ or alimentary or colon$ or gallbladder$ or duoden$ or gastrointestinal$ or anal or intestinal$ or liver or digestive or abdom$) adj2 (tumor$ or tumour$ or cancer$ or neoplasm$ or carcinoma$)).tw.
2. or/1-2
3. (delay$ adj3 practitioner$).tw.
5. (delay$ adj3 patient$).tw.
6. (diagnos$ adj1 delay$).tw.
7. (diagnos$ adj earl$).tw.
8. early diagnosis/
9. or/4-16
10. "referral and consultation"/
11. referral$.tw.
12. (late$ adj refer$).tw.
14. Disease progression/
15. Time factors/
16. Physician-patient relations/
17. or/18-24
18. (200906: or 200907: or 200908: or 200909: or 200910: or 200911: or 200912: or 2010: or 2011: or 2012: or 2013: or 2014: or 2015:).ed.
19. 3 and 17 and 25 and 26
20. limit 27 to (english language and humans)

Database: EMBASE
Search Strategy:

1. digestive system tumor/ or gastrointestinal stromal tumor/ or gastrointestinal tumor/ or digestive system cancer/ or exp intestine cancer/ or exp intestine tumor/
2. ((rect$ or colorectal$ or alimentary or colon$ or gallbladder$ or duoden$ or gastrointestinal$ or anal or intestinal$ or liver or digestive or abdom$) adj2 (tumor$ or tumour$ or cancer$ or neoplasm$ or carcinoma$)).tw.
3. or/1-2
4. Cancer diagnosis/
5. early diagnosis/
(earl$ adj diagnos$).tw.
diagnos$ earl$.tw.
Delayed Diagnosis/
(delay$ adj3 diagnos$).tw.
(diagnos$ adj1 delay$).tw.
(delay$ adj3 practitioner$).tw.
Patient attitude/
Attitude to health/ or Attitude to illness/ or Illness behavior/
(delay$ adj3 patient$).tw.
earl$ detection.tw.
detect$ adj earl$.tw.
(earl$ adj present).tw.
earl$ adj symptom$.tw.
or/4-18
patient referral/
referral$.tw.
(earl$ adj refer$).tw.
(late$ adj refer$).tw.
Time factors/
exp disease course/
25 and (5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 22 or 23)
clinical practice/
or/20-24,26-27
3 and 19 and 28
(200906: or 200907: or 200908: or 200909: or 200910: or 200911: or 200912: or 2010: or 2011: or
2012: or 2013: or 2014: or 2015:).ew.
29 and 30
limit 31 to (human and english language)
OUTCOMES DEFINITION

1. EDUCATION AND INFORMATION - EDUCATION AND INFORMATION means that a Clinical Expert and/or Expert Panel has reviewed new evidence pertaining to the guideline topic and determined that the guideline is out of date or has become less relevant. The document will no longer be tracked or updated but may still be useful for academic or other informational purposes. The document is moved to a separate section of our website and each page is watermarked with the words “EDUCATION AND INFORMATION.”

2. ENDORSED - ENDORSED means that a Clinical Expert and/or Expert Panel has reviewed new evidence pertaining to the guideline topic and determined that the guideline is still useful as guidance for clinical decision making. A document may be endorsed because the Expert Panel feels the current recommendations and evidence are sufficient, or it may be endorsed after a literature search uncovers no evidence that would alter the recommendations in any important way.

3. UPDATE - UPDATE means the Clinical Expert and/or Expert Panel recognizes that the new evidence pertaining to the guideline topic makes changes to the existing recommendations in the guideline necessary but these changes are more involved and significant than can be accomplished through the Document Assessment and Review process. The Expert Panel advises that an update of the document be initiated. Until that time, the document will still be available as its existing recommendations are still of some use in clinical decision making, unless the recommendations are considered harmful.